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The apelin system is an evolving transmitter system consisting of the G protein coupled 
apelin receptor and two endogenous peptide ligands, apelin and elabela. It is 
implicated as a potential therapeutic for a number of diseases; however, the 
endogenous peptides are limited by half-life and bioavailability. This study aims to 
identify and pharmacologically characterise apelin agonists in vitro and in vivo and to 
evaluate their therapeutic potential in pulmonary arterial hypertension as a model 
disease. 
CMF-019 was identified as the first G protein biased apelin agonist. To date, suitable 
small molecule apelin agonists as experimental tool compounds have been limited and 
CMF-019 represents an important advance. CMF-019 was active in vivo, producing an 
increase in cardiac contractility and vasodilatation, similar to apelin. These effects were 
achieved without receptor desensitisation, supporting the remarkable G protein bias 
observed in vitro. Furthermore, it was disease-modifying in vitro in an endothelial cell 
apoptosis assay but despite this, did not prevent pulmonary arterial hypertension in a 
monocrotaline rat model of the disease.  
An apelin mimetic peptide possessing an unnatural amino acid, MM202, conjugated 
chemically via a polyethylene glycol linker to an anti-serum domain antibody 
(AlbudAbTM) was also characterised. The product MM202-AlbudAbTM represents the 
first time an AlbudAbTM has been conjugated chemically to an unnatural peptide 
mimetic, providing protection from proteolysis and glomerular filtration. Importantly, it 
retained binding to albumin and demonstrated in vitro and in vivo activity at the apelin 
receptor. 
In conclusion, this thesis has identified and pharmacologically characterised two novel 
apelin agonists that possess significant advantages over the endogenous peptides. 
CMF-019 is suitable as an experimental tool compound and, as the first G protein 
biased small molecule, provides a starting point for more suitable therapeutics. In 
addition, MM202-AlbudAbTM proves that unnatural peptides can be conjugated to 
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human LV (●), rat whole heart (■) and mouse whole heart (▲) 
homogenates with increasing concentrations of [Pyr1]apelin-13. 
p.81 
Figure 3.3 Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to 
human LV homogenates with increasing concentrations of either 
CMF-013, -015, -019 or -021. 
p.82 
Figure 3.4 Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to rat 
whole heart (■) and mouse whole heart (▲) homogenates with 
increasing concentrations of CMF-019. 
p.83 
Figure 3.5 Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to 
human LV homogenates with increasing concentrations of CMF-
087. 
p.83 
Figure 3.6 Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to 
human LV (●) and rat whole heart (■) homogenates with 
increasing concentrations of MM239 or MM240. 
p.84 
Figure 3.7 Pathway selectivity of ▲ CMF-013, ▼ -015, ■ -019 and ♦ -021 in 
CHO cell-based assays measuring β-arrestin recruitment and 





Figure 3.8 ▲ CMF-013, ▼ -015, ■ -019 and ♦ -021 in a U20S cell-based 
internalisation assay compared to the endogenous agonist ● 
[Pyr1]Apelin-13. 
p.85 
Figure 3.9 ■ CMF-087, ▲ MM239 and ▼ MM240 in CHO cell-based assays 
measuring β-arrestin recruitment and cAMP inhibition compared 









Figure 3.11 A series of regression analyses between functional signalling 
assays, ΔΔLogR values and binding affinities to the native apelin 
receptor in human LV homogenates. 
p.96 
Figure 3.12 Computational docking of CMF-019 into a homology model of the 
apelin receptor. 
p.100 
Figure 3.13 The scaffold structures of five reported series of small molecule 
apelin agonists from Amgen, Bristol-Myers Squibb, RTI 
International, Sanford-Burnham and Sanofi.  
p.103 
Figure 3.14 The apelin receptor structure from PDBID 5VBL (Ma et al. 2017) 
with docked poses of five series of apelin agonists.  
p.104 
Table 3.1 Values of ΔLogR and Relative effectiveness (RE) for CMF-019 
compared to [Pyr1]apelin-13 in β-arrestin, internalisation and 
cAMP assays. 
p.88 
Table 3.2 ΔΔLogR and bias factors (BF) for CMF-019 compared 
[Pyr1]apelin-13 in β-arrestin, internalisation and cAMP assays. 
p.88 
Table 3.3 Ki and pKi values for all apelin agonists compared to [Pyr1]apelin-
13 in radioligand competition binding assays performed either in 
cells expressing the human apelin receptor (Cerep) or in 
homogenates of heart tissue from humans, rats or mice.  
p.90 
Table 3.4 EC50, pD2, ΔΔLogR and bias factors for all apelin agonists 













4. In Vivo Cardiovascular Assessment of [Pyr1]apelin-13 
and CMF-019 Responses in Normotensive Male Sprague-
Dawley Rats 
 
Figure 4.1 An example baseline PV loop. p.106 
Figure 4.2 Chemical structure of the potassium salt of CMF-019. p.108 
Figure 4.3 Dosing schedule for the second acute in vivo study of CMF-019. p.109 
Figure 4.4 An example trace showing cardiovascular responses to saline 
and [Pyr1]apelin-13 (50nmol) in vivo in one male Sprague-Dawley 
rat. 
p.110 
Figure 4.5 Cardiovascular responses to [Pyr1]apelin-13 (50nmol n=32, 
400nmol n=10) or saline (n=17 and 10, respectively) 
administration in vivo. 
p.112 
Figure 4.6 The cardiac contractile responses to CMF-019 and [Pyr1]apelin-
13 in vivo in the first acute study. 
p.113 
Figure 4.7 Cardiovascular responses to CMF-019 and [Pyr1]apelin-13 in vivo 
in the first acute study. 
p.114-5 
Figure 4.8 The cardiac contractile response to CMF-019 and [Pyr1]apelin-13 
in vivo in the second acute study. 
p.116 
Figure 4.9 The arterial pressure change in response to CMF-019 and 
[Pyr1]apelin-13 in vivo in the second acute study. 
p.117 
Figure 4.10 Cardiovascular responses to CMF-019 and [Pyr1]apelin-13 in vivo 
in the second acute study. 
p.118-9 
Figure 4.11 Cardiovascular responses to [Pyr1]apelin-13 at 50nmol 
administered as a fourth dose following three cumulative doses of 
either saline (pH9), CMF-019 or [Pyr1]apelin-13 in vivo in the 
second acute study. 
p.120-1 
Figure 4.12 PV loops demonstrating artificial elevation of the end-systolic 
pressure due to catheter movement into the endocardial wall 
following a single 150nmol dose of ELA-32, a very powerful 
inotrope through the apelin receptor. 
p.124 







5. CMF-019 and MM07 as Disease-Modifying Compounds 
for Pulmonary Arterial Hypertension In Vitro and In Vivo 
 
Figure 5.1 Dot plot of the percentage of annexin+/PI- stained human PAECs 
with mean±SEM data superimposed for ‘control’ (EBM-2 
2%FBS), ‘apoptotic’ (TNFα/CHX) or cells pre-treated with 
rhVEGF (10ng/mL) or [Pyr1]apelin-13 (10µM) prior to induction of 
apoptosis with TNFα/CHX. 
p.135 
Figure 5.2 Dot plots of annexin staining vs PI staining in human PAECs when 
‘healthy’ (EGM-2 10% FBS), ‘control’ (EBM-2 2% FBS), 
‘apoptotic’ (TNFα/CHX) or pre-treated with rhVEGF (10ng/mL), 
[Pyr1]apelin-13 + PIC or PIC only prior to induction of apoptosis 
with TNFα/CHX. 
p.136 
Figure 5.3 Dot plot of the percentage of annexin+/PI- stained human PAECs 
with mean±SEM data superimposed when ‘healthy’ (EGM-2 
10%FBS), ‘control’ (EBM-2 2% FBS) or treated with rhVEGF 
(10ng/mL) or [Pyr1]apelin-13 (10µM). 
p.137 
Figure 5.4 Dot plot of the raw percentage of annexin+/PI- stained human 
PAECs with mean±SEM data superimposed when ‘control’ (EBM-
2 2% FBS), ‘apoptotic’ (TNFα/CHX) or pre-treated with rhVEGF, 
MM07 (10µM) or CMF-019 (1-10µM) prior to induction of 
apoptosis with TNFα/CHX. 
p.138 
Figure 5.5 Dot plot of the percentage of annexin+/PI- human PAECs with 
mean±SEM data superimposed when ‘healthy’ (EGM-2 
10%FBS), ‘control’ (EBM-2 2%FBS) or treated with rhVEGF 
(10ng/mL), MM07 (10µM) or CMF-019 (1-10µM). 
p.139 
Figure 5.6 Terminal (day 21) measurements from a rat MCT-induced model 










6. An Apelin Mimetic Peptide, MM202, Linked to an Anti-
Serum Albumin Domain Antibody (AlbudAbTM) is 
Efficacious In Vitro and In Vivo 
 
Figure 6.1 The structures of the endogenous peptides, [Pyr1]apelin-13 and 
apelin-17, the analogue, MM202, and the MM202-AlbudAbTM 
construct. 
p.149 
Figure 6.2 Concentration vs absorbance at 450nm for [Pyr1]apelin-13, 
MM202 and MM202-AlbudAbTM in an ELISA. 
p.152 
Figure 6.3 Competition radioligand binding of the endogenous peptides 
[Pyr1]apelin-13 and apelin-17, as well as the synthetic peptide 
MM202 and its albudAb™ conjugate against 
[Glp65,Nle75,Tyr77][125I]apelin-13 in human LV homogenates. 
p.154 
Figure 6.4 The functional activities of the endogenous peptides [Pyr1]apelin-
13 and apelin-17, as well as the synthetic peptide MM202 and its 
AlbudAb™ conjugate in human apelin receptor expressing CHO 
cell β-arrestin recruitment (A) and cAMP inhibition assays (B). 
p.155 
Figure 6.5 In vivo cardiovascular responses in normotensive male Sprague-
Dawley rats to administration of either saline (n=12) or MM202-
albudAb™ (5nmol, n=15). 
p.157 
Figure 6.6 In vivo cardiovascular responses in normotensive male Sprague-
Dawley rats to administration of [Pyr1]apelin-13 (50nmol, n=12) 
following a dose of either saline (n=3) or MM202-albudAb™ 
(5nmol, n=9). 
p.159 
Figure 6.7 A time-course of concentrations of apelin-like cross-reactivity 
(mean±SEM) measured in plasma samples (n=3) when spiked 
with 3nmol/L or 0.3nmol/L of either [Pyr1]apelin-13, MM202 or 
MM202-AlbudAbTM. 
p.160 
Figure 6.8 Terminal (day 21) measurements from an MCT-induced model of 
PAH assessing MM202-AlbudAbTM as a preventative therapeutic 
agent. 
p.162 
Figure 6.9 Plasma concentrations of apelin-like cross-reactivity measured in 
an ELISA from end-point plasma samples collected following 
chronic IP administration of MM202-AlbudAb™ in rats twice 




Table 6.1 Average changes in cardiovascular parameters from baseline 
values following bolus administration of MM202 (5-50nmol, n=2). 
p.156 







The apelin receptor is a class A G protein coupled receptor (GPCR) identified in 1993 
(O'Dowd et al., 1993) and paired with its cognate ligand apelin in 1998 (Tatemoto et 
al., 1998). Since then, there has been a large body of work studying the relationship 
between the ligand and receptor, as well as their physiological and pathophysiological 
roles in a number of diseases. Only recently has an additional ligand at the apelin 
receptor been discovered. Elabela/Toddler is a 54 amino acid peptide which is cleaved 
to produce a 32 amino acid mature secreted protein (Chng et al., 2013, Pauli et al., 
2014). Here the preferred nomenclature that will be used is elabela (ELA), following 
the precedence of discovery (Chng et al., 2013).  ELA is an endogenous ligand and 
functional in the adult mammalian system (Yang et al., 2017b). Interestingly, although 
it shows little sequence homology to apelin with only about 25% conservation (Xie et 
al., 2014), there is some similarity in the location of hydrophobic residues. 
The discovery of this new ligand opens up a number of exciting possibilities. It greatly 
enhances the spatiotemporal signalling potential through the apelin receptor and how 
it is modulated in disease, with evidence that ELA is downregulated in human 
pulmonary arterial hypertension and animal models of the disease already 
demonstrated (Yang et al., 2017b). Meanwhile, it also offers the possibility to explore 
a new class of ligand at the apelin receptor based on the structure of ELA. However, 
perhaps most of all, it suggests that, in addition to ELA, there may be other genes of 
pharmacological importance located in regions of the genome that have previously 
been overlooked.  
This introduction will discuss the structure and signalling pathways of the apelin 
receptor and its endogenous ligands, apelin and ELA, before moving on to the 
developments that have occurred for the production of synthetic agonists and 
antagonists. It will discuss some of the roles that apelin and ELA have been shown to 
play in both physiological and pathophysiological conditions; therefore, highlighting the 
importance of the two ligands and the therapeutic potential of targeting the apelin 
system. Finally, it will explore concepts designed to improve the therapeutic targeting 
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of the apelin system, such as the development of biased agonists and peptide-antibody 
























1.2 Apelin Receptor Structure 
The human apelin receptor has a seven transmembrane structure and consists of 380 
amino acids. It was initially identified through homology with the angiotensin II type 1 
receptor (AT1) with which it shares 54% sequence similarity. Despite this homology 
the apelin receptor does not bind angiotensin and, until the recent discovery of ELA, 
was thought to bind only its cognate ligand, apelin. There are no known apelin receptor 
subtypes in mammals and the receptor is well conserved with 91% and 89% homology 
with the 377 amino acid long mouse and rat receptors, respectively. In the zebrafish, 
there are two receptor subtypes, aplnra and aplnrb. Aplnrb shows greater homology 
with mammalian apelin receptors and it is in this receptor that the only known naturally 
occurring mutation occurs, the grinchs608 mutation. This mutation involves a Trp85 to 
Leu85 amino acid change in the second transmembrane domain and a loss of apelin 
binding which, in the most severely affected mutants, causes a failure of the heart to 
develop (Scott et al., 2007). It is unknown whether the second zebrafish apelin receptor 
is a result of duplication or whether mammalian systems have lost this as a vestigial 
receptor, perhaps offering an explanation for the limited homology between apelin and 
ELA.   
Ma et al. (2017) have recently reported the 2.6-Ångstrom resolution crystal structure 
of the human apelin receptor in a complex with a synthetic 17-amino-acid apelin 
analogue agonist. The receptor shows the expected seven transmembrane helical 
structure with a short eighth helix also observed in other GPCRs. The structure is in 
reasonable agreement with studies using nuclear magnetic resonance (Langelaan et 
al., 2013) and molecular dynamics simulations (Macaluso and Glen, 2010, Yang et al., 
2017b). However, a number of changes to the receptor and ligand were introduced to 
achieve crystallisation and it is worth noting some caveats that prompt a cautious 
interpretation of the data. Looking at the receptor, residues were removed from the N-
terminus (residues 1–6) and C terminus (residues 331–380); meanwhile mutations 
V117A and W261K were introduced. These mutations force the intracellular portion 
into an inactive state and render the receptor unable to bind apelin-13. Looking at the 
ligand, a synthetic 17-amino-acid apelin analogue agonist was used, which is 
significantly different from apelin. In particular, a macrocycle and significant mutations 
have been introduced to it and these may alter the peptide conformation and its 
interactions. Finally, the crystal structure is unable to explain the importance of the 
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Arg2 and Leu5 residues of apelin 13, known key binding elements from mutation data 
(Fan et al., 2003, Medhurst et al., 2003). 
Although the structure confirms the presence of two disulphide linkages present in a 
number of class A GPCRs (Cys19-Cys281 and Cys102-Cys181), it does not clarify the 
importance of post-translational modifications in the apelin receptor. The receptor is 
likely to be glycosylated (Medhurst et al., 2003) and contains two glycosylation motifs 
expected at residues in the N-terminal tail (Asn15) and ECL2 (Asn175), both of which 
appear to be involved in agonist binding. Glycosylation is known to be significant in 
GPCR function (Lanctot et al., 1999) and, in some cases, affects agonism and bias 
(Soto et al., 2015) but its importance in the case of the apelin receptor is not known. In 
addition, there are a number of potential palmitoylation sites in the intracellular C-
terminal region of the receptor. Based on predictions from the SwissPalm protein S-
palmitoylation database (Blanc et al., 2015) and CSS-Palm (Ren et al., 2008), residues 
Cys325 and Cys326 on the putative helix TM8 are expected to be palmitoylated. 
Palmitoylation is key in GPCR expression and function (Qanbar and Bouvier, 2003). 
Finally, the C-terminus appears to contain a “phosphorylation barcode” (Nobles et al., 












1.3 Apelin Receptor Signalling in the Cardiovascular System 
Infusion of apelin leads to vasodilatation, in humans in vitro (Maguire et al., 2009) and 
in vivo (Brame et al., 2015) and in rodents in vivo (Tatemoto et al., 2001), as well as 
cardiac inotropy in vitro (Maguire et al., 2009, Perjes et al., 2014, Szokodi et al., 2002) 
and in vivo in rats (Atluri et al., 2007, Berry et al., 2004, Jia et al., 2006), mice (Ashley 
et al., 2005) and humans (Japp et al., 2008) without hypertrophy. Interestingly, in 
denuded vessels, apelin promotes vasoconstriction (Katugampola et al., 2001, 
Maguire et al., 2009) and it is only in intact tissues that the endothelium-dependent 
vasodilatation is observed. This endothelium-dependent vasodilatation has been 
suggested to be either nitric oxide-dependent (Tatemoto et al., 2001) or prostanoid-
dependent (Maguire et al., 2009), perhaps reflecting species or whole organism versus 
isolated vessel differences.  
Figure 1.1: The key signalling pathways suspected to be activated in vascular endothelial cells (VEC) 
and smooth muscle cells (VSMC) by the apelin receptor. Apelin binding can promote Gαi, Gαq and β-
arrestin recruitment to the receptor. In the presence of the endothelium, both Gαi and Gαq promote 
relaxation of smooth muscle cells through nitric oxide and prostacyclin release. In the absence of the 
endothelium, apelin binds directly to the receptor on the smooth muscle cells and leads to constriction 
through undetermined intermediate steps but most likely involving PKC, phosphoinositide 3-kinase 
(PI3K) and myosin light chain phosphorylation. Figure taken from Yang et al., (2015a).  
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Mechanistically, these processes are poorly understood, although the apelin receptor 
is thought to signal primarily through Gαi, leading to decreased intracellular cyclic 
adenosine monophosphate (cAMP) by inhibition of adenylyl cyclase, as evidenced by 
inhibition of forskolin-stimulated cAMP production (Habata et al., 1999) and pertussis 
sensitivity (Hosoya et al., 2000, Masri et al., 2002). Figure 1.1 shows a summary of the 
possible downstream pathways activated following Gαi activation by the apelin receptor 
as  suggested by (Yang et al., 2015a).  
As well as activating Gαi, there is also significant evidence that the apelin receptor may 
couple Gαq, particularly in cardiomyocytes (Szokodi et al., 2002), promoting 
phospholipase C (PLC) and, in turn, inositol triphosphate (IP3) and protein kinase Cε 
(PKCε, but not PKCα; Perjes et al., 2014). IP3 activates IP3 receptors (IP3R) and Ca2+ 
release, which can feed-back to ryanodine receptors (RyR); leading to calcium induced 
calcium release (CICR). PKCε might enhance Na+-H+ exchange (NHE) on the 
sarcolemma; thus, increasing intracellular Na+ and consequently, enabling the Na+-
Figure 1.2: The key signalling pathways suspected to be activated in cardiomyocytes by the apelin 
receptor. Apelin binding can promote Gαi, Gαq and β-arrestin recruitment to the receptor, these pathways 
are thought to ultimately lead to cardiac inotropy without hypertrophy. However, in the absence of 
apelin, β-arrestin recruitment may lead to stretch-mediated hypertrophy.  
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Ca2+ exchanger (NCX) to raise intracellular Ca2+ concentrations (Chandrasekaran et 
al., 2008). It has also been suggested that mitogen activated protein kinase (MAPK) 
and extracellular signal regulated kinases 1/2 (ERK1/2) can regulate cardiac 
contractility through an independent mechanism (Perjes et al., 2014), though how this 
pathway is activated or increases contractility is not clear. Finally, it has also been 
suggested that apelin can activate myosin light chain kinase (MLCK), which can 
phosphorylate the regulatory light chain (RLC) of myosin II resulting in greater Ca2+ 
sensitivity of the force generating machinery (Perjes et al., 2014). These pathways are 



































































































































1.4 Endogenous Agonists 
To date, two endogenous peptide agonists have been identified at the apelin receptor, 
apelin and ELA. Though they show limited sequence homology, they have similarity in 
the location of hydrophobic residues and can be docked into the same binding pocket 
in a molecular dynamics simulation of the receptor (Figure 1.3). Apelin was discovered 
in bovine stomach extracts by Tatemoto et al. in 1998, since then there has been 
significant advance in our understanding of the isoforms of apelin and their binding to 
the apelin receptor. ELA, however, has only been discovered relatively recently by two 
groups working independently (Chng et al., 2013, Pauli et al., 2014) and as such, there 
is still much to be learnt about its endogenous isoforms and interactions at the apelin 
receptor. The important question of why there are two endogenous ligands for the 














Figure 1.3: An overlay of ELA-11 (green) and apelin-13 (blue) docked in the apelin receptor binding 
pocket. The peptide sequences are shown alongside with the same colour scheme. The red amino acids 




Apelin is expressed as a 77-amino acid pre-protein, pre-pro-apelin, consisting of the 
55-amino acid pro-apelin fragment and an N-terminal secretory sequence. Following 
secretion, pro-apelin is cleaved to produce three main apelin fragments; apelin-36, 
apelin-17 and apelin-13, the last of which can undergo cyclisation of the glutamine at 
its N-terminus to produce pyroglutamated apelin-13 ([Pyr1]apelin-13; Figure 1.4) (Pitkin 
et al., 2010). It was originally hypothesised that cleavage occurred sequentially with 
pro-apelin first cleaved to apelin-36 and then in turn to the smaller apelin-17 and apelin-
13 fragments, always retaining the bioactive C-terminus. These cleavages were 
predicted due to expected basic cleavage sites in the peptide sequence and the 
identification of apelin-36, -17 and -13 as active sequences found in biological samples 
(Kleinz and Davenport, 2005). However, because of this, the enzymes involved are not 
well characterised and warrant further investigation. This is especially true for the 
production of apelin-36 and -17. Recently, Shin et al. (2013) proposed that furin can 
directly cleave pro-apelin to apelin-13 in vitro without producing these longer isoforms. 
Apelin-36 is also cleaved by angiotensin converting enzyme 2 (ACE2) with high 
catalytic efficiency to remove the C-terminal phenylalanine. Similarly, apelin-13 can be 
cleaved by ACE2 to produce apelin-13(1-12) (Vickers et al., 2002). Interestingly, apelin-
13(1-12) retains activity as demonstrated by recruitment of β-arrestin to the apelin 
receptor in vitro, constriction of saphenous vein ex vivo and positive inotropy and blood 
pressure decrease in vivo. However, most critically it was also able to induce an 
increase in forearm blood-flow in human volunteers (Yang et al., 2017a). Additional 
support for this is evidenced by the retention of activity when the terminal phenylalanine 
of apelin-13 is mutated to alanine (Fan et al., 2003, Medhurst et al., 2003, Yang et al., 
2017a) and furthermore C-terminal truncation studies have suggested activity is 
retained even as far as apelin-13(1-11) (Zhang et al., 2014). This last study also reported 
that the N-terminal glutamine in position 1 is not essential for binding either, suggesting 
that the 10-amino acid apelin-13(2-11) fragment is the smallest active fragment (Zhang 
et al., 2014). Although the N-terminal glutamine residue is not essential to binding, the 
cyclisation to pyroglutamate is widely observed in vivo and enhances the stability of 
the peptide fragment (Habata et al., 1999, Van Coillie et al., 1998). Interestingly, while 
the C-terminal amino acids of apelin-36 make the smallest active fragment for binding 
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to the apelin receptor, it has been suggested that N-terminal portions may aid the 






Having considered the smallest active fragments of apelin, it is important to discuss 
how the different fragments bind to the receptor and maintain activity to inform the 
development of synthetic molecules. Deductions of apelin binding have been largely 
achieved through alanine scanning mutagenesis and receptor modelling approaches; 
a crystal structure has only very recently been reported (Ma et al., 2017). It was initially 
found that mutating the arginine residues in positions 2 and 4 of the apelin peptide 
greatly reduced the ability of the fragment to bind to the receptor (Fan et al., 2003, 
Medhurst et al., 2003). This, alongside the detrimental effect of mutating the lysine in 
position 8, suggested the importance of positive charge on the apelin peptide for 
interacting with the receptor (Fan et al., 2003). Indeed, concurrent studies utilising the 
receptor identified that the second ten N-terminal residues of the apelin receptor are 
essential to interact with the ligand. These residues are largely negatively charged, 
with the N-terminus of the apelin receptor possessing a net charge of -7, supporting 
the hypothesis that ionic interactions play a critical role in apelin binding to its receptor 
(Zhou et al., 2003a). Meanwhile, Medhurst and colleagues reported that the largest 
loss of binding observed in their alanine mutagenesis studies occurred with loss of 
leucine in position 5 and postulated that the ‘RPRL’ motif from positions 2-5 plays a 
critical role in apelin binding. Macaluso and Glen (2010) confirmed the importance of 
the RPRL motif through elegant cyclisation experiments. They showed that the RPRL 
sequence produces a favourable β-turn motif which is essential in interaction with the 
apelin receptor, indeed, when they locked the peptide in an unfavourable turn at the 
Figure 1.4: The amino acid sequences of cleaved apelin fragments. [Pyr1]apelin-13 is the most 
abundant form in the cardiovascular system and is shown in red with the pyroglutamate residue in pink. 
The smallest active fragment is highlighted, as well as the RPRL motif which has been thought critical 
to binding.  
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RLSH sequence, these cyclised peptides were unable to bind the receptor efficiently 
despite higher sequence homology to the endogenous agonist.  
Recent studies have found support for both ionic and RPRL sequence interactions and 
propose a two-step binding process for apelin peptides to the receptor. First initial ionic 
interactions occurring between the N-terminal tail of the receptor and the ligand 
promote binding of the ligand to the receptor. Following this, the ligand moves deeper 
into the binding pocket where it is able to find more stable interactions and promote 
receptor activation (Gerbier et al., 2015, Langelaan et al., 2013, Iturrioz et al., 2010b). 
This greater understanding of how apelin peptides bind to the receptor has informed 
the design of a number of synthetic agonists based on the apelin sequence and these 
will be discussed in Section 1.5.  
As well as binding the receptor differentially, the different length fragments may 
activate different pathways at the receptor, leading to different signalling bias. It is 
important to understand this as any differences could be exploited physiologically by 
enhanced production of one isoform in a given tissue or at a given time. Additionally, 
the endogenous bias observed could also be utilised to inform the development of 
synthetic biased molecules. One area which has been explored is the rate of 
internalisation and recycling of receptor-ligand complexes, which appear to be highly 
ligand dependent (Lee et al., 2010, Zhou et al., 2003a). Lee et al. (2010) demonstrated 
that apelin-13 mediated internalisation could be rapidly reversed when washed out; 
however, apelin-36 resulted in more prolonged receptor internalisation. El Messari et 
al. (2004) have also reported that apelin-17 is better able to recruit β-arrestin and 
internalise the receptor than apelin-13. Meanwhile, it has been shown that loss of the 
C-terminal phenylalanine can induce bias towards G protein signalling (Ceraudo et al., 
2014). These studies, therefore, suggest that longer length peptides are able to reach 
a binding pocket that is not accessible to the shorter apelin-13 isoform to induce β-
arrestin recruitment and internalisation. This is further supported by longer length ELA 
peptides also possessing β-arrestin bias (Yang et al., 2017b). Accessing this deeper 
pocket in the receptor likely leads to the ultimate phosphorylation of the C-terminal 
Ser348 residue which when mutated, showed abolition the G protein receptor kinase/ 
β-arrestin pathway signalling, whilst preserving signalling through the G protein 
pathway (Chen et al., 2014). It is interesting that β-arrestin recruitment and 
internalisation of the apelin receptor appear to be mediated by only one 
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phosphorylation site and not by a more complex ‘phosphorylation barcode’ as 
suggested with other GPCRs (Tobin et al., 2008, Butcher et al., 2011). Furthermore, it 
has been suggested that the β-arrestins are not internalised with the ligand-receptor 
complex, unlike for some other GPCRs (Evans et al., 2001).  
1.4.2 Elabela 
The endogenous agonist, ELA, was named following its discovery (Chng et al., 2013). 
It was independently given the name ‘toddler’ following its discovery as a motogen 
during gastrulation (Pauli et al., 2014). Previously, it had been designated Ende when 
studied as a novel transcript involved in the development of mouse endoderm (Hassan 
et al., 2010). Since then the gene encoding the peptide has been renamed apela 
(apelin receptor early endogenous ligand) by the HUGO (human genome organisation) 
gene nomenclature committee (HGCN).  
Interestingly, ELA was identified in a previously designated non-coding region of the 
genome and had already been predicted due to discrepancies between apelin and 
apelin receptor mutations (Charo et al., 2009). Notably, knock-outs of the apelin 
receptor in mice caused pre-natal mortality (Ishida et al., 2004, Roberts et al., 2009, 
Charo et al., 2009, Scimia et al., 2012, Kang et al., 2013) due to disrupted cardiac 
development with rudimentary or no heart (Kang et al., 2013). In contrast, apelin knock-
outs had normal heart development (Kidoya et al., 2008, Charo et al., 2009), though 
they were at greater risk from age-related and induced disease (Kuba et al., 2007). 
Studies exploring ELA knock-outs in zebrafish found that these phenocopied the apelin 
receptor mutations (Chng et al., 2013, Pauli et al., 2014). Furthermore, it has been 
shown that during development, the apelin receptor was expressed during gastrulation, 
at the same time as ELA whereas, apelin was not expressed until the end of 
gastrulation (Pauli et al., 2014, Scott et al., 2007). While this ligand was first discovered 
in zebrafish embryos as a factor involved in cardiac development, it has since been 
shown to have activity in adult mammalian systems (Murza et al., 2016, Perjes et al., 
2016, Yang et al., 2017b) and its expression is altered in disease (Yang et al., 
2017b).During its discovery in zebrafish development, ELA was found to be a 54 amino 
acid peptide which was cleaved to produce a 32 amino acid mature secreted protein. 
This mature protein was in turn predicted to undergo cleavage by furin to produce two 
more fragments of length 21 and 11 amino acids  (Chng et al., 2013, Pauli et al., 2014), 
all of which have been pharmacologically characterised by Yang et al. (2017b; Figure 
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1.5). Murza et al. (2016) have also suggested fragments of 22 and 14 amino acids with 
a potential 23 amino acid variant. It is notable that the 11 amino acid fragment is 
invariant between species suggesting strong evolutionary conservation. Interestingly, 
ELA is more strongly positively charged than apelin and also displays higher binding 
affinities to the receptor at corresponding fragment sizes (Table 1.1), lending support 









Figure 1.5: The amino acid sequences of the predicted cleaved ELA fragments compared to 
[Pyr1]apelin-13, the most abundant apelin isoform in the cardiovascular system. There is little sequence 
homology between ELA and apelin fragments; however, there are some similarities in the positioning of 
charged residues. Disulphide bridges are yellow lines, hydrophobic amino acids are shown in green, 
uncharged polar amino acids in pink, basic amino acids in blue and pyroglutamate in red. Figure taken 
from Yang et al. (2017b). 
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1.5 Synthetic Agonists 
Given the evidence that apelin treatment can be beneficial in a number of models of 
disease (discussed below), it is unsurprising that there have been many attempts to 
produce synthetic apelin agonists with improved characteristics. Such improvements 
have largely focused on increasing half-life due to the potential limitations of apelin 
therapeutically as a short-lived peptide. Many of these efforts have produced modified 
peptides based on the smallest active fragments of apelin, employing techniques such 
as polyethylene glycol (PEG-)ylation, the addition of unnatural amino acids and 
cyclisation. One anticipates that soon modified peptides based on the structure of the 
ELA will be identified and characterised. Finally, while small molecule synthetic 
agonists would prove to be most useful, only a few small molecule agonists have been 
reported and these have generally proven unsuitable for experimental or therapeutic 
use.  
1.5.1 Peptide Modifications 
PEGylation of certain drugs has previously been shown to improve their 
pharmaceutical properties and has led to 12 drugs in the clinic since 1990 (Turecek et 
al., 2016).  For peptides these benefits for the most part consist of an improvement in 
half-life through shielding from proteolytic enzymes. Attempts to PEGylate apelin have 
met with reasonable success. Jia et al. (2012) demonstrated that PEGylation of apelin-
12 resulted in a 400-fold loss in binding affinity but that N-terminal PEGylation of apelin-
36 with a 40kDa PEG conjugate was tolerated. Moreover, in vivo assessment of 
ventricular ejection fraction following 20 minute infusion showed maintained potency. 
These inotropic effects could still be observed 100 minutes following cessation of 
infusion, whereas the response was already lost after 30 minutes using the 
endogenous peptide. In another study, Murza et al. (2012) illustrated that modification 
of C-terminal and central amino acids by addition of (PEG)4, (PEG)6 and (Ala)4 linkers 
to apelin-13 was able to extend plasma stability. These studies support PEGylation as 
a means to improve the plasma stability of apelin peptides without compromising 
functionality if the modifications are made appropriately.   
The addition of unnatural amino acids can help to improve stability and potency. For 
apelin-13 the key modifications have generally been made at the C-terminus as this is 
where cleavage by ACE2 occurs to remove phenylalanine. Wang. et al. (2013b) 
reported two apelin analogues which were resistant to cleavage of this phenylalanine 
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residue and identified that one was effective as an apelin mimetic being able to protect 
against ischaemia-reperfusion injury both in vivo and ex vivo. Similarly, Murza et al. 
(2015) focussed on replacing the terminal phenylalanine with unnatural amino acids 
and identified several peptides with improved affinity. In particular, the use of large 
aromatic groups significantly improved binding with F13Tyr(OBn) displaying a 60-fold 
improvement over the native peptide and remarkably, the alpha methylated D-
analogue, F13(αMe)DTyr(OBn), displaying picomolar affinity. Interestingly, they 
reported that these molecules were more effective than apelin-13 in preventing cAMP 
accumulation but were equipotent in β-arrestin recruitment, suggesting that 
modifications at the C-terminus of the apelin peptide may be important for imparting 
biased signalling properties. Recently, a group has reported that through a combination 
of using unnatural amino acids and lipidation of apelin-13, they were able to produce 
an apelin agonist with a greatly enhanced in vitro half-life of 29 hours in rat plasma 
(Juhl et al., 2016). Such a finding is remarkable, particularly since they report that the 
molecule maintains a high potency at the receptor.  
Cyclisation of peptides results in conformational restriction and can improve stability 
by preventing peptidase action, especially in small peptides, such as apelin, where 
there is ordinarily a large amount of free movement. Initial experiments showed that 
apelin-12 peptides when cyclised could retain potency in recombinant human apelin 
receptor expressing cell lines (Hamada et al., 2008). Experiments by Macaluso and 
Glen (2010), as discussed earlier, demonstrated the importance of the RPRL motif and 
some following attempts focussed on cyclisation around the RPRL motif. From this 
approach, MM07 (Figure 1.6) was identified by Brame et al. (2015) and showed greater 
stability over [Pyr1]apelin-13 with a half-life of 17 minutes compared to 2 minutes in rat 
plasma. Interestingly, this peptide also displayed bias at the receptor, an effect that 
was maintained in humans when tested using both Aellig hand-vein and forearm 




Figure 1.6: The amino acid sequence of MM07. The disulphide bridge is shown as a yellow line, 




Murza et al. (2017) have also reported on biased cyclised apelin-like peptides. Instead 
of cyclising around the RPRL motif they replaced His-7 and Met-11 with allylglycine 
and cyclised between these residues. They further replaced the C-terminal 
phenylalanine residue with Tyr(OBn) and produced various modifications upon this 
scaffold structure. They were able to display that replacement of the Tyr(OBn) residue 
with non-aromatic residues or transfer into the ring structure markedly reduced the 
ability to recruit β-arrestins. Such bias towards G protein signalling was similar to 
MM07; however, unlike MM07 which produced clear decreases in blood pressure in 
human volunteers, Murza et al. (2017) reported that their G-protein biased compounds 
had a reduced ability to induce hypotensive effects in rats. Such an observation is 
supported by the report of modified apelin-17 peptide fragments biased towards the β-
arrestin pathway which were more able to induce decreases in blood pressure in rats 
(El Messari et al., 2004). Of the compounds described by Murza et al. (2017), 
compound 18 is notable, despite its low micromolar affinity. This is due to its lack of 
the RPRL motif, a motif previously thought critical to binding. Additional studies that 
have looked at cyclisation away from the RPRL motif include a patent by Novartis 
(Golosov et al., 2013) producing peptides based on [Pyr1]apelin-13 with a range of 
bridging linkers including, esters, disulfides, amides, and short polyether bridges. Of 
these, some showed improved half-lives and a few were reported to possess similar 
potency to Pyr1]apelin-13. 
While many studies have focussed on unnatural amino acid addition, cyclisation and 
PEGylation as a means to improve the pharmacological properties of peptides, one 
very interesting study has looked at the use of pepducins. These are lipidated peptide 
sequences usually 8-16 amino acids in length and based on the structure of the 
intracellular loops of G-protein coupled receptors. McKeown et al. (2014) produced a 
complete array of N-lipidated 12-mer peptide sequences for the apelin receptor and 7 
demonstrated agonism at 1µM or 10µM and were resynthesized. One compound, 
designated compound 1, displayed activity and was found to be selective for the apelin 
receptor. This result was not unexpected given the sequence from which it was based 
is a poorly conserved region of the GPCR. Furthermore, to confirm selectivity they 
produced the peptide with D-amino acids as well as without the N-terminal palmitate 
lipidation and demonstrated a complete loss of activity. Such a unique approach is very 
interesting and could be widely applicable to drug discovery at orphan GPCRs. 
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1.5.2 Small Molecules 
While the above studies have produced a number of improved apelin peptide 
molecules, particularly with regards to enhanced plasma half-life, they still possess the 
limitations that all peptide therapies inevitably have, most notably poor oral 
bioavailability. Sufficient improvements in plasma half-life could reduce the impact of 
this and, as evidenced by diabetic therapy, daily injections are tolerable if necessary. 
However, the production of a small molecule apelin agonist would nevertheless have 
much greater potential therapeutically and could be used much more widely and easily 
as a pharmacological tool compound than a peptide. For these reasons there have 
been a number of attempts to produce a small molecule apelin agonist. Only relatively 
recently have suitable molecules started to emerge.  
One of the first reports of a peptidomimetic small molecule was E339-3D6 (Iturrioz et 
al., 2010a) which showed a reasonable affinity for the apelin receptor (Ki~400nM in 
radioligand binding experiments) and selectivity over other related GPCRs. However, 
with a molecular weight of 1400Da it is debatable whether it would qualify as a small 
molecule; moreover, it was later shown to be a mixture of polymethylated species 
(Margathe et al., 2014). The constituents of this mixture were separated and some 
were found to bind to the apelin receptor with improved affinity compared to the parent 
mixture, however, these affinities were still relatively low and the molecules too big.   
Another attempt to identify a small molecule agonists utilised a high-throughput screen 
of ~330,600 molecules and found ML233 (Khan et al., 2010). This molecule conformed 
to the traditional definition of a small molecule with a molecular weight of 359Da under 
the usual 500Da cut-off defined by Lipinski’s rules. Unfortunately, it showed poor 
solubility in saline at room temperature and its structure indicated it would likely be 
toxic through being both a Michael acceptor and possessing a reactive activated 
quinone group (Lagorce et al., 2015). Indeed observations in animal studies have 
supported this suspected toxicity (Pers. Comm. Yang, Maguire and Davenport).  
Recently, several studies and patents have reported the development of more suitable 
drug-like small molecules. Narayanan et al., (2016) used a drug library of 
approximately 100 compounds screened in a high-throughput Ca2+ mobilisation assay 
and identified four compounds based on the same structural scaffold which they 
designated compound 1. By experimenting with three key side chain sites, they 
explored the changes that were tolerated by the scaffold and suggested that this could 
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act as a starting point for the production of more suitable drug-like small molecules. 
While these molecules were small (molecular weight ~500Da), they possessed 
relatively low potencies in the micromolar range. The important question will be 
whether potency can be improved by side-chain experimentation or if it is a limit of the 
scaffold itself.  
1.5.3 Summary 
There have been significant advances in the development of synthetic agonists at the 
apelin receptor. Studies utilising peptide modification have been able to improve 
plasma stability and affinity through a variety of methods, including PEGylation, 
cyclisation and the addition of unnatural amino acids. Initial studies to identify small 
molecules have had significant issues and newer more suitable small molecules are 
required. Such molecules would be very useful as tool compounds and in the 


















































































































































































































1.6 Synthetic Antagonists 
Just as there has been much interest in the development of agonists at the apelin 
receptor, antagonists at the receptor have also been sought. So far, though a number 
have been described, there is still a need to find more suitable molecules for use both 
in in vitro and in vivo studies. Apelin antagonists might also possess therapeutic 
potential themselves and recently there has been interest in their use for the treatment 
of cancer due to their anti-angiogenic effects.  
One of the first antagonists described was F13A, an apelin analogue in which the C-
terminal phenylalanine was mutated to an alanine residue. Initially, De Mota et al. 
(2000) described alterations in the apelin peptide K17F (a 17 amino acid chain 
stretching from lysine (1) to phenylalanine (17) of the apelin sequence) and identified 
that the first four amino acids were not required for activity, thus, describing apelin-13. 
They further suggested that substitution of the terminal phenylalanine for alanine 
completely abolished activity. Lee et al. (2005) later described the antagonist activity 
of F13A in spontaneous hypertensive rats through the blockade of hypotensive 
responses induced by apelin. Despite these two studies suggesting F13A does not 
possess agonist activity and the latter describing it as an antagonist, other studies 
dispute this. Both Fan et al. (2003) and Medhurst et al. (2003) describe it in alanine 
mutagenesis studies as an agonist as discussed in Section 1.4.1. Fan et al. (2003) 
reported that F13A possessed equal potency to apelin-13 in inducing receptor 
internalisation, meanwhile, Medhurst et al. (2003) reported a decrease in both binding 
affinity to the apelin receptor (2-14-fold) and in potency in a FLIPR assay (8-fold). In a 
recent study, Yang et al. (2017a) also reported on the activity of F13A, demonstrating 
that it possessed similar activity to [Pyr1]apelin-13(1-12) in an in vitro β-arrestin 
recruitment assay and that it was also able to contract saphenous vein ex vivo with 
sub-nanomolar potency.  These studies suggest, therefore, that F13A retains agonistic 
activity and is not in fact an antagonist. Perhaps, the best explanation is that it acts as 
a partial agonist - this would explain its ability to antagonise hypotensive responses to 
apelin (Lee et al., 2005) and its agonist activity when tested on its own (Medhurst et 
al., 2003, Yang et al., 2017a).  
Another reported peptide antagonist is ALX40-4C (Zhou et al., 2003b). It was originally 
identified at the CXCR4 chemokine receptor in the context of HIV infection (it was 
through this that Zhou and colleagues identified its activity at the apelin receptor which 
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acts as a co-receptor for HIV infection; Section 1.7.6). They demonstrated direct 
binding to the receptor with an IC50 of 2.9µM and inhibition of internalisation induced 
by apelin. Despite antagonistic effects, there is little evidence that it could be used as 
a selective apelin antagonist. Indeed, it was identified initially as a CXCR4 antagonist 
and although its sequence of a string of highly charged amino acids might make it 
effectual in blocking the apelin receptor, it is unlikely to aid selectivity over other 
GPCRs. Without selectivity it is unlikely to find use either as a pharmacological tool 
compound or in therapy.  
A peptide agonist, MM54, designed based on known functionality of apelin sequences 
at the apelin receptor would be expected to show more promising selectivity (Macaluso 
et al., 2011). Macaluso and colleagues started with the RPRL motif to produce two 
cyclic ‘anchors’ with a dipeptide linker in between. They hypothesised that the linker 
could be altered to act as a ‘switch’, thus, alternating receptor stabilisation between 
agonist and antagonist states. MM54, bound to the human apelin receptor in left 
ventricular (LV) heart homogenates with micromolar affinity (KD = 3.42µM) and was 
able to competitively antagonise [Pyr1]apelin-13 in cAMP accumulation assays in 
Chinese hamster ovary (CHO)-K1 cells giving a similar affinity in Schild analysis (KD = 
1.32µM). While the affinity of MM54 is not especially high, the fact that it is a designed 
apelin antagonist should aid in the development of new antagonists based on the same 
structure. Recently Harford-Wright et al. (2017) have reported on the use of MM54 to 
treat glioblastoma. In this study, they tested MM54 for selectivity for the apelin receptor 
by screening it in radioligand binding assays against a panel of 55 other GPCRs or ion 
channels. They found that MM54 at 10µM inhibited 50% of agonist binding in apelin 
and only 6 other potential off-target receptors. 
A small molecule, ML221, displayed antagonistic action in the micromolar range to 
both cAMP and β-arrestin signalling through the apelin receptor (Maloney et al., 2012). 
However, it showed a poor pharmacokinetic profile with very limited solubility in 
aqueous media at pH7.4 and poor stability. Despite these drawbacks, it could still be 
useful for in vitro studies and has good selectivity for the apelin receptor, only showing 
significant activity at the benzodiazepinone and κ-opioid receptors. Its use is not 
recommended for in vivo studies as it has been observed to possess high toxicity 
(Pers. Comm. Yang, Maguire and Davenport).  
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Most recently, the U.S Food and Drug Administration (FDA)-approved compound, 
protamine, has been identified as an antagonist at the apelin receptor (Le Gonidec et 
al., 2017). This compound is usually used after cardiac surgery as it binds to heparin 
and therefore, reverses anticlotting activity. The study demonstrates a binding affinity 
of 390nM at the apelin receptor and full antagonistic activities against both G protein 
and β-arrestin signalling, as well as against in vivo dilatation in mice. Screening against 
several other homologous GPCRs, such as, the AT1 receptor suggests some degree 
of selectivity. However, caution is advised as the structure of protamine is based on a 
series of highly positively charged arginine residues and is reminiscent of ALX40-4C.  
There is still a need for a selective antagonist at the apelin receptor as currently 
available molecules possess limitations. Future studies will hopefully lead to selective, 

















1.7 Apelin Physiology and Pathophysiology 
1.7.1 Development  
ELA appears to be the principal developmental peptide at the apelin receptor. It was 
in part due to discrepancies in apelin receptor and apelin peptide knock-out zebrafish, 
as well as the fact that apelin is not expressed until much later in development than its 
receptor, that prompted the discovery of ELA (Pauli et al., 2014). Nevertheless, apelin 
has been shown to have some developmental roles. Kidoya et al. (2015) found that 
apelin through its receptor was important for arterial-venous alignment in the skin. They 
demonstrated that knock-out mice of both the receptor and peptide were less able to 
deal with hot or cold heat stress, suggesting an important role in thermoregulation.  
1.7.2 Cancer 
Apelin expression is elevated in a number of cancers, such as, lung non-small cell 
carcinomas, gastroesophageal, colon, hepatocellular, prostate, endometrial and oral 
squamous cell carcinoma. It induces endothelial cell migration and proliferation, 
supporting a role in tumour neoangiogensis; for a detailed review on the subject see 
Yang et al. (2016). The high expression of apelin in cancerous tissues raises the 
possibility of using it as a biomarker and clinical trials are underway to determine if a 
reduction in serum apelin levels can be used to assess the efficacy of bevacizumab 
treatment as a measure of tumour vasculature normalisation following similar 
observations in a mouse model (Zhang et al., 2016). 
Directly targeting the apelin receptor with antagonists could prove a useful therapy if 
used in appropriate combination with current market drugs. In a recent study, Harford-
Wright et al. (2017) reported on MM54 treatment of glioblastoma. They demonstrated 
that glioblastoma stem-like cells expressing higher apelin levels were better able to 
initiate tumour development. Furthermore, knocking down apelin with shRNA could 
reduce the number of progressing tumours in an in vivo implant model. They went on 
to look at pharmacological inhibition with MM54 and showed that it impaired the 
expansion of glioblastoma stem-like cells that were resistant to standard therapy in 
vitro. This translated to the in vivo tumour xenograft model with MM54 reducing tumour 
growth and promoting survival of transplanted mice. Interestingly, targeting the apelin 
receptor in this model proved beneficial by reducing vascularisation and proliferation 
in the tumour, however, another recent study has identified loss-of-function mutations 
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in the apelin receptor in patients refractory to immunotherapy (Patel et al., 2017). They 
showed a role for the apelin receptor in modifying T-cell responses through the JAK-
STAT pathway, leading to an augmentation of the interferon-γ response. This response 
appeared to be independent of canonical G protein signalling through the apelin 
receptor and whereas the authors demonstrated that knocking-down the apelin 
receptor in mouse melanoma models reduced the efficacy of T-cell-based therapies, 
they did not show whether an antagonist would do the same. This question should be 
addressed as, if the JAK-STAT response is ligand-independent, this could avoid the 
potential complication of apelin receptor blockade reducing host immune responses in 
cancer.  
1.7.3 Fibrosis 
Apelin is involved in fibrotic mechanisms in a number of tissues, including kidney, liver, 
heart and lung; for a detailed review see Huang S. et al. (2016). Intriguingly, apelin 
displays conflicting roles in these different tissues, protecting against renal, myocardial 
and pulmonary fibrosis, whilst potentially promoting liver fibrosis.  
In the kidney, plasma apelin levels are significantly lower in patients with autosomal 
dominant polycystic kidney disease compared to controls and apelin levels correlated 
with estimated glomerular filtration rate (Kocer et al., 2016). The mechanism by which 
apelin is protective has been suggested to involve transforming growth factor β (TGFβ) 
signalling with demonstrations that apelin is able to reduce renal interstitial fibrosis 
through suppressing tubular epithelial to mesenchymal transition via a smad-
dependent mechanism (Wang et al., 2014). Moreover, in a renal ischaemia/reperfusion 
model in rats, apelin was down-regulated and infusion of apelin-13 could reduce acute 
injury through suppressing of TGF- β1 (Chen et al., 2015). 
In addition to its involvement in renal fibrosis, TGFβ is known to have roles in numerous 
fibrotic mechanisms (Leask and Abraham, 2004) including in the myocardium 
(Koitabashi et al., 2011). A downstream miRNA of TGF- β, miR-125b, has been shown 
to be upregulated in cardiac fibrosis and to inhibit apelin (Nagpal et al., 2016). This 
supports a role for apelin down-regulation in fibrosis and provides a mechanism 
through which it may occur. It also suggests that apelin replacement could be 
beneficial. Indeed, it has been shown that infusion of various apelin isoforms is 
beneficial in several models of myocardial damage, for example, in mice with ligated 
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coronary arteries to induce infarction and subsequent cardiac hypertrophy and fibrosis, 
apelin-13 was protective (Li et al., 2012). Furthermore, apelin recruited bone marrow 
cells and adenovirally-mediated overexpression of apelin in these cells enhanced 
cardiac repair (Li et al., 2013). In isolated perfused rat hearts, infusion of apelin-12 
analogues were beneficial in reducing myocardial infarct size, cell membrane damage 
and cardiac dysfunction. This protection was associated with activation of various 
cellular kinases, leading to activation of numerous downstream targets including, nitric 
oxide synthase, mitochondrial KATP channels and the sarcolemmal Na+/H+ and 
Na+/Ca2+ exchangers (Pisarenko et al., 2015a). Additionally, these apelin-12 
analogues reduced reactive oxygen species, resulting in a reduction in cellular 
membrane damage (Pisarenko et al., 2015b). Other reports have suggested that 
apelin-13 can protect against in vivo myocardial ischaemia-reperfusion by inactivation 
glycogen synthase kinase 3β, preventing the opening of the mitochondrial permeability 
transition pore involved in the reperfusion injury salvage kinase pathway (Yang et al., 
2015b). In apoE-KO mice infused with angiotensin II to induce atherosclerosis of the 
coronary arteries, co-infusion of apelin-13 could activate nitric oxide and thereby, 
attenuate atherosclerosis of these vessels, as well as preventing vascular remodelling 
in a vein graft model (Chun et al., 2008).  
Pulmonary fibrosis occurs in many lung pathologies and there is evidence that apelin 
can help to prevent this from occurring. In a rat model of bronchopulmonary dysplasia 
(a chronic disease which normally occurs in premature infants treated with oxygen and 
positive pulmonary pressure) treated with apelin-13, pulmonary fibrin deposition and 
inflammation were reduced (Visser et al., 2010). Meanwhile, in a rat model of acute 
respiratory distress syndrome induced by oleic acid, apelin-13 treatment could reduce 
inflammation and lung injury. F13A also reduced oleic acid induced histopathological 
changes, although the authors erroneously refer to F13A as an antagonist (Fan et al., 
2015a).  
Unlike in kidney, myocardial and lung fibrosis where apelin is beneficial, in hepatic 
fibrosis the role of apelin is less clear. In cirrhotic rat liver, both the apelin receptor and 
peptide are increased, meanwhile in cirrhotic patients, circulating apelin levels are 
increased (Principe et al., 2008). However, treatment of cirrhotic rats with F13A led to 
an alleviation of liver fibrosis (Principe et al., 2008, Reichenbach et al., 2012). This 
might suggest that the lower activity of F13A is sufficient to partially antagonise the 
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elevated endogenous apelin, supporting a role as a partial agonist. Alternatively, it is 
possible that the elevation of apelin is a protective mechanism and hence, F13A is 
protective as an agonist. Further studies are required to clarify the role of apelin in liver 
fibrosis.  
Overall, apelin is beneficial in a number of different disease models of tissue fibrosis 
in kidney, heart and lung tissues; however, it may accentuate liver fibrosis. Such a role 
in myocardial and pulmonary fibrosis could be particularly useful in treating heart failure 
and PAH where substantial fibrosis is known to occur in both organs (Murtha et al., 
2017, Thenappan et al., 2018) and where apelin has already been identified as a 
potential therapeutic strategy.   
1.7.4 Pulmonary Arterial Hypertension (PAH) and Heart Failure (HF) 
The vasodilatory and inotropic effects of apelin signalling have made it of particular 
interest as a potential therapeutic for diseases, such as, PAH and heart failure (HF) 
(Yang et al., 2015a). Interestingly, there is significant evidence that the apelin peptide 
is downregulated in both diseases. In PAH this has been found in human patient 
plasma (Goetze et al., 2006), sugen-hypoxia and monocrotaline (MCT) models in rats 
(Kim et al., 2013, Falcao-Pires et al., 2009) and a mouse model with an endothelial cell 
specific PPARγ (peroxisome proliferator-activated receptor gamma) deletion (Alastalo 
et al., 2011). In HF it has been shown in several studies that apelin levels are 
decreased in human patient plasma (Chong et al., 2006, Foldes et al., 2003, Francia 
et al., 2007), in tissues from a number of rat models (Iwanaga et al., 2006, Koguchi et 
al., 2012), in mouse doxorubicin-induced cardiotoxicity and in a dog model (Wang et 
al., 2013a). Another study in human patients has suggested that apelin plasma levels 
are only decreased in late stage HF and are in fact increased in early stage disease 
(Chen et al., 2003). Such an effect would be unsurprising, given what is known about 
HF progression, with an often compensatory early stage followed by maladaptation 
later. However, these results were not corroborated in a study on Dahl-salt sensitive 
rats in which there was no change in apelin levels in the early stage of the disease but 
the levels did decrease as expected in later disease (Iwanaga et al., 2006). Overall, 
these studies support plasma apelin levels as a useful biomarker of disease 
progression. Importantly, apelin levels can also be modulated in disease and it has 
been shown that patients fitted with LV assist devices display higher apelin levels in 
addition to improved disease parameters (Chen et al., 2003, Francia et al., 2007).   
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Even though apelin is highly downregulated, expression of the apelin receptor appears 
to be less strongly suppressed in these diseases and crucially, remains responsive to 
apelin. In rats induced to develop PAH by hypobaric hypoxia, apelin receptor levels 
were unchanged (Andersen et al., 2009), whereas in an MCT model, the apelin 
receptor was downregulated in concert with apelin (Falcao-Pires et al., 2009). In rat 
models of HF, apelin receptor expression has mostly been found to decrease. This 
was the case in LV myocytes from hypertensive animals, where infusion of 
[Pyr1]apelin-13 restored some receptor expression (Pang et al., 2014), as well as in 
the myocardium of an isoproterenol-induced injury model (Jia et al., 2006). Studies 
using Dahl salt-sensitive hypertensive rats have demonstrated a decrease in apelin 
receptor expression in the same pattern as observed for the apelin peptide (Koguchi 
et al., 2012, Iwanaga et al., 2006) while one also found no change in the early stage 
of the disease (Iwanaga et al., 2006), perhaps suggesting that earlier intervention could 
be more beneficial. Mice induced to exhibit cardiotoxicity with doxorubicin also 
displayed reductions in apelin receptor expression (Hamada et al., 2015). A study 
using microembolisation-induced HF in dogs, showed that the apelin receptor was not 
decreased compared to controls, even though apelin was (Wang et al., 2013a). 
However, most crucially human subjects with HF were still able to respond to infused 
[Pyr1]apelin-13 and this was more efficacious in patients receiving PDE5 inhibitor 
treatment (Barnes et al., 2013, Brash et al., 2018) . Additionally, it has been shown in 
patients fitted with LV assist devices that the apelin receptor is the most upregulated 
gene, in concert with improved disease parameters (Chen et al., 2003). Together these 
studies demonstrate that while the apelin receptor may undergo some downregulation 
in disease, this is susceptible to modulation and its expression is seen to increase 
alongside positive changes in cardiac parameters.  
Given the downregulation of apelin but maintenance of signalling through the receptor, 
replacement of the downregulated endogenous agonist could be useful therapeutically. 
One concern with this strategy is that in the diseased state, one would anticipate the 
endothelium becoming damaged and therefore, less responsive to apelin, limiting 
therapeutic efficacy. However, previous work has shown that infusion of apelin is 
beneficial in a number of disease models. [Pyr1]apelin-13 given intraperitoneally (IP) 
was able to alleviate right ventricle (RV) hypertrophy and diastolic dysfunction in the 
MCT rat model of PAH (Falcao-Pires et al., 2009). It has also been shown that ELA is 
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able to replace the missing endogenous apelin peptide and prevent PAH in an MCT 
model (Yang et al., 2017b). In several rat models of HF, including isoproterenol-
induced (Jia et al., 2006), Dahl salt-sensitive hypertensive (Koguchi et al., 2012), two-
kidney, one clip hypertensive (Pang et al., 2014) and in left anterior descending 
coronary artery ligation (Atluri et al., 2007, Berry et al., 2004), apelin induced beneficial 
changes in the disease state. In mice subjected to transverse aortic constriction to 
induce a pressure-overload model of HF, [Pyr1]apelin-13 administered IP in liposomal 
nanocarriers displayed a longer duration of action and a reduction in LV size and 
fibrosis compared to controls or even mice administered [Pyr1]apelin-13 (Serpooshan 
et al., 2015). Such a result is promising in suggesting that simply by extending the 
duration of action, rather than the dose of [Pyr1]apelin-13 administered, it would be 
possible to extend the benefits observed in disease. The improvements in rodent 
models were recapitulated in the microembolism-induced dog model given apelin-13 
discussed earlier, with an improvement in ejection fraction and LV systolic parameters 
observed acutely (Wang et al., 2013a). As well as demonstrating that apelin can be 
beneficial when infused, studies have also shown that deletion of the apelin receptor 
and ligand exacerbate disease. In a doxorubicin-induced mouse model of 
cardiotoxicity, deletion of the apelin receptor led to a more severe reduction in cardiac 
contractility and accelerated myocardial damage compared to control animals 
(Hamada et al., 2015). At the same time, apelin knock-out mice developed impaired 
cardiac contractility when aged, or chronic HF when subjected to pressure-overload 
(Kuba et al., 2007). An interesting study in patients has also hinted at beneficial effects 
of apelin in humans (Boal et al., 2015). This study discussed the idea that patients with 
higher body mass indices and decompensated HF displayed lower in-hospital 
mortality, while apelin is also increased in these obese patients. Using an obese mouse 
model subjected to ischaemia-reperfusion to test this hypothesis, they suggest a 
mechanism whereby apelin prevents the nuclear translocation of a transcription factor 
critical to mitochondrial regulation, FoxO3, thus, promoting cell survival pathways and 
consequent cardioprotection.  
In conclusion, there is strong evidence that the apelin-apelin receptor signalling axis is 
perturbed in both PAH and HF and that modulation of this system by reintroduction of 
the downregulated apelin ligand or of ELA could be beneficial.  
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1.7.5 Obesity and Diabetes  
Apelin is increased in the morbidly obese (Soriguer et al., 2009) and patients with Type 
2 diabetes mellitus (Li et al., 2006). Interestingly, apelin has been suggested to have 
beneficial effects in metabolic disease and diabetes in a number of studies. It is 
reviewed in detail in Castan-Laurell et al. (2012).  
[Pyr1]apelin-13 is beneficial in promoting brown adipose tissue differentiation, in 
addition to promoting brown adipose tissue basal activity, as shown by the enhanced 
expression of uncoupling protein 1, increased mitochondrial biogenesis and increased 
oxygen consumption. Furthermore, it has been suggested from in vitro and in vivo 
experiments that it can even promote brown-like adipose tissue characteristics in white 
adipose tissue (Than et al., 2015).  
Apelin has been shown to be expressed in beta and alpha cells of the pancreas, while 
the receptor is found on INS-1 clonal beta cells in mice and humans (Ringstrom et al., 
2010). Selective deletion of the apelin receptor in pancreatic islet β-cells of mice 
resulted in a reduction of islet size, density and cell mass. These cells showed a 
decreased insulin secretion in vitro and the mice displayed decreased glucose 
tolerance (Han et al., 2015). Furthermore, apelin administration reduced insulin 
resistance during a hyperinsulinemic-euglycemic clamp in mice, by stimulating glucose 
uptake in soleus muscle (Dray et al., 2008). Further studies in mice have shown that 
chronic apelin treatment decreases insulin resistance by increasing fatty acid oxidation 
and mitochondrial biogenesis (Attane et al., 2012). Finally, in a study to assess whether 
apelin could be beneficial when administered in a diabetic rat model, it was found that 
[Pyr1]apelin-13 could induce a reduction in plasma insulin and glucose levels with a 
concurrent reduction in blood pressure (Akcilar et al., 2015).  These studies, therefore, 
indicate an important role for the apelin system in the regulation of glucose in diabetes 
and suggest it could potentially be used as a therapeutic intervention.  
Observational human studies have confirmed the presence of increased apelin 
concentrations in type 2 diabetes mellitus and obesity (Castan-Laurell et al., 2011) and 
they have raised the possibility of its use as a biomarker (Ma et al., 2014). Studies in 
patients receiving either metformin alone or in combination with vildagliptin 
demonstrated that apelin levels were enhanced when compared to controls for those 
receiving the monotherapy and even more greatly increased when on combinatorial 
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therapy (Fan et al., 2015b). These increases in apelin were seen alongside an 
improvement in fasting glucose and glycosylated haemoglobin levels, supporting the 
use of apelin as a marker of improved diabetic control in patients.  
Only one published study has measured the metabolic effects of intravenously infused 
apelin in humans. Gourdy et al. (2018) demonstrated that apelin infused over a 2-hour 
period during hyperinsulinemic-euglycemic clamping improves insulin sensitivity in 
overweight men. Meanwhile, unpublished data from our group demonstrated a 
decrease in blood glucose in non-diabetic volunteers following a 6 minute apelin 
intravenous infusion (100 nmol/min) (Pers. Comm. Brame and Davenport, 2013). 
1.7.6 HIV/SIV Co-Receptor 
Human immunodeficiency viruses (HIV) and Simian immunodeficiency viruses (SIV) 
generally use the CD4 receptor and a co-receptor, usually one of the chemokine 
receptors CCR5 or CXCR4, to infect host cells. However, the apelin receptor (which 
displays some structural similarities to CXCR) can also perform this function for a 
number of HIV-1 and SIV strains (Choe et al., 1998, Edinger et al., 1998, Zhang et al., 
1998, Puffer et al., 2000) and this can be blocked by apelin (Puffer et al., 2000, 
Cayabyab et al., 2000, Zou et al., 2000). Zhou et al., (2003a) demonstrated that the 
key interactions occur through the first 20 N-terminal amino acids of the apelin receptor 
and the gp120 HIV-1 viral protein and that apelin blocked this by interacting with the 
second ten residues of the N-terminus. Since these early studies, there have been few 
follow-up studies and the relevance and implications of apelin receptor involvement in 
HIV-1/SIV infection have not been addressed.  
1.7.7 Fluid Homeostasis 
Apelin has been shown to have roles in the uptake and retention of fluid as reviewed 
by Flahault et al. (2017). These responses were modest and appear mostly to be 
through interactions with regions of the central nervous system associated with 
arginine-vasopressin. Apelin receptor knock-out mice drank less than wild-type mice 
though the volume and osmolality of urine excreted did not differ. Furthermore, 
although wild-type mice showed reduced urine volume and increased osmolality 
following 24 hour water deprivation, apelin receptor knock-out mice did not (Roberts et 
al., 2009). In rats injected intracerebroventricularly with [Pyr1]apelin-13, a dose-
dependent increase in drinking behaviour and water uptake was observed (Taheri et 
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al., 2002). It has also been shown more recently that apelin-17 can directly affect the 
collecting ducts in the kidney to counteract the anti-diuretic effects of vasopressin, thus, 
enhancing the diuretic effects of apelin and the complexity of apelin-vasopressin 






















1.8 ELA Physiology and Pathophysiology  
1.8.1 Developmental Roles 
ELA was first discovered as a critical developmental peptide in zebrafish cardiogenesis 
(Chng et al., 2013, Pauli et al., 2014), an important role which is supported by the high 
degree of conservation at the functional C-terminal end of the peptide. This effect is 
mediated through the apelin receptor and may occur through an enhancement of 
nodal/TGFβ signalling. In fact, nodal elevation in aplnra/b double knock-out zebrafish 
embryos is sufficient to rescue them from the resulting cardiac differentiation defects 
(Deshwar et al., 2016). Following its identification, it was not initially clear whether ELA 
was involved in other developmental mechanisms and consequently, a number of 
studies set out to investigate this.  
In experiments also studying zebrafish embryos Helker et al., (2015) demonstrated 
that ELA was important for angioblast migration during the formation of large axial 
vessels, dorsal aorta and cardinal vein. Crucially, this was through the apelin receptor 
with knock-out embryos unable to form the vessels correctly. Additionally, WT 
angiobalsts injected into a knock-out background embryo were able to restore function, 
showing that these cells were responding to secreted ELA.  
In mammalian development, ELA has been studied in human embryonic stem cells 
(ECSs; Ho et al., 2015) and mouse ESCs (Li et al., 2015). Both of these studies 
reported that neither human nor mouse ESCs express the apelin receptor; however, 
in both cases they do demonstrate ELA expression. Ho et al., (2015) reported that a 
loss of ELA by shRNA knock-down leads to a loss of morphology and an inability to 
form teratomas, a characteristic trait of stem cells. This could be rescued by 
exogenously applied ELA, perhaps suggesting an alternative receptor in this cell type. 
Li et al. (2015), meanwhile, found that ELA was a downstream target of p53 whose 
knock-down could prevent DNA damage-induced apoptosis in mouse ESCs. They 
performed a BLAST search to identify potential additional targets of ELA with similar 
sequences to the apelin receptor but claim not to have identified any. They instead 
suggested that ELA RNA is involved in a feedback loop with p53 in mouse ESCs to 
regulate DNA damage-induced apoptosis and demonstrated that the coding region of 
ELA is dispensable to function in support of this. Recently, it has been shown that the 
ELA-apelin receptor axis plays an important role in coronary artery development in the 
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mouse heart (Sharma et al., 2017), supporting zebrafish studies and the vasculature 
defects observed in knock-out organisms. In this study, Sharma et al. (2017) 
genetically labelled apelin receptor expressing cells and found that these cells were 
found in sinus venosus and not endocardial coronary progenitors. In both homo- and 
heterozygous apelin receptor mutants, the sinus venosus coronary progenitors failed 
to migrate properly to form vasculature structures in the heart but this failure could be 
compensated by enhanced endocardial progenitor proliferation. ELA mutant hearts 
phenocopied the receptor mutants but apelin mutants did not, supporting ELA as the 
important signalling peptide in this pathway.  
1.8.2 Adult Cardiovascular Roles 
In addition to being present in various mammalian cell types including human 
pluripotent stem cells, Wang. et al., (2015) showed that ELA was able to perform 
functions in adult cell types and tissues. They demonstrated that ELA could induce 
angiogenesis of human umbilical vein endothelial cells in vitro in Geltrex coated wells 
and that this was abolished if apelin receptor was knocked-down. They also reported 
that ELA could induce relaxation in mouse aortic blood vessels. Since then further 
studies have identified ELA as a positive inotrope and vasodilatory agent ex vivo 
(Perjes et al., 2016) and in vivo in rats (Murza et al., 2016, Yang et al., 2017b). The 
study by Yang et al. (2017b) also looked at the ability of ELA peptides to bind to the 
apelin receptor in homogenates of human LV and to activate signalling pathways in 
cell-based assays expressing the human receptor. This study went on to demonstrate 
that ELA is present in both large and small diameter human blood vessels, as well as 
in human plasma.  
1.8.3 Disease and the Possibility of a Second Receptor for ELA 
Perhaps most interestingly, the study by Yang et al. (2017b) showed that ELA was 
down-regulated in plasma serum, pulmonary arterial endothelial cells and pulmonary 
microvascular endothelial cells from patients with PAH, raising the possibility that ELA 
is not only functional in the adult human but also altered in the diseased state. They 
went on to demonstrate that ELA was able to attenuate the onset of PAH in a MCT rat 
model. A number of other studies have also looked at the ability of ELA to modify 
disease in animal models. Chen. et al. (2017a) demonstrated that both ELA-32 and 
ELA-11 could protect against renal ischaemia-reperfusion injury, while Schreiber et al. 
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(2016) showed that adenovirally-delivered ELA could protect against kidney damage 
in a Dahl-salt sensitive rat model. However, what is still unclear is whether ELA 
mediates these protective effects through the apelin receptor or through a distinct 
receptor. Several studies have produced contradictory evidence regarding this. 
Chen et al. (2017a) used siRNA knock-down of the apelin receptor in NRK-52E cells 
and did not observe any changes in cell viability either in normoxic or hypoxic 
conditions. Meanwhile, Ho et al. (2017) looked at ELA and apelin knock-out in pregnant 
mice. They showed that ELA and not apelin knock-outs displayed preeclampsia-like 
symptoms and that infusion of ELA could alleviate them. They also demonstrated that 
ELA knock-out mice placentas were not rescued by apelin but were by ELA infusion, 
again suggesting differences in signalling pathways. They conclude that the 
preeclampsia alleviation is likely achieved through apelin receptor signalling in 
endothelial cells. They also do not rule out a possible contribution from additional 
unidentified ELA receptors. On the contrary, Sato et al. (2017) suggested that 
administration of ELA peptide could protect against cardiac dysfunction, hypertrophy 
and fibrosis in pressure overload mice. Importantly, apelin receptor knock-out mice did 
not respond to ELA administration, demonstrating that the protection was mediated by 
the ELA-apelin receptor axis. These studies raise important questions about whether 
such a second receptor for ELA exists, since if this receptor was another GPCR, it 
would be remarkable that it should be selective between apelin and ELA. It is likely 
that, as many ligands do, apelin and ELA have different signalling profiles in different 
tissues/organs (as well as between cell and animal models) and this could explain 
discrepancies in ELA and apelin knock-outs; however, it would not be able to explain 
the differences in outcomes observed when the receptor is knocked-out. There has 
been some evidence, as mentioned previously, of ELA RNA having a role in 
development before the apelin receptor is expressed (Li et al., 2015) and it could be 
that such mechanisms are maintained to adulthood. The interactions of apelin, ELA 





1.9 Knock-out Mouse Models 
As discussed earlier, the second peptide at the apelin receptor, now identified as ELA, 
was predicted due to the discrepancies observed between embryonic knock-outs of 
apelin and its receptor (Charo et al., 2009). Knock-outs of the receptor in mice caused 
pre-natal mortality (Ishida et al., 2004, Charo et al., 2009, Roberts et al., 2009, Scimia 
et al., 2012, Kang et al., 2013) with a failure in cardiac development as the cause (Kang 
et al., 2013). Furthermore, neonates that survived to later embryonic stages displayed 
incomplete vascular maturation, in part due to a deficiency in vascular smooth muscle 
cells, as well as incomplete ventricular wall development (Kang et al., 2013). Those 
surviving to adulthood have been shown to display decreased contractile function in 
the heart which translates to a reduced exercise capacity (Charo et al., 2009). 
Interestingly, they also displayed a reduced propensity to develop HF in response to 
pressure overload (Scimia et al., 2012). In contrast, apelin peptide knock-outs had 
normal heart development (Kidoya et al., 2008, Charo et al., 2009) and were born in 
Mendelian ratio. They also displayed defects in contractility and exercise tolerance 
(Charo et al., 2009) but were at a greater risk from age-related and pressure overload-
induced HF (Kuba et al., 2007).   
In zebrafish, ELA knock-outs phenocopied apelin receptor mutations (Chng et al., 
2013, Pauli et al., 2014) and it was this, among other observations, which aided in its 
identification as an endogenous apelin receptor ligand. It is only very recently that 
mouse ELA mutants have been produced (Freyer et al., 2017, Ho et al., 2017). The 
knock-out was embryonically lethal, in agreement with its role as a critical 
developmental signalling molecule. The likely cause of death was misregulation of 
haematopoietic progenitors at late gatrulation stages, leading to cardiac and vascular 
defects, thus, mimicking some of the observations of Kang et al (2013). Apelin and 
ELA double knock-outs did not further increase embryonic lethality, supporting the 
hypothesis that in mammalian systems it is ELA, and not apelin, that plays the crucial 
developmental role (Freyer et al., 2017). However, the authors suggest that some 
discrepancies, particularly with regards to survival rates between ELA and apelin 
receptor knock-outs, are suggestive of independent actions of the apelin receptor 
either though alternative ligands or potential stretch-mediated responses.  
Therefore, while it seems evident that ELA plays a critical role in the early development 
of the cardiovascular system through the apelin receptor, it remains to be seen whether 
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the apelin receptor may have additional developmental roles. Furthermore, generation 
of an inducible ELA knock-out would be interesting by allowing further exploration of 
its roles in the adult mammalian system. Recent studies have illustrated activity in the 
adult cardiovascular system, as well as changes in ELA expression in the diseased 
state (Yang et al., 2017b). Given that the apelin peptide mutant shares some 
similarities with the adult apelin receptor mutants (Kuba et al., 2007), it is tempting to 
propose a dichotomous situation with ELA as the key developmental ligand through 
the apelin receptor and apelin as the key adult signalling peptide. Such a reductionist 
view is likely too simplistic and further exploration of the roles of ELA in the adult system 
will help to shed light on the possible interplay between the two endogenous apelin 


























































































































































































































1.10 Biased Small Molecule Agonists as a Therapeutic Strategy at 
the Apelin Receptor 
It is remarkable that a peptide with a half-life of two minutes (Brame et al., 2015) is 
able to induce the vast number of changes observed and to promote such a beneficial 
response in a multitude of deleterious circumstances. It is also promising that by 
something as simple as extending the release time of the peptide, through 
encapsulation in nanoparticles, these effects can be further improved (Serpooshan et 
al., 2015). The logical next step in advancing apelin as a treatment is to produce either 
longer-lasting peptide mimetics or to produce small molecules which will not be broken-
down, thus, further extending the therapeutic benefits. Small molecules could also 
have the added benefit of being orally bioavailable, greatly increasing their ease of 
administration. This might improve patient compliance by making regular dosing an 
easier task, especially for those suffering from chronic diseases who will likely require 
treatment for the remainder of their lives, for example, those with diabetes, metabolic 
disease, HF and PAH. 
A potential issue of using apelin as a therapy is that, upon activation of the receptor, 
bound apelin is rapidly internalised with the receptor through the β-arrestin pathway, 
potentially limiting clinical efficacy. Furthermore, there is evidence that activation of the 
β-arrestin pathway in the absence of ligand can lead to stretch-mediated hypertrophy 
(Scimia et al., 2012), an effect that would be accentuated in disease where the 
endogenous ligands are downregulated. One may envisage a situation where a biased 
molecule is utilised which does not activate the deleterious internalisation pathway but 
only activates the beneficial G protein signalling pathways to provide a therapeutic 
effect (Figure 1.7).  
Biased agonism (or agonist trafficking among other names) is an emerging concept for 
GPCRs (Kenakin, 1995, Urban et al., 2007, Galandrin et al., 2007, Smith et al., 2011) 
and it is only now that its therapeutic potential is being realised. The concept relies on 
the idea that in order to activate downstream signalling pathways, GPCRs must alter 
their conformation upon binding of agonists. Originally, this was thought to be an ‘on-
off’ switch mechanism, whereby when unbound the receptor was ‘off’ and when bound 
to an agonist it was ‘on’. It is now evident that, as complex proteins consisting of seven 
transmembrane domains, GPCRs can exist in a multitude of conformations determined 
by their energy state and that these states can fluctuate; an excellent discussion of this 
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is provided by Vaidehi and Kenakin (2010). In short, certain agonists can stabilise 
these conformations to different degrees. For example, if a GPCR spends more time 
in a G protein signalling energy state over a β-arrestin signalling energy state, it would 
display bias towards G protein signalling and vice versa. A biased molecule must, in 
that case, bind in certain regions of the endogenous agonist binding pocket at the 









It is important to note that although biased agonism is a novel idea, all current non-
endogenous clinical therapies will be biased ligands in some way, even if the nature of 
that bias is poorly understood. The question, therefore, becomes not whether clinical 
drugs possess bias but rather, is this bias clinically relevant? A good example of this 
is illustrated by studies conducted on β-adrenoceptor antagonists (or β-blockers) and 
their role in chronic HF treatment. Although originally contraindicated in HF due to their 
negative chronotropic and inotropic effects potentially leading to excessive cardiac 
suppression in an already failing heart, β-blockers have since become a key treatment 
in chronic HF. The argument stems from the idea that in chronic HF compensatory 
mechanisms lead to a ‘catecholamine storm’, excessive β1 stimulation, receptor 
downregulation and an altered receptor profile which promotes further catecholamine 
release in a positive feedback loop. Ultimately, this leads to cardiomyocyte apoptosis 
through catecholamine-induced toxicity. β-blockers can interrupt this positive feedback 
and exert beneficial effects, as can partial agonists, such as Pindolol. However, there 
Figure 1.7: A schematic illustrating the proposed beneficial biased signalling profile at the apelin 
receptor. Apelin the endogenous agonist can activate Gαi, Gαq and β-arrestin. A biased agonist would 
aim to only activate the G protein signalling pathways at the expense of the β-arrestin pathway. 
Such an effect would reduce receptor internalisation and potential stretch mediated hypertrophy.  
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is now evidence that the 3rd generation of β-blockers, such as Carvedilol, possess 
ligand bias and may exert some of their beneficial effects through such mechanisms. 
Wisler et al. (2007) argue that carvedilol while antagonising the canonical Gαs pathway 
as expected, also promotes β-arrestin recruitment, receptor internalisation and ERK1/2 
phosphorylation in the β2 adrenergic receptor and that such effects were maintained in 
a G protein uncoupled mutant. Therefore, these 3rd generation β-blockers provide an 
example where, although the ligands were not designed with bias in mind, bias may 
nonetheless be critical to their mechanism of action. 
Currently, there are a small number of molecules that have been designed to possess 
bias in a therapeutic setting. As yet none are approved for clinical use and only three 
have progressed to clinical trials. Two of these are Oliceridine (TRV-130) and TRV734 
(Phase I), µ-opioid agonists that display bias towards G protein signalling over β-
arrestin, thereby promoting beneficial analgesic effects with a similar potency to the 
classical analgesic morphine, without inducing gastrointestinal side-effects (Viscusi et 
al., 2016), www.trevena.com). It has been reported that these compounds still evoke 
respiratory depression as seen with morphine, though this is generally only problematic 
in cases of overdose. Oliceridine has been granted breakthrough status by the FDA 
and it was recently announced that it will be reviewed for approval later this year 
(www.trevena.com). Another new biased opioid ligand, PZM21, identified through 
computational docking experiments, displayed remarkably high bias towards G protein 
signalling over β-arrestin and, in contrast to Oliceridine, did not cause respiratory 
depression in mice in vivo, though it should be noted that these are recent and pre-
clinical data (Manglik et al., 2016). Another compound that entered clinical trials was 
also from Trevena. TRV027 is an angiotensin type II receptor agonist biased towards 
β-arrestin signalling. It aims to reduce afterload while increasing cardiac performance 
and maintaining stroke volume, allowing it to be used for acute HF (Felker et al., 2015); 
however, no benefits were observed through a 30-day follow-up in a phase IIB clinical 
trial (Pang et al., 2017).  
At the apelin receptor, it is hoped that biased agonism could be exploited such that it 
would not detract from the therapeutic signalling benefits of apelin but would ensure a 
longer duration of action and a consequent improvement in efficacy. Indeed, 
internalisation of the apelin receptor is rapid and 50% of receptors have been shown 
to be internalised after ten minutes in stably transfected CHO cells (Evans et al., 2001). 
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Furthermore, it is interesting that the rate of recycling of the apelin receptor back to the 
plasma membrane is highly dependent on the ligand (Lee et al., 2010, Zhou et al., 
2003a). Thus, by altering the properties of the agonist, one might not only be able to 
reduce the propensity of receptor internalisation but also to increase the recycling rate 
back to the membrane of the receptors that are internalised.  
A previously designed cyclised apelin peptide analogue, MM07, displayed G protein 
bias (Brame et al., 2015). This strategy resulted in an improved duration of action in a 
forearm blood flow study in human subjects with no decrease in response observed 
upon repeated dosing following a saline flush. An increase in efficacy over [Pyr1]apelin-
13 was observed both in vasodilatation in the human forearm study and in cardiac 
output in rat heart. Finally, it was demonstrated that MM07 can attenuate RV 
hypertrophy in the MCT model of PAH (Yang et al. In Revision). These data support 
the idea that the apelin receptor is tractable to biased signalling. Additional evidence 
is provided by a study in which alteration of a specific serine residue (Ser348) in the 
apelin receptor showed abolition the G protein receptor kinase/ β-arrestin pathway 
signalling, whilst preserving signalling through the G protein pathway (Chen et al., 
2014). Meanwhile, it has been reported that removal of the C-terminal phenylalanine 
of apelin-17 can induce bias towards G protein signalling (Ceraudo et al., 2014).  
Having observed that the apelin receptor is tractable to bias and the previously 
demonstrated success of this approach with MM07, one of the aims of this study was 
to identify small molecules that can bind to the human apelin receptor with high affinity 
and exert biased signalling through the G protein pathway. Such small molecules 
should allow for a further improvement over peptides, such as MM07, by allowing for 








1.11 Albudab™ Platform and Antibodies as a Therapeutic Delivery 
Strategy 
Antibodies are increasingly being used in a therapeutic setting as they display some 
major advantages over other treatment strategies; however, they can also show 
serious limitations. Their key advantage stems from the high affinity of protein-protein 
interactions meaning they can be targeted to a specific pathway with a high degree of 
selectivity, limiting off-target effects. Moreover, if properly designed to avoid immune 
targeting, these molecules can have very long half-lives. For example, Alemtuzumab 
(Campath) is given as a treatment for multiple sclerosis in a series of 4 hour infusions 
for 5 days spaced 12 months apart (Multiple Sclerosis Society UK). Despite these 
advantages, antibodies must be given intravenously (though this issue is largely 
negated by their long half-life) and due to their high selectivity, resistance can develop; 
often it is required that they are given in combination with pre-existing treatments.  
An example of an antibody combinative therapy is infliximab (an anti-tumour necrosis 
factor α (TNFα) antibody) given in combination with the anti-proliferative methotrexate 
for the treatment of rheumatoid arthritis. However, resistance to TNFα blockade, 
especially etanercept monotherapy, often occurs and more second line therapies are 
required (Anecchino et al., 2015). One such antibody, toclizumab (an anti-IL-6 
antibody), has been approved, despite reports of serious adverse events, because 
benefits were observed in patients refractive to infliximab treatment, (this was not the 
case for patients switching from etanercept monotherapy; Wakabayashi et al., 2013). 
One of the issues highlighted by this example of antibody therapy is that, due to their 
high selectivity, direct antibody therapies provide relief only in situations where patients 
are known to possess a reported defect.  
One of the best examples of a successful designed antibody therapeutic is imatinib 
which was designed to target the BCR-ABL fusion protein. A translocation between 
chromosome 9 and 22 occurs in all cases of chronic myeloid leukaemia (CML) leading 
to the production of this gene which encodes a permanently activated tyrosin kinase 
receptor (Nowell, 1962, Rowley, 1973). By targeting this aberrant growth receptor with 
imatinib, the progression of CML could be slowed (Savage and Antman, 2002). This is 
an excellent, albeit limited, example of a situation where a direct antibody therapy to 
target a known defect is successful. Perhaps with better and cheaper genome 
sequencing technologies, it will become easier to identify which antibodies or antibody 
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combinations will provide the best benefit in individual patients and antibodies will 
become increasingly the treatment of choice in an era of personalised medicine.  
Although antibodies may be used to directly engage targets in disease, they are 
increasingly being explored as a potential mechanism for drug delivery. To do this 
linker motifs must be carefully chosen to link the antibody to the drug as these must be 
sufficiently stable so that the complex remains intact in vivo but breaks apart upon 
antibody-target engagement, allowing for optimal drug delivery. Novel approaches, 
such as, cyclisation, the use of unnatural amino acids and PEG spacers may be used 
to reduce proteolysis and retain antibody-drug complexes.  
Antibody-drug combinations have gained particular interest in cancer treatments where 
targeted drug ‘payload’ delivery could reduce the chemotherapeutic doses required 
and thereby reduce debilitating side-effects. Two FDA approved antibody-drug 
combinations are Adcetris (brentuximab vedotin) and Kadcyla (trastuzumab 
emtansine) for refractory Hodgkin lymphoma and HER2 positive breast cancer, 
respectively. Adcetris consists of brentuximab an anti-CD30 antibody which binds and 
internalises on CD30 expressing cells to release the payload, monomethyl auristatin 
E, a powerful antimitotic through preventing tubulin polymerisation. Meanwhile, 
Kadcyla consists of trastuzumab, an anti-HER2 antibody, and emantisine, another 
tubulin-binding antimitotic. Since the approval of these antibody-drug combinations in 
2011 and 2013, respectively, there has been a surge in investment and there are now 
more than 50 in various stages of clinical trials for a number of different cancers (Dan 
et al., 2018).  
Rather than using antibodies to target specific cells, an alternative approach is to utilise 
them to extend the half-life and stability of other compounds. One platform to do this is 
conjugation to a human anti-serum albumin domain antibody (AlbudAb™). The 
AlbudAbTM construct consists of a single variable domain of immunoglobulin G (IgG) 
and is approximately 1/10th the size of a conventional antibody. In vivo it binds rapidly 
with human serum albumin (HSA) to form a complex of approximately 81kDa, thus 
avoiding the size cut-off for glomerular filtration of around 50kDa and enhancing 
plasma half-life. By combining short peptides, which are susceptible to clearance 
through the kidneys, with an AlbudAb™ construct, the molecule can be protected and 
the transit time in the blood can be greatly increased.  
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Such an approach has been demonstrated previously with endogenous molecules 
conjugated genetically to AlbudAbTM, such as soluble IL-1Rα (interleukin-1 receptor 
type 1; Holt et al., 2008), GLP-1 (glucose-dependent insulinotropic peptide 1; 
O'Connor-Semmes et al., 2014, Bao et al., 2013, Lin et al., 2015), tumour necrosis 
factor receptor 1 (TNF-R1; Goodall et al., 2015) and interferon-α2b (Walker et al., 
2010), all of which demonstrated half-life extension with retained activity. A similar 
approach might be taken with apelin or apelin mimetic peptides. Importantly, in order 
to conjugate mimetic peptides that contain unnatural amino acids that cannot be 
genetically coded, the AlbudAbTM construct has also been modified such that it 
contains only one cysteine residue, Cys108. This cysteine is distant from the albumin 
binding site, enabling it to be linked using maleimide chemistry to target molecules. 
Such an approach would use a linker, such as PEG, as well as unnatural amino acids 
to protect the molecule from peptidase degradation. Meanwhile, the AlbudAb™ would 

















1.12 Hypothesis and Aims 
The apelin system is clearly an important regulatory system and is perturbed in a 
number of diseases, particularly those affecting the cardiovascular system. In PAH 
both of the endogenous ligands apelin and ELA are downregulated but the apelin 
receptor expression levels are not decreased. This supports the hypothesis that 
targeting the apelin receptor in the disease could be beneficial. Prevention studies in 
the MCT rat model of PAH have confirmed this, with exogenous administration of 
[Pyr1]apelin-13 and ELA-32 significantly improving outcome. This suggests that other 
apelin agonists may also show benefit in PAH and it is particularly noteworthy that 
there are no suitable small molecule agonists at the apelin receptor. Such molecules 
while having potential for the generation of novel therapeutics, would also crucially be 
able to progress the field of apelin research by providing suitable tool compounds for 
experimental study.    
Therefore, the primary aim of this study was to identify a novel G protein biased small 
molecule agonist at the apelin receptor. Such a molecule would follow-up previous 
work in the laboratory which identified MM07 as a cyclic G protein biased peptide 
agonist of the apelin receptor and confirm that G protein bias can be retained in small 
molecules at the apelin receptor.  Importantly, such a discovery would provide a much 
needed experimental tool compound for research and could provide a platform for the 
development of additional biased small molecule agonists that might be suitable for 
use as therapeutics in disease. This study discovered CMF-019 as such a molecule 
and then aimed to characterise its in vitro and in vivo pharmacology, as well as its 
potential as a disease-modifying therapeutic in PAH.  
A secondary aim of the study built upon work already performed in the laboratory that 
generated an apelin peptide mimetic-AlbudAb™ conjugate. This conjugate utilised an 
apelin mimetic containing unnatural amino acids, MM202, linked to a (PEG)4 spacer to 
reduce proteolysis. MM202-(PEG)4 was then conjugated to AlbudAb™ using 
maleimide chemistry to enhance transit time of the molecule. The purpose here was to 
pharmacologically characterise MM202-AlbudAbTM by assessing its in vitro and in vivo 





2.  Methods 
2.1 Materials 
Chemicals were obtained from Sigma Aldrich Co. Ltd (Poole, UK) unless otherwise 
stated. [Pyr1]apelin-13 (Glp-RPRLSHKGPMPF), Apelin-17, MM07, MM202, and 
MM202-AlbudAbTM were manufactured and tested for greater than 95% purity using 
mass spectrometry by Severn Biotech (Kidderminster, UK). 
[Glp65,Nle75,Tyr77][125I]apelin-13 was from Perkin Elmer (MA, USA) and had a specific 
activity of 81.4MBq/nmol. CMF compounds (Figure 3.1) were synthesised in the 
School of Chemistry, University of Leeds. For in vivo studies the potassium salt of 
CMF-019 (Figure 4.2) dissolved in saline at pH9 was used as it showed better solubility 
than the parent compound. This was initially also synthesised in the School of 
Chemistry, University of Leeds, however, for later in vivo studies a large batch was 
synthesised by Tocris, (Bristol, UK).  Human tissues were obtained with informed 
consent from the Papworth Hospital Research Tissue Bank (08/H0304/56) and ethical 
approval (05/Q104/142) and conformed to the principles outlined in the declaration of 
Helsinki. Animal experiments were performed in accordance with guidelines from the 
local ethics committee (University of Cambridge) and the Home Office (UK) under the 





























2.2 Preparation of Tissue Homogenates 
Human LV tissue, whole rat and whole mouse hearts were first cut into small pieces 
and stored on ice. Homogenisation buffer (50mmol/L Tris-HCl, 5mmol/L MgCl2, 
5mmol/L EDTA, 1mmol/L EGTA, 1:500 protease inhibitor cocktail (PIC), pH 7.4 at 4°C) 
was added (10mL/g of tissue). The tissue was then homogenised in three twenty 
second bursts with cooling in between. The homogenate produced was centrifuged at 
a slow speed for a short time (1000g, 2min, 4°C) to produce a soft pellet. The 
supernatant was removed and then subjected to prolonged high speed centrifugation 
(40,000g, 30min, 4°C). Following this, the supernatant was discarded and the pellet 
resuspended in homogenisation buffer (2.5mL/g of tissue) before undergoing high 
speed centrifugation. This process was repeated once more. After the final high speed 
centrifugation, the pellet was resuspended in HEPES buffer (50mmol/L HEPES, 
pH7.4) and stored at -70°C until required. Samples were taken and assessed for 
















2.3 Competitive Radioligand Binding Assays 
Homogenised human LV (1.5mg/mL) was used to determine binding affinities in native 
human receptors. Whereas, to determine binding affinities to rat and mouse receptors, 
whole heart homogenates (1.5mg/mL) were used. Compounds were incubated with 
the homogenate for 90min in assay buffer (Tris 50mmol/L, MgCl2 5mmol/L, pH7.4, 
22ºC) and 0.1nmol/L [Glp65,Nle75,Tyr77][125I]apelin-13. Sigmacote® was used to 
siliconise apparatus and prevent label loss. Binding in the presence of 2μmol/L 
[Pyr1]apelin-13 was deemed non-specific. Following incubation, the solutions were 
spun (20,000g, 10min, 4ºC), washed (50mmol/L Tris-HCl, pH7.4, 4˚C), spun again 
(20,000g, 10min, 4˚C) and the pellet counted using a gamma counter (Cobra 5003, 
Packard). Measurements were made in triplicate and data analysed using GraphPad 
Prism™. The binding affinities were calculated by the Cheng-Prusoff methodology 
using measured IC50 vales (Cheng and Prusoff, 1973). The Ki of 





















2.4 Cell Signalling Assays 
2.4.1 β-Arrestin Assay 
PathHunter® eXpress β-Arrestin GPCR assays were purchased from DiscoveRx 
(Fremont, CA, USA), this assay utilises CHO cells expressing the apelin receptor 
(AGTRL1). The assay provides a chemiluminescent read-out of β-arrestin (isoform 2) 
recruitment to the receptor through the use of ProLink™ technology (Figure 2.1). Upon 
activation of the receptor and recruitment of β-arrestin, the ProLink™ (a β-
galactosidase fragment) attached to the β-arrestin complements its partner on the 
receptor, leading to production of a functional enzyme. This enzyme then cleaves the 
substrate located in the detection reagent and produces the chemiluminescent read-
out. 
 
To perform the assay, the CHO cells were first thawed and resuspended in cell plating 
media (F12 HAM media containing 10% serum penicillin/streptomycin/glutamine)  
before being plated in 96-well plates and incubated for 48h (37˚C, 5% CO2). Following 
this period, serial dilutions of stock compounds in cell plating media were performed to 
obtain a concentration range upon addition of 5µL of each dilution per well, with the 
final concentration of dimethylsulphoxide (DMSO) not exceeding 1%. DMSO controls 
were used at a concentration of 1%. Where possible, measurements were made in 
triplicate. After incubation for 90min with the agonist at 37°C, cell detection reagent 
Figure 2.1: The mechanism of action of the β-arrestin cell signalling assay. Kits were purchased 




was added and left for a further 120min protected from light at room temperature. 
Luminescence was detected using a LumiLITE™ Microplate 4 Reader (DiscoveRx) 
and measured as relative light units (RLUs). Agonist responses were normalised to the 
mean maximal response detected for the endogenous agonist [Pyr1]apelin-13 in that 
experiment. The data were then fitted to a four-parameter model using GraphPad 
Prism™ and the pD2 (-log10 of the EC50) and EMax values calculated and compared.  
Validation 
This screening assay was purchased from DiscovRx and performed according to their 
instructions. They have reported that there are no differences in pH across the assay 
plating media and that there is no background expression of the apelin receptor in CHO 
cells.  
Additional experiments have been performed in our laboratory to further validate the 
assay. Using [Glp65,Nle75,Tyr77][125I]apelin-13, receptor affinity and density were 
compared to human LV homogenate (experiments performed by Mrs Rhoda Kuc and 
data provided by Dr Janet Maguire). The radioligand bound to the receptor in CHO 
cells (KD=0.16±0.04nM) and this was of the same order of magnitude to the binding in 
human LV homogenates (KD=0.08±0.01nM). Crucially, the density of receptors 
measured were 45.3±8.2fmol/mg and 13.8±1.8fmol/mg, respectively, a 3-fold 
difference and within the same order of magnitude. This is important as often in cell 
expression systems, receptors can be greatly overexpressed, resulting in dramatic 
differences in receptor-G protein stoichiometry to those observed in clinically relevant 
human tissues. This can lead to the appearance of new signalling states and give a 
false interpretation of bias (Luttrell et al., 2015, Kenakin, 1995, Zhu et al., 1994, 
Cordeaux et al., 2000, Nasman et al., 2001).  
Another factor that can lead to errors is the timing of the end-point reading as drug-
receptor kinetics may vary in the assays. The biased calculations used to quantify bias 
rely upon adaptation of the Black and Leff operational model of agonism, one of the 
fundamental assumptions of which is that the reaction has reached equilibrium 
(Kenakin et al., 2012, Rajagopal et al., 2011, Black and Leff, 1983). Studies have 
shown that there is a kinetic variable to quantification of bias (Lane et al., 2017, Klein 
Herenbrink et al., 2016). To isolate the kinetics of the assay as a variable, 
concentration-response curves to both [Pyr1]apelin-13 and MM07 have been 
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performed at different time-courses (experiments performed by Mrs Rhoda Kuc). It was 
found that the pD2 to both compounds did not vary when readings were taken at 20, 
30, 45 and 90 minutes, suggesting the potencies of the agonists are not dependent on 
incubation time.  
2.4.2 cAMP Assay 
cAMP Hunter™ eXpress GPCR assays were purchased from DiscovRx, this assay 
utilises CHO cells expressing the apelin receptor (AGTRL1). The assay provides a 
chemiluminescent read-out of cAMP activity (Figure 2.2). At low basal levels of cAMP 
activity, anti-cAMP antibodies bind to the endogenous cAMP, as well as cAMP 
molecules which have been modified with the addition of a β-galactosidase fragment. 
At high levels, the antibodies become saturated with endogenous cAMP allowing the 
β-galactosidase fragment-modified cAMP molecules to bind to their complementary 
partner fragment in solution. This leads to a functional enzyme that hydrolyses its 
substrate in the detection reagent and produces a chemiluminescent read-out.   
 
To perform the assay, the CHO cells were first thawed and resuspended in cell plating 
media (F12 HAM media containing 10% serum/penicillin/streptomycin/glutamine) 
before being plated in 96-well plates and incubated for 48h (37˚C, 5% CO2). Following 
this period, the cell plating media was substituted with 45µL of a solution containing 
the cAMP antibody reagent and forskolin made up in cell assay buffer (Hanks’ 
balanced salt solution modified with 10mM HEPES). Forskolin (15nmol/L) was required 
Figure 2.2: The mechanism of action of the cAMP cell signalling assay.  Kits were purchased from 
DiscovRx™ and performed as described in the text. Figure taken from http://www.discoverx.com. 
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as the apelin receptor couples to Gαi in this system. Serial dilutions of stock compounds 
were then made in cell assay buffer to obtain a concentration range upon addition of 
15µL of each dilution per well, with the final concentration of DMSO not exceeding 1%. 
DMSO controls were used at a concentration of 1%. Where possible, measurements 
were made in triplicate. After incubation for 30min with the agonist at 37°C, cAMP 
working detection reagent consisting of cAMP lysis buffer (containing IBMX), substrate 
reagent 1, substrate reagent 2 and cAMP solution D (enzyme donor) was added and 
left for a further 60min, protected from light at room temperature. cAMP solution A 
(enzyme acceptor) was then added and the plates incubated for 180min protected from 
light at room temperature. Luminescence was detected as for the β-arrestin assay. 
Agonist responses were normalised to the maximal forskolin response at the lowest 
concentration of a given agonist. The data were fitted to a four-parameter model using 
GraphPad Prism™ and the pD2 (-log10 of the EC50) and EMax values calculated and 
compared. 
Validation 
This screening assay was purchased from DiscovRx and performed according to their 
instructions. They have reported that there are no differences in pH across the assay 
plating media and that there is no background expression of apelin receptor in CHO 
cells.  
Optimisation experiments performed in the laboratory (experiment performed by Mr 
Thomas L. Williams and data provided by Dr Janet Maguire) showed that the EC80 for 
forskolin stimulation occurred at 45µmol/L (Figure 2.3). The value recommended and 
expected by the manufacturer (DiscoveRx) was 15µmol/L forskolin.  15µmol/L forskolin 
was used in subsequent experiments so that the DMSO concentration was not too 
high, although this was closer to the EC50 as measured in our controls. As this meant 
the forskolin concentration was closer to the linear portion of the concentration-
response curve, the baseline activation by forskolin controls was more variable than 
expected. To reduce this variability in the baseline, the data in subsequent analyses 
have been normalised to the maximal forskolin response of the given concentration-
response curve. The inhibition of the forskolin response by the compounds can thus 












cAMP standard curves were performed to ensure the amounts of cAMP detected for 
apelin compounds in the assay measured in RLUs were within the detection range of 
the assay. The cAMP standard curve elicited a maximal response of just over 
200,000RLUs and the response to forskolin at 15µmol/L (Figure 2.4) was 
approximately 100,000RLUs. This was similar to the maximal responses measured for 
the tested compounds as expected, thus, indicating that even the maximal cAMP levels 
measured for the experimental compounds were easily within the detectable range of 






Figure 2.3: A forskolin control curve performed prior to experiments to establish the optimal forskolin 
concentration for use in the cAMP assay (experiment performed by Mr Thomas L. Williams and data 
provided by Dr Janet Maguire). The data show that the EC80 of forskolin stimulation occurred at 
about 45µmol/L as indicated by the dotted red line. The 15µmol/L concentration recommended by 
the manufacturer was closer to an EC50. 
Figure 2.4: A cAMP standard control curve performed prior to experiments to establish that the 
cAMP levels detected in the assay were within the assay range (experiment performed by Mr 
Thomas L. Williams and data provided by Dr Janet Maguire). The data show that the range of RLUs 
detected were between 0 and 200,000RLUs putting the 15µmol/L forskolin concentration used in 
the assay well within the detectable range.  
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2.4.3 Internalisation Assay 
PathHunter® eXpress Activated GPCR Internalisation assays were purchased from 
DiscoveRx, this assay utilises U20S cells expressing the apelin receptor (AGTRL1). 
The assay provides a chemiluminescent read-out of receptor internalisation through 
the use of ProLink™ technology (Figure 2.5). Upon receptor internalisation following 
binding of β-arrestin (isoform 2), the ProLink™ (a β-galactosidase fragment) attached 
to the β-arrestin complements its partner on the endosome, leading to a functional 
enzyme. This enzyme then cleaves the substrate located in the detection reagent and 












To perform the assay, the U20S cells were first thawed and resuspended in cell plating 
media before being plated in 96-well plates and incubated for 48h (37˚C, 5% CO2). 
Following this period, serial dilutions of stock compounds in cell plating media were 
performed to obtain a concentration range upon addition of 5µL of each dilution per 
well, with the final concentration of DMSO not exceeding 1%. DMSO controls were 
used at a concentration of 1%. Where possible, measurements were made in triplicate. 
After incubation for 120min with the agonist at 37°C, working detection reagent was 
added and left for a further 120min protected from light at room temperature. 
Luminescence was detected and analysis performed as for the β-arrestin assay.  
Figure 2.5: The mechanism of action of the receptor internalisation cell signalling assay. Kits were 





This screening assay was purchased from DiscovRx and performed according to their 
instructions. Since the assay was in a different cell line to the other cell-based assays, 
it was largely used as a screening tool to check for consistency with the β-arrestin 





2.5 Apoptosis Assay Using Human PAECs 
Human pulmonary artery endothelial cells (human PAECs) were purchased from 
Lonza (Cambridge, UK; n=5 donors: 1(lot#0000479486), 2(lot#4F3041), 
3(lot#4F3034), 4(lot#000657513) and 5(lot#0000662151) passages 4-6). The human 
PAECs were maintained in endothelial cell growth media 2 (EGM-2 containing basal 
media, EBM-2, with added human  epidermal growth factor (hEGF), hydrocortisone, 
GA-1000 (Gentamicin, Amphotericin-B), vascular endothelial growth factor (VEGF), 
human fibroblast growth factor-B (hFGF-B), R3-IGF-1 (an analogue of human insulin-
like growth factor 1), ascorbic acid and heparin (Lonza, UK) supplemented with 10% 
heat inactivated foetal bovine serum (FBS; Gibco, NY, USA). In later experiments 
owing to an inability to supply further media by Lonza, Promocell (UK) EGM-2 was 
used. Again this was supplemented with 10% heat inactivated FBS; however, it did not 
contain antibiotics (GA-1000) and, though it was chosen for its similarity to the Lonza 
media, most likely had slightly different concentrations of the same growth factors 
(GFs).  
Assays were performed largely as described by Long et al. (2015) although 
optimisation of the protocol was performed. The assay relies on the fact that, although 
tumour necrosis factor α (TNFα) usually prevents apoptosis of endothelial cells through 
activation of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
pathway, in conditions of global protein synthesis suppression, such as, concurrent 
application of cycloheximide (CHX), apoptosis is induced through TNF-R1 leading to 
JNK and p-38 MAPK phosphorylation.  
Briefly, at 80-90% confluency, human PAECs were seeded in three six-well tissue 
culture plates at 200,000cells/well in EGM-2 with 10% FBS and allowed to attach. On 
the next day, wells were washed with phosphate buffered saline (PBS) and the media 
changed to either EBM-2 with 2% FBS to serum and growth factor (GF) starve the cells 
or to EGM-2 10% FBS ‘healthy’ controls. [Pyr1]apelin-13 (10 µM), MM07 (10µM), CMF-
019 (1-10µM) or recombinant human vascular endothelial growth factor (rhVEGF) 
(10ng/mL; R&D Systems; Minneapolis, MN, USA) were added to the wells and 
incubated for 18 hours.  Apoptosis was induced by incubating the cells with TNFα (R&D 
Systems) and CHX for 5 hours in the experimental wells. A plate map for the control 
plate is shown in Table 2.1; this was used to compensate between fluorescent 
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In addition to the control plate there were two experimental plates in each experiment. 
These plates featured one well of the serum and GF starved and one well of the 
TNFα/CHX treated conditions per compound at a given concentration. All compounds 
were added to the cells 18 hours prior to the TNFα/CHX treatment regardless of 
whether they were in the control or experimental group.  
Cells were then washed in PBS, trypsinised (Lonza), transferred into 1x binding buffer 
for the apoptosis assay (Thermoscientific;  Waltham, MA, USA) and stained with anti-
annexin-V FITC-conjugated antibody and propidium iodide (PI, 20µg/mL) for 15 
minutes at room temperature. Cells were filtered through 50µM filters (Sysmex/Partec; 
Görlitz, Germany) and kept on ice before flow cytometry (Canto II, BD Biosciences; 
San Jose, CA, USA). 10,000 events were recorded for each condition. Human PAECs 
were selected based on forward and side scatter areas and single cells selected by 
comparing forward scatter width vs area. Data analysis was performed on FlowJo v10 
(FlowJo LLC; Ashland, OR, USA) and each experiment compensated between 
channels using the internal unstained, annexin-only and PI-only controls. Annexin+/PI+ 
cells were classified as ‘dead’, Annexin+/PI- cells ‘apoptotic’ and Annexin-/PI- as 
‘healthy’. Gates were adjusted such that approximately equal numbers of ‘healthy’ and 
‘apoptotic’ cells occurred in the TNFα/CHX treated group as this provided a large 
window for either further induction or rescue of apoptosis; this is illustrated in Figure 
2.6. These gates were applied to the rest of the experimental conditions for that 
experiment.  
Table 2.1: The control plate set-up for the human PAEC apoptosis assay. Each quadrant represents 
one well of a six well plate and the treatments administered to that well are listed. The control plate 
provided controls for both compensation of the flow cytometry data and the controls for the experiment. 
In addition to this plate there were two experimental plates in which the two rightmost well conditions 












2.5.1 Use of Low Passage Number Human PAECs  
Low passage numbers (passages 4-6) were used in experiments to ensure human 
PAECs were healthy prior to the start of experimentation as it was observed that later 
passage numbers (>7) were less susceptible to apoptosis induced by TNFα/CHX. This 
may reflect the fact that later passages are more susceptible to serum and GF 
starvation induced apoptosis (Varani et al., 1995) and so less able to respond to further 
apoptotic stimuli. Endothelial cells are known to start endothelial-to-mesenchymal 
transition and elongate in culture if exposed to fibroblast-derived soluble factors 
(Kuzuya and Kinsella, 1994). Similar observations have been seen if endothelial cells 
are cultured for long periods of time or too sparsely. Cells were tested by Lonza prior 
to purchase for α-actin staining and cell morphology was carefully monitored 
throughout culture. Endothelial cells should maintain a classical rounded ‘cobblestone’ 
morphology in culture and not form cell projections or elongate. 
 
Figure 2.6: An example of a scatter plot collected by flow cytometry of human PAECs treated with 
TNFα/CHX and stained with annexin-FITC and PI. The quadrants clockwise from bottom left show 
the annexin-/PI- ‘healthy’, annexin-/PI+, annexin+/PI+ ‘dead’ and annexin+/PI- ‘apoptotic’ populations. 
The gates were adjusted such that approximately equal numbers of ‘apoptotic’ and ‘healthy’ cells 
(highlighted in the red boxes) occurred under this condition before being applied to the rest of the 
experimental conditions tested for that experiment.  
60 
 
2.5.2 Annexin Concentration Optimisation 
In order to obtain the maximum apoptotic window induced in the TNFα/CHX treatment 
compared to the EBM-2 2% FBS control, the concentration of annexin used was 
adjusted from that suggested in the protocol by Thermoscientific. These experiments 
were performed in donors 2 and 3. Using the stock concentration (Figure 2.7, top 
panel), there was a large amount of annexin staining in the serum and GF starved 
(EBM-2 2% FBS) control which would narrow the window for apoptotic induction by 
TNFα/CHX treatment. Therefore, a 1:10 dilution of the stock (Figure 2.7, middle panel) 
was tested but this resulted in minimal staining compared to the unstained control. 
Finally, a 1:2 dilution (Figure 2.7, bottom panel) was tested. This concentration of 
annexin resulted in moderate staining in the EBM-2 2% control, such that the peak of 
the population was central and clearly distinguishable from the unstained population 
but there was also potential for a rightward shift upon TNFα/CHX treatment. Using a 
lower concentration of annexin was also advantageous as this was the limiting 




































Figure 2.7: Histogram plots of annexin staining collected by flow cytometry in unstained and serum 
and GF starved (EBM-2 2% FBS) treated human PAECs. Each panel horizontally illustrates differing 
concentrations of annexin diluted from the stock concentration provide by Thermoscientific. The 
optimal condition was a 1:2 dilution (bottom panel) as this demonstrated a clear rightward shift in 
annexin staining with serum and GF starvation but was not so great that it would restrict further shifts 
being observed following apoptotic induction with TNFα/CHX treatment. This also conserved the 
annexin solution which was the limiting substrate in the assay.  
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2.5.3 TNFα and CHX Concentration Optimisation 
The initial concentrations of TNFα/CHX used were 3ng/mL and 50µg/mL, respectively, 
after discussion with the authors of the Long et al. (2015) paper. However, these 
concentrations were found to be too severe in the cell lines used and different 
concentrations of TNFα/CHX were tested both with and without the positive control, 
rhVEGF, in donor 2 to find the optimal concentrations to use. The highest 
concentrations used were 3ng/mL TNFα and 20µg/mL CHX. However, due to the six-
well format limiting assay space, rescue with rhVEGF could not be tested at this 
concentration. This had previously been tested in other experiments using donor 2 with 
little success, suggesting that the TNFα/CHX treatment was still too harsh to allow for 
rescue of the induced apoptosis. The concentrations of TNFα/CHX were reduced to 
test at 1.5ng/mL and 20µg/mL, 1.5ng/mL and 10µg/mL and 0.5ng/mL and 10µg/mL, 
respectively; the results are shown in Figure 2.8. There was little difference in apoptotic 
induction between the 3ng/mL and 1.5ng/mL concentrations of TNFα with a fixed 
concentration of 20µg/mL CHX. With the lower 10µg/mL CHX concentration there were 
approximately 10% fewer annexin stained cells and this dropped by a further 5% when 
the TNFα concentration was reduced to 0.5ng/mL. Since the rescue from rhVEGF was 
fairly consistent at all concentrations in restoring annexin staining to the basal level 
observed in the EBM-2 2% control but 1.5ng/mL TNFα and 20µg/mL CHX induced the 
most apoptosis; this concentration provided the largest window for potential rescue 






















Figure 2.8: Scatter plots of annexin staining vs PI staining detected by flow cytometry in human 
PAECs treated with either EGM-2 10% FBS (‘healthy’ controls), EBM-2 2% FBS (serum and GF 
starved) or different concentrations of TNFα/CHX with or without rhVEGF. The numbers in each 
corner give the percentage of cells located in that quadrant. TNFα/CHX resulted in a rightward shift 
of the population leading to a greater number of cells in the annexin+/PI- ‘apoptotic’ quadrant which 
was reduced by rhVEGF treatment in each condition. The condition that provided the largest window 
of apoptotic rescue was 1.5ng/mL TNFα and 20µg/mL CHX.  
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2.5.4 Data Analysis 
Experiments were performed at least in triplicate in the five donor human PAEC lines 
using passages 4-6. Optimisation experiments were performed in lines 1-3. It was 
found that, at the optimal concentrations chosen of 1.5ng/mL TNFα and 20µg/mL CHX, 
there was no significant induction of apoptosis in lines 4 and 5 (2.80±1.60%, ns). 
Moreover, although there was no induction of apoptosis over the EBM-2 2% FBS 
control, rhVEGF still reduced Annexin+/PI- staining. This suggests that the response to 
rhVEGF was a rescue of GF and serum starvation. GF and serum starvation is 
something that has been widely observed in various endothelial cell lines (Gama Sosa 
et al., 2016, Gerber et al., 1998b, Karsan et al., 1997, Ueda et al., 2005, Date et al., 
2005, Raymond et al., 2004) and the mechanisms for rescue with rhVEGF are thought 
to occur by both upregulation of the MAPK/ERK pathway alongside downregulation of 
JNK pathway (Gupta et al., 1999), leading to enhanced bcl-2 and decreased bax 
signalling (Gerber et al., 1998a, Ueda et al., 2005, Karsan et al., 1997). In contrast, 
TNFα/CHX stimulates apoptosis primarily through the TNF-R1 leading to induction of 
the JNK and p-38 MAPK pathways. 
Data where there was insufficient apoptotic induction by TNFα/CHX were excluded 
because the mechanisms of induction were not comparable to those in donors 1-3. 
Similarly, experiments that showed less than 5% induction of apoptosis were excluded 
from the analysis as these provided insufficient window and again suggest different 
mechanisms involved in apoptotic induction. The average induction of apoptosis of the 
analysed experiments using donors 1-3 was 19.53±1.76% (****p<0.0001).  
Since raw percentages of annexin staining were compared in this assay, variability in 
the basal amount of apoptotic induction between the replicates was observed. This 
likely reflects differences in the cell line and their susceptibility to TNFα/CHX induced 
apoptosis, as well as passage number. It has been reported that older passages are 
more susceptible to serum and GF starvation (Varani et al., 1995) and this may render 
them less able to respond to further apoptotic stimuli, thus restricting the window of 
observation in the experiment. To remove this variability and compare the data trends 
which can be observed in the raw data between experiments (Figure 2.9), a matched 














In this assay it was very difficult to compare across cell lines and passage numbers 
due to the variability in apoptotic induction. Furthermore, the assay had to be 
thoroughly optimised from a previously published protocol (Long et al. 2015). The 
number of controls that were required and the small six-well plate format meant that it 
was very limited in throughput and the concentrations that could be tested; hence, 
concentration-response data could not be collected. Overall this suggests that the 
assay is not sufficiently robust and alternative assays with greater throughput and 





Figure 2.9: Dot and line plot of the percentage of annexin+/PI- human PAECs detected by flow 
cytometry for each experimental condition. Each line represents one experimental replicate (8 
replicates over 3 cell lines) such that trends in the data can be observed. It can be seen that the 
relative amounts of initial annexin+/PI- staining were variable but the staining across each experiment 




























































2.6 Surgical Techniques 
Surgical techniques were developed based on the heart catheterisation protocols 
described previously by Pacher et al., 2008. In later experiments, a technique for 
femoral artery catheterisation was also devised and incorporated into the protocol.  
These techniques enabled the assessment of acute cardiovascular responses to bolus 
intravenous drug administration in vivo, as well as RV and LV catheterisation to assess 
RVSP and LVSP following a MCT PAH prevention study.  
2.6.1 Surgical Procedures to Assess Acute Cardiovascular Responses 
The equipment used for surgery is shown in Figures 2.10 and 2.11. Preparation of the 
animal for surgery is shown in Figure 2.12. In brief, normotensive Male Sprague-
Dawley rats (Charles River Laboratories, Margate, UK) were induced to anaesthesia 
with inhalation of 5% isoflurane in an induction box (reduced to 3% once unconscious) 
and then maintained under 1.5-2% isoflurane via a face mask. Temperature was 
monitored throughout the surgical procedure using a rectal probe. Prior to the start of 
surgery, it was ensured that pain reflexes had ceased by use of a hind-paw pinch test. 
The breathing rate and, once catheterised, the heart rate were monitored to determine 
and maintain a suitable depth of anaesthesia. The catheters (SPR-869, Millar Inc.; 
Houston, TX, USA) were electronically calibrated using the MPVS Ultra system 
























Experimental set-up for surgery.  
Top panel, Figure 2.10: The equipment required for maintenance of anaesthesia, temperature and 
performing surgery.  
Bottom panel, Figure 2.11: The computational equipment and display used for recording the data 







Figure 2.12: Procedures for the preparation of the rat for surgery. The animal was anaesthetised 
and tested for responsivity. The catheters were calibrated prior to the start of surgery.  
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The surgical procedures are shown in Figures 2.13, 2.14 and 2.15. In brief, the right 
external jugular vein was exposed, cannulated (Figure 2.13) and flushed with heparin 
solution (2%, 0.9% saline, pH5, Macopharma; Tourcoing, FR). The right common 
carotid artery was then located and a catheter inserted and advanced to the LV (Figure 
2.14). Once a stable pressure-volume (PV) loop could be observed, the femoral artery 
was exposed and a second catheter inserted to record arterial pressure responses 
simultaneously to ventricular responses (Figure 2.15). Drugs or saline controls were 
then administered intravenously via the jugular vein catheter, followed by a saline flush 
(0.9%, 0.1mL, pH5) at a minimum of ten minute intervals or when a stable baseline 
was reached before the next injection. Data were acquired using the MPVS Ultra 
system (ADIstruments) and analysed using LabChart 8 (ADIstruments). Values for the 
maximal change in arterial pressure, left ventricular systolic pressure (LVSP), stroke 
volume, cardiac output, heart rate, contractility (dP/dtMAX) and lusitropy (dP/dtMIN) from 
baseline were calculated from the raw data and compared. Following completion of the 














Figure 2.13: Surgical procedures for 
cannulation of the right external jugular vein. 
On next page, Figure 2.14: Surgical 
procedures for catheterisation of the LV via 







Figure 2.15: Surgical procedures for 




2.6.2 Surgical Procedures to Measure LVSP and RVSP Following a MCT Prevention 
Study of PAH 
The MCT prevention study of PAH was performed as previously described (Falcao-
Pires et al., 2009, Yang et al., 2017b). Briefly, male Sprague-Dawley rats (Charles 
River Laboratories, Margate, UK) received a single subcutaneous injection of MCT 
(60mg/kg) or a saline control. Thereafter, they received IP injections of either the 
treatment or saline (equivalent volume by weight) for 21 days. On the final injection 
date, the LV and RV were catheterised using broadly the same surgical techniques 
described above to measure LVSPs and right ventricular systolic pressures (RVSPs). 
The Fulton index recorded as a measure of hypertrophy (Fulton et al., 1952). The 






Preparation for surgery was largely the same as shown in Figures 2.12, however, in 
this case only one catheter (Millar Inc., SPR-869) was required. Especially careful 
monitoring throughout anaesthesia was required with MCT-treated animals due to their 
impaired lung function increasing the chance of asphyxiation from isoflurane inhalation. 
No cannula was inserted for the surgery as described previously, and instead a PV 
catheter was inserted into the RV through the right external jugular vein by the same 
methodology (Figure 2.13). When this was complete, it was sealed off with a single 
tight suture and the LV then catheterised as described in Figure 2.14 via the right 
common carotid artery with the same catheter. The femoral artery was not 
catheterised. Following termination by exsanguination under high flow isoflurane (5%), 
the heart was excised and dissected carefully to remove the atria. The Fulton index, a 
Figure 2.16: Timeline of events for a MCT prevention study of PAH. Male Sprague-Dawley rats 
received a single SC injection of either MCT or saline to induce PAH. Thereafter, they received daily 
IP injections of either the intervention or saline control up to and including day 21 at which point their 




measure of hypertrophy calculated as the RV wet weight divided by the LV and 

























2.7 Apelin Enzyme-Linked Immunosorbent Assay  
Apelin-12 enzyme-linked immunosorbent assays (ELISA; EK-057-23) were purchased 
from Phoenix Pharmaceuticals Inc. (Burlingame, CA, USA) and performed according 
to the manufacturer’s instructions with the exception of using [Pyr1]apelin-13 as a 
standard. In brief, samples, primary antibody and the biotinylated peptide were 
incubated on an orbital shaker (300-400rpm) for two hours at room temperature in a 
secondary antibody pre-coated 96-well plate. All wells were then washed four times 
with assay buffer, thoroughly dried and incubated with streptavidin-horseradish 
peroxidase for one hour at room temperature (300-400rpm). Next, the wells were 
washed and dried again before the enzyme substrate added for a further hour at room 
temperature and protected from light (300-400rpm). Finally, the plate was treated with 
2N hydrochloric acid to stop the reaction and the plate read on a microtiter plate reader 
at 450nm absorbance. Since the apelin-like immunoreactivity in the sample competes 
against the biotinylated peptide for binding to the primary antibody in this assay, the 
greater the concentration of peptide in the sample then the less streptavidin-
horseradish peroxidase is available to react with the substrate and the lower the 
absorbance detected. Samples were performed in duplicate and concentrations 














2.8 Statistical Analysis 
All data are expressed as mean±SEM values and statistical analyses were performed 
with GraphPad Prism 6 (La Jolla, CA, USA) unless otherwise stated. Binding and cell-
based DiscovRx experiments were performed in triplicate. For DiscovRx assays, n-
values are given as the number of replicates/number of experiments.  
For flow cytometry, experiments were performed at least in triplicate. Donors 4 and 5 
were excluded from the analysis as they showed a particularly small window of 
apoptotic cell induction using TNF-α and CHX (2.80±1.60%), this was not significantly 
different to the EBM-2 2% FBS control (Matched ANOVA). Of the remaining donors, 
technical replicates were excluded if the apoptotic induction was less than 5%. The 
average induction of apoptosis of the analysed experiments was 19.53±1.76%. Data 
were normally distributed using the D’Agostino-Pearson omnibus K2 test and trends 
were compared using a matched ANOVA to account for variability observed in the 
basal amount of apoptotic induction observed between replicates.  
For the acute in vivo studies, values for the cardiovascular parameters measured in 
saline and treated animals were compared using a two-tailed Student’s t-test. For the 
cross study analysis of [Pyr1]apelin-13 responses in vivo, the doses compared were 
not always given at the corresponding dose schedule so that while the dose 
administered is always the same, it may have been given as the first or second dose 
the animal received. Data have not been included where the preceding dose was not 
either a saline dose or a lower dose of [Pyr1]apelin-13. A number of saline controls 
from different dose schedules have been included to attempt to control for this. Data 
were tested for normality using the D’Agostino-Pearson omnibus K2 test and analysed 
using a two-tailed Student’s t-test. Statistical significance was taken as 5%. 
For the chronic MCT study, parameters were compared to their corresponding controls 
using a two-tailed Student’s t-test. N values were too small to use the recommended 
D’Agostino-Pearson omnibus K2 test to test for normality; however, data were normally 






3. Identification and Characterisation of CMF-019, the 
First G Protein Biased Apelin Agonist  
3.1 Introduction 
One of the primary aims of this study was to identify small molecule agonists at the 
apelin receptor. To date, very few small molecule agonists have been identified at this 
receptor and those that have possess significant limitations in their use, this was 
discussed at length in Section 1.4. The identification of small molecule ligands that 
bind to the receptor with high affinity could greatly progress the apelin research field 
by providing cheaper and more easily manufactured molecules for experimental study. 
Additionally, such molecules might be suitable either as therapeutics themselves in 
disease, for example in PAH, as discussed in Section 1.6, or they might provide a 
starting point for the development of a newer generation of agonists for treatment.  
To identify small molecules that bind to the apelin receptor, a patent search was 
performed, revealing two series of structures, one from Sanford-Burnham (Pinkerton 
and Smith, 2015) and one from Sanofi (Hachtel et al., 2014). Compounds from both 
series have previously been screened in the laboratory and the Sanford-Burnham 
series deemed unsuitable due to a lack of solubility. However, the Sanofi series based 
upon the benzimidazole scaffold was taken forwards and of the 20 assessed, four 
compounds, CMF-013, CMF-015, CMF-019 and CMF-021 (Figure 3.1), were selected 
for further screening. CMF-019 was chosen as the lead compound and modifications 
of the structure were made. In the first instance, the structural scaffold of CMF-019 
was altered to introduce an additional nitrogen atom into the benzimidazole ring, 
producing a molecule designated CMF-087. CMF-087 then underwent side-chain 
modifications to produce two further molecules for study, MM239 and MM240. In a 
later series, an attempt was made to amalgamate the structure of CMF-087 with the 
structures of the Sanford-Burnham triazole series (Pinkerton and Smith, 2015) and the 
recently identified RTI International pyrazole series (Narayanan et al., 2016); the 
resulting compound was designated CMF-167.  
This chapter details the screening of the four original CMF compounds -013, 015, -019 
and -021, before going on to compare the CMF-019 derivatives to the parent molecule. 
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Ultimately, CMF-019 was selected as the most promising compound and was taken 












Figure 3.1: The chemical structures of the four original CMF compounds based on the 
benzimidazole scaffold, CMF-013, -015, -019 and -021. The molecular weights of each compound 
are displayed below.  
79 
 
3.2 Methods  
3.2.1 Materials 
All CMF compounds and synthetic modifications to previous structures were designed 
and synthesised by Christopher Fitzpatrick, Dr Richard Foster (University of Leeds) 
and Professor Robert Glen (University of Cambridge).  
3.2.2 Competitive Radioligand Binding Assays 
Human LV homogenate, whole rat and whole mouse hearts were homogenised as 
described in Section 2.2. [Pyr1]apelin-13 (5µmol/L-1pmol/L), CMF-013, -015, -021, 
MM239 and MM240 (0.1mmol/L-50pmol/L), CMF-019 (5µmol/L-1pmol/L)  and CMF-
087 (50µmol/L-10pmol/L) were competed against 0.1nmol/L 
[Glp65,Nle75,Tyr77][125I]apelin-13 as described in Section 2.3. In one experiment 
competing [Pyr1]apelin-13 in whole mouse heart homogenate, the concentration of 
protein used was 1mg/mL rather than 1.5mg/mL as used in all other experiments.   
3.2.3 Cell Signalling Assays  
3.2.3.1 β-Arrestin Assay 
[Pyr1]apelin-13 (n=9/33) (1µmol/L-10pmol/L), CMF-013 (n=3/8), -015 (n=3/8), -019 
(n=4/13), -021 (n=4/11), -087 (n=4/12), MM239 (n=4/12) and MM240 (n=4/11) 
(0.1mmol/L-1nmol/L) were assessed for their ability to recruit β-arrestin to the apelin 
receptor in a CHO based cell assay as described in Section 2.4.1.  
3.2.3.2 cAMP Assay 
[Pyr1]apelin-13 (n=12/36) (30nmol/L-1pmol/L), CMF-013 (n=4/11), -015 (n=3/9), -021 
(n=4/9) (10µmol/L-1pmol/L), CMF-019 (n=5/14) (30nmol/L-0.1pmol/L), CMF-087 (3/9) 
(1µmol/L-1pmol/L), MM239 (n=4/12) and MM240 (n=4/10) (1µmol/L-10pmol/L) were 
assessed for their ability to reduce cAMP expression following forskolin stimulation in 
a CHO based cell assay as described in Section 2.4.2. 
3.2.3.3 Internalisation Assay 
[Pyr1]apelin-13 (n=3/8) (1µmol/L-10pmol/L), CMF-013 (n=1/3), -015 (n=1/3), -021 
(n=1/3)  (0.1mmol/L-1nmol/L) and CMF-019  (n=3/9) (0.1mmol/L-0.1nmol/L) were 
assessed for their ability to internalise the apelin receptor in a U20S based cell assay 
as described in Section 2.4.3.  
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3.2.4 Statistical Analysis 
Binding experiments were performed in triplicate and Ki values calculated using the 
Cheng-Prusoff methodology (Cheng and Prusoff, 1973). Binding data are displayed 
graphically over the same concentration range for ease of comparison. Data are listed 
as pKi±SEM; however the Ki values without error have been included in summary 
tables for ease of comparison.  
Cell signalling assays were performed in triplicate where possible and are listed as 
n=biological replicates/technical replicates and analysis was performed as means of 
means. Data are listed as pD2±SEM but EC50 values calculated as geomeans have 
been listed without error in summary tables for ease of comparison. Where sufficient 
biological replicates are available, bias calculations have been performed (van der 
Westhuizen et al., 2014) to obtain values for relative effectiveness compared to 
[Pyr1]apelin-13 within each cell-based assay and bias factors to compare the relative 
activities of the agonists between the different pathways.  
Linear regression analysis was performed on pKi±SEM, pD2±SEM and ΔΔlogR±SEM 
values and presented as the line of best fit calculated and the goodness of the fit as 
















3.3.1 Competitive Radioligand Binding Studies 
3.3.1.1 [Pyr1]apelin-13 Bound to Apelin Receptors  
The endogenous agonist [Pyr1]apelin-13 bound to native apelin receptors in human LV 
(8.82±0.05), rat whole heart (9.50±0.06) and whole mouse heart (8.73±0.06) 
















Figure 3.2: Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to human LV (●), rat whole 
heart (■) and mouse whole heart (▲) homogenates with increasing concentrations of [Pyr1]apelin-
13. Ki values were calculated from IC50 values using the Cheng-Prusoff methodology 
(Ki[Glp65,Nle75,Tyr77][125I]apelin-13=0.076nmol/L). In whole mouse heart homogenate the 
concentration of protein used was 1mg/mL rather than 1.5mg/mL as in all other experiments. Data 
displayed over the same concentration range for ease of comparison. 
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3.3.1.2 CMF-013, -015, -019 and -021 Bound to the Human Apelin Receptor  
In human LV homogenates, CMF-013, -015, -019 and -021 bound competitively with 
nanomolar affinity to the native apelin receptor (7.89±0.06, 7.59±0.07, 8.58±0.04, 


















Figure 3.3: Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to human LV homogenates 
with increasing concentrations of either CMF-013, -015, -019 or -021. Ki values were calculated from 
IC50 values using the Cheng-Prusoff methodology (Ki[Glp65,Nle75,Tyr77][125I]apelin-





3.3.1.3 CMF-019 Bound to Rat and Mouse Apelin Receptors  
Similar binding was observed in rat and mouse whole heart homogenates for CMF-









3.3.1.4 CMF-087 Bound to the Human Apelin Receptor  
The CMF-019 analogue, CMF-087, bound to the native apelin receptor in human LV 








Figure 3.4: Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to rat whole heart (■) and 
mouse whole heart (▲) homogenates with increasing concentrations of CMF-019. Ki values were 
calculated from IC50 values using the Cheng-Prusoff methodology 
(Ki[Glp65,Nle75,Tyr77][125I]apelin-13=0.076nmol/L). Data displayed over the same concentration 
range for ease of comparison. 
 
Figure 3.5: Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to human LV homogenates 
with increasing concentrations of CMF-087. The Ki value was calculated from IC50 values using 




3.3.1.5 MM239 and MM240 Bound to Native Human and Rat Apelin Receptors  
The CMF-087 analogues, MM239 and MM240, bound to the native human apelin 
receptor in LV homogenates with higher affinities than CMF-087 (8.67±0.05 and 
7.64±0.07, respectively; Figure 3.6). They also both bound to the native rat apelin 
receptor in whole rat heart homogenates with lower affinities than to the human 

















Figure 3.6: Specific binding of 0.1nM [Glp65,Nle75,Tyr77][125I]apelin-13 to human LV (●) and rat whole 
heart (■) homogenates with increasing concentrations of MM239 or MM240. Ki values were 
calculated from IC50 values using the Cheng-Prusoff methodology 
(Ki[Glp65,Nle75,Tyr77][125I]apelin-13=0.076nmol/L). Data displayed over the same concentration 





3.3.2 Cell Signalling Assays  
3.3.2.1 CMF-013, -015, -019 and -021 Displayed G Protein Signalling Bias  
CMF-013, -015, -019 and -021 were assessed for their ability to reduce cAMP levels 
following forskolin stimulation via the Gαi pathway and their ability to recruit β-arrestin 
(Figure 3.7). They were also tested for the ability to induce receptor internalisation 
(Figure 3.8). All four compounds were biased towards the G protein pathway 












Figure 3.7: Pathway selectivity of ▲ CMF-013, ▼ -015, ■ -019 and ♦ -021 in CHO cell-based assays 
measuring β-arrestin recruitment and cAMP inhibition compared to the endogenous agonist ● 
[Pyr1]Apelin-13.  
Figure 3.8: ▲ CMF-013, ▼ -015, ■ -019 and ♦ -021 in a U20S cell-based internalisation assay 
compared to the endogenous agonist ● [Pyr1]Apelin-13. No SEM values are shown for ▲ CMF-013, 
▼ -015 or ♦ -021 as only one biological replicate was performed.  
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3.3.2.2 CMF-087, MM239 and MM240 Displayed Reduced G Protein Signalling Bias 
Compared to the Parent Molecule, CMF-019 
CMF-087, MM239 and MM240 were assessed for their ability to reduce cAMP levels 
following forskolin stimulation via the Gαi pathway and their ability to recruit β-arrestin 
(Figure 3.9). The compounds also displayed G protein bias but this was markedly 





3.3.2.3 Bias Calculations  
For the most promising compound, CMF-019, bias calculations were performed for 
cAMP, β-arrestin and internalisation pathways. The data for CMF-019 from Figures 3.7 
and 3.8 above are displayed in Figure 3.10 below for clarity and ease of comparison 
to the corresponding [Pyr1]apelin-13 controls. CMF-019 induced β-arrestin recruitment 
to the apelin receptor (6.65±0.29) and subsequent receptor internalisation (6.23±0.25) 
but was less potent than [Pyr1]apelin-13 (8.50±0.10; 9.30±0.13, respectively). In 
contrast, CMF-019 potently inhibited Gαi-mediated cAMP production (9.95±0.17), 
comparable to [Pyr1]apelin-13 (9.75±0.11).  
 
Figure 3.9: ■ CMF-087, ▲ MM239 and ▼ MM240 in CHO cell-based assays measuring β-arrestin 















In order to quantify the degree to which CMF-019 displayed bias towards the G protein 
signalling pathway compared to the reference agonist [Pyr1]apelin-13, relative 
effectiveness and bias factors were calculated as described previously by van der 
Westhuizen et al. (2014) and are shown in Tables 3.1 and 3.2, respectively. Similar 
bias calculations were performed between β-arrestin and cAMP signalling assays for 
CMF-013, -015, -021, -087, MM239 and MM240. None of these compounds were as 
biased as CMF-019 with some displaying limited to no bias at all. The bias factors 
calculated were 82, 21, 104, 23, 4 and 11, respectively, and are shown in Summary 
Table 3.4.  
 
 
Figure 3.10: Pathway selectivity of CMF-019 determined from cell-signalling assays. Bias was 
calculated as described previously by van der Westhuizen et al., 2014; relative effectiveness and 



















Table 3.1: Values of ΔLogR and Relative effectiveness for CMF-019 compared to [Pyr1]apelin-13 in 
β-arrestin, internalisation and cAMP assays. ΔLogR is Log10(τ/KA) where τ is a measure of agonist 
efficacy and KA a measure of functional affinity as described by van der Westhuizen et al. (2014).  
Table 3.2: ΔΔLogR and bias factors for CMF-019 compared [Pyr1]apelin-13 in β-arrestin, 
internalisation and cAMP assays. ΔΔLogR is the difference between ΔLogR values in the different 
pathways and the bias factor is 10^ΔΔLogR as described by van der Westhuizen et al. (2014).  
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3.3.3 Summary Tables  
3.3.3.1 Binding Affinities  
The binding affinities of [Pyr1]apelin-13, CMF-013, -015, -019, -021, -087, MM239 and 
MM240 in CHO-K1 cells expressing the human apelin receptor (experiments 
performed by Cerep; Celle L’Evescault, France) and human LV, whole rat and whole 
mouse heart homogenates are shown in Table 3.3 below as Ki and pKi±SEM values. 
Not all compounds have been performed in each assay and only the most promising 
compounds were tested in rodent heart homogenates to inform potential in vivo study. 
A dash indicates where no data have been collected for this condition.  
3.3.3.2 Bias Factors  
The EC50, pD2±SEM and n-values in cAMP inhibition and β-arrestin recruitment 
assays, as well as the ΔΔlogR±SEM and bias factors for CMF-013, -015, -019, -021, -














































































































































































































































































































































3.4.1 CMF-019 is a G protein Biased Small Molecule with High Nanomolar Affinity to 
the Apelin Receptor  
Two screening methods were employed to pharmacologically characterise the small 
molecule apelin receptor agonists described. First, the compounds were tested for 
binding to the native apelin receptor in homogenates of human LV tissue using a 
competitive radioligand binding assay. Crucially, this assay utilised clinically relevant 
human tissue. Second, the compounds were tested for their cell signalling capabilities 
in human apelin receptor expressing cells. These assays focussed on β-arrestin 
recruitment to the receptor and cAMP inhibition through the Gαi pathway. By comparing 
the differences in signalling through these pathways to the endogenous agonist, 
[Pyr1]apelin-13, it was possible to establish the degree to which the compound 
displayed signalling bias. We have previously hypothesised that a G protein biased 
molecule would be beneficial by preventing receptor downregulation and thus, would 
be a desirable trait for a small molecule apelin agonist, as discussed in Section 1.9.  
Starting with CMF-013, -015, -019 and -021 identified from a patent and based upon 
the benzimidazole scaffold (Hachtel et al., 2014), it was found that they all bound to 
the native apelin receptor in human LV homogenates with high nanomolar affinity. 
CMF-019 bound with the highest affinity of 2.64nM which was very similar to the 
endogenous peptide, [Pyr1]apelin-13, at 1.52nM. The higher affinity of CMF-019 
translated into functional efficacy, with it demonstrating the highest potencies in cAMP 
inhibition, β-arrestin recruitment and receptor internalisation. When assessed for bias 
between the Gαi and β-arrestin pathways, it was found that the much higher efficacy 
through the Gαi pathway translated into a greater bias factor of 264 for CMF-019 than 
observed for -013 (82), -015 (21) or -021 (104). CMF-019 also demonstrated a bias 
factor of 3553 between the Gαi and receptor internalisation assays, however, this result 
must be interpreted cautiously. The internalisation assay was performed in U20S cells 
rather than CHO cells and there could be system bias that might confound the data. It 
was decided to not continue further study in this system and fewer than 3 biological 
replicates were obtained for CMF-013, -015 and -021. The data for this assay have 
been presented separately, do not include SEMs and bias calculations have not been 
performed. Nevertheless, the rank order of potency between the β-arrestin assay and 
internalisation assay are consistent, supporting the data obtained.  
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Since CMF-019 demonstrated the highest binding affinity and greatest degree of bias 
at the apelin receptor, it was chosen as the most suitable compound to take forward 
from the four compounds involved in this initial screen. To assess its suitability for 
future in vivo experiments, the binding affinity at both mouse and rat apelin receptors 
was performed by the same methodology as for the human receptor. These 
experiments were very important for assessing the usefulness of the apelin system for 
the development of future therapeutics. Although the primary binding screen in the 
study used clinically relevant human tissue to establish the compound’s usefulness in 
man, without similar binding affinity at rodent receptors, compound development can 
be significantly hampered. An example of such a case is with Palosuran, a non-peptide 
urotensin-II antagonist, which demonstrated more than a thousand-fold lower affinity 
at rat urotensin-II receptors compared to human (IUPHAR Guide to Pharmacology, 
Ligand ID: 3516; Lawson et al., 2009; Kim et al., 2010), complicating the interpretation 
of subsequent in vivo experiments. Importantly, CMF-019 bound with nanomolar 
affinities to all three mammalian apelin receptors, similarly to [Pyr1]apelin-13, 
supporting its future use in animal studies.  
Modification of the benzimidazole scaffold to introduce a nitrogen atom into the ring 
was performed to try to develop suitable CMF-019 derivatives with improved 
characteristics. The resulting compound, CMF-087, was found to have markedly 
reduced (100-fold) binding to the apelin receptor compared to the parent compound in 
I125 binding assays performed in CHO-K1 cells expressing the human apelin receptor 
(Cerep; Celle L’Evescault, France). In human LV homogenates, although the binding 
to the native receptor was reduced, it was not as severe as predicted with only a 20-
fold loss of affinity. Side chain modification of CMF-087 to produce molecules MM239 
and MM240 was able to rescue some of this binding affinity and was most pronounced 
for MM239, which demonstrated similar affinity to CMF-019 at the native human 
receptor. For potential future in vivo study, the binding in rat heart homogenates was 
also assessed and interestingly both compounds displayed slightly reduced binding 
affinities compared to at the human receptor; nonetheless, they bound strongly with 
nanomolar affinities.  
Assessing the functional activities of the molecules, revealed that the scaffold 
modification in CMF-087 reduced efficacy in both the β-arrestin and cAMP assays and 
largely abolished bias towards the Gαi pathway. This may in part be a reflection of the 
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20-fold decrease in binding affinity but this is unlikely to be the only cause, since the 
relative decreases in efficacy were greater than 20-fold in both assays. This suggests 
that the way the molecule engages the receptor helices within the binding pocket has 
likely been perturbed. Notably, a greater loss of efficacy was observed for the cAMP 
assay than the β-arrestin assay, leading to the loss of bias. Both MM239 and MM240 
displayed improved binding and improved efficacy in β-arrestin signalling compared to 
CMF-087 but showed very little improvement in cAMP inhibition, resulting in an almost 
complete abolition of biased signalling for these molecules. Overall, this suggests that 
the new scaffold structure based on CMF-087 has less inherent bias than the original 
benzimidazole scaffold, and while side-chain extension can improve binding, it also 
leads to a reduction in bias. This is not unexpected as longer peptides have previously 
been thought to reach deeper within the binding pocket of the receptor to better engage 
β-arrestin signalling motifs, as previously discussed in Section 1.3. It is possible that 
the side-chain extensions are capable of performing a similar role with these 
compounds.  
Following exploration of this series of compounds, an attempt was made to 
amalgamate the structure of CMF-087 with the structures of two other recently 
identified small molecule apelin agonists from the Sanford-Burnham triazole series 
(Pinkerton and Smith, 2015) and the RTI International pyrazole series (Narayanan et 
al., 2016). It was hoped that the resulting compound, designated CMF-167, would 
combine three series of diverse agonists, providing a molecule with strong activity at 
the apelin receptor. However, the molecule displayed no binding in the I125 Cerep 
screening assay or activity in a β-arrestin assay, suggesting that the molecule lacked 
any engagement with the receptor.  
After screening the compounds based on CMF-019, none of them demonstrated an 
improvement on the parent molecule. Although MM239 and MM240 rescued binding 
affinity compared to CMF-087, they showed a loss of bias and it was decided that CMF-





3.4.2 CMF-019 is a Full Agonist at the Apelin Receptor 
Potencies between compounds have been compared and bias factors calculated. This 
did not take into account EMAX values and whether they function as full or partial 
agonists. Looking at the β-arrestin and internalisation assays for CMF-013, -015 and -
021 it can be seen that the EMax values do not reach 100% of the [Pyr1]apelin-13 
maximal response. However, it is difficult to assess whether this is a demonstration of 
genuine partial agonism in these compounds because concentrations higher than 
0.1mmol/L could not be achieved without increasing the DMSO concentration (in which 
the compounds were dissolved) above 1% in the assay. It is not recommended that 
the DMSO concentration exceeds this level as it causes depression in responses close 
to or above this threshold. Indeed, the lower EMAX values with these compounds may 
be a result of the signal beginning to drop at the maximal 1% DMSO concentration 
used. A similar effect was also seen in the β-arrestin assay with CMF-087 and was 
particularly pronounced with MM240. The highest concentration of 0.1mmol/L for 
MM240 was excluded from the data (Figure 3.9) as a substantial drop in signal was 
observed at this concentration, perhaps suggesting some cell toxicity at high 
concentrations with this compound. Therefore, without higher concentrations of CMF-
013, -015, -021, -087 and MM240 being attainable in these assays, it is difficult to 
establish full or partial agonism. Nevertheless, one can be confident that both CMF-
019 and MM239 displayed full agonism as they achieved stimulation of the apelin 
receptor to a level that was the same as the endogenous agonist, [Pyr1]apelin-13. 
3.4.3 Regression Analyses 
A series of regression analyses were performed (Figure 3.11) to try to further 
understand the relationship between functional signalling, bias and binding affinity for 
the small molecules tested in this chapter. 
Binding in human LV correlated to some extent with both β-arrestin signalling (y=1.5x-
6.0; r2=0.71) and Gαi signalling (y=1.2x-1.1; r2=0.60). This is as expected and 
demonstrates some correlation between efficacy and affinity through both pathways. 
The basal level of signalling through the Gαi pathway seemed greater than for β-arrestin 
for these small molecules. This is an interesting observation as it has been suggested 
that longer apelin peptides, such as, apelin-17, have greater binding affinity and also 
greater β-arrestin bias than the shorter forms, such as, apelin-13 (El Messari et al., 
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2004, Ceraudo et al., 2014, Iturrioz et al., 2010b). The hypothesis is that these longer 
peptides can reach deeper into the apelin binding pocket and stabilise the β-arrestin 
signalling confirmation better than shorter molecules. Perhaps the higher intrinsic basal 
signalling through the Gαi pathway compared to the β-arrestin for these small 
molecules is indicative of the fact that they are less able to reach these deeper regions 









Although β-arrestin and Gαi signalling correlate to some extent with binding affinity, the 
fact that the correlation is not perfect is unsurprising and indicates how the efficacy in 
either β-arrestin or Gαi signalling will depend greatly upon the contacts made by the 
compound’s functional groups with the receptor helices within the binding pocket once 
bound. This is reinforced by the fairly poor correlation between the two signalling 
pathways themselves (y=0.6x+4.5; r2=0.56) and is clearly illustrated by the fact that 
ΔΔLogR values (measuring bias) did not correlate with binding affinity at all 
Figure 3.11: A series of regression analyses between functional signalling assays, ΔΔLogR values 
and binding affinities to the native human apelin receptor in human LV homogenates. The line of 
best fit is shown and the goodness of fit given as the r2 value. All correlations significantly differed 
from zero except for the correlation between ΔΔlogR and human LV binding. The key indicates the 
location of each compound, [Pyr1]apelin-13 is not included in the ΔΔlogR vs human LV binding 
correlation as by definition it possess a ΔΔlogR of 0.  
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(y=0.02x+1.4; r2=0.0002). Interestingly, this last result suggests that, while longer 
peptides may show higher binding affinities, which correlates with greater β-arrestin 
signalling, such a hypothesis does not seem to hold for these small molecules where 
any extensions of the molecule will be much shorter. Ultimately, the bias for these small 
molecules depends on where and not how well the molecule binds to the receptor, 
something that can only be assessed by measuring the individual signalling pathways 
involved.  
3.4.4 CMF-019 is the First Evaluated Biased Small Molecule Agonist at the Apelin 
Receptor 
The work presented in this chapter has focussed on the investigation of small molecule 
apelin agonists with the aim of identifying molecules with high binding affinities to the 
native human apelin receptor and with a desirable biased pharmacological profile. To 
our knowledge, CMF-019 is the first report of a biased small molecule apelin agonist.  
Previous synthetic apelin agonists have lacked the desirable characteristics required 
of drug-like molecules. E339-3D6, a reported peptidomimetic agonist exhibited 
vasoactivity in rat aorta preconstricted with noradrenaline and in vivo prevented 
vasopressin release when injected intracerebroventricularly in water-deprived mice 
(Iturrioz et al., 2010a); however, the high molecular weight (1400Da) suggests it would 
be an unsuitable drug molecule, particularly for oral dosing. Moreover, it was later 
shown to be a mixture of polymethylated species from which a number of analogues 
were subsequently purified (Margathe et al., 2014). These molecules, displayed low 
micromolar binding affinities for the apelin receptor compared to CMF-019 which binds 
in the nanomolar range. ML233, a small molecule of molecular weight of 359Da, was 
limited by low solubility in saline at room temperature (Khan et al., 2010). Moreover, 
the structure suggests that it would likely have toxicity, including being a Michael 
acceptor and having an activated quinone (Lagorce et al., 2015). This is supported by 
unpublished observations from our laboratory which have suggested the compound 
displays significant in vivo toxicity when given to male Sprague-Dawley rats (Pers. 
Comm. Yang, Maguire and Davenport). Finally, the RTI International series 
(Narayanan et al., 2016) (which was reported at a similar time to the publication of 
CMF-019 (Read et al., 2016)), although containing the most suitable small molecules 
(~500Da) identified up to that point, showed much weaker activity than CMF-019 with 
potencies in the micromolar range. Therefore, CMF-019 represents a first-in-class 
small molecule apelin agonist and has the potential to greatly progress the apelin field 
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as an experimental tool compound and in the development of small molecule 
therapeutic agonists. 
3.4.5 CMF-019 Displays Bias in a Therapeutically Relevant Range 
One important consideration when assessing compound bias is how much bias is 
necessary to achieve a therapeutically desirable effect? Indeed it is becoming 
increasingly clear that different studies are seeing dramatically different observations 
of bias. Whereas some observe only a few fold changes in activity over the 
endogenous molecule, some see a complete abolition of signalling through a given 
pathway. Since there are currently no designed biased ligands in therapeutic use and 
only a few in clinical trials, it is not easy to answer which of these situations is desirable. 
Logically, one would think that a complete abolition of signalling could be a dangerous 
prospect. This would particularly be the case for compounds biased to limit β-arrestin 
mediated internalisation, such as CMF-019, since without any ability to internalise the 
receptor, one could see a situation where overstimulation of the receptor could 
potentially lead to toxicity and on-target side effects. Considering the Trevena 
compound oliceridine (TRV130), which has been granted breakthrough status by the 
FDA and will be reviewed for approval later this year (www.trevena.com), the bias of 
the compound is only 3-fold over the endogenous agonist morphine (DeWire et al., 
2013). Therefore, even a bias factor of 3-fold seems enough to have a clinically useful 
outcome. CMF-019 displayed a bias factor of 264 between cAMP and β-arrestin 
signalling which should, therefore, be sufficient to observe a measurable and real 
therapeutic effect over the endogenous molecule.  
A potential limitation of any assay designed to measure bias is whether assay-specific 
factors could have an impact on the interpretation of bias. Although in these 
experiments some validation of receptor expression levels and kinetics have been 
performed previously (Section 2.4), there were additional factors that could have 
impacted the bias measured. The kinetics of the assay have been considered for both 
[Pyr1]apelin-13 and MM07 and equilibrium was found to be reached. Nevertheless, it 
is possible that if CMF-019 possessed remarkably different kinetics to these other 
apelin agonists, then this could have had an impact on the bias measured. Additionally, 
differences in some of the reagents between assays could have potentially impacted 
the interpretation of bias. Most notably, the phosphodiesterase inhibitor, IBMX, was 
present in the cAMP lysis buffer in the cAMP assay but there was no equivalent in the 
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β-arrestin assay. In future experiments, if the proprietary information could be obtained, 
an equivalent concentration of IBMX could be added to the β-arrestin assay as an 
additional control.  
A more notable limitation of this study is whether the G protein bias observed from the 
Gαi signalling pathway is able to predict similar Gαq bias that would be in a 
therapeutically useful range. It is arguable that an assay measuring Gαq signalling 
would be more useful as a predictive tool for therapeutic use of apelin agonists given 
its importance in promoting cardiac inotropy in the heart, as well as vasodilatation in 
the vasculature, as discussed in Section 1.2. Previous studies in the laboratory were 
unable to identify a suitable Gαq signalling assay using the DiscovRx platform, 
something that was considered desirable to reduce system bias, as previously 
discussed. The development of a novel and suitable assay for measuring Gαq signalling 
in the apelin system was beyond the scope of this project due to limitations of time. 
Hopefully, future studies will be able to identify robust Ca2+ signalling assays to 
measure Gαq signalling for use in further screening of biased apelin agonists.  
3.4.6 CMF-019 Binds in a Critical Region of the Apelin Receptor 
The experiments in this chapter identified CMF-019 as the lead candidate for further 
study based upon its binding affinity and biased signalling profile. Although from 
competitive radioligand binding experiments it was known that the molecule bound into 
an orthosteric site on the receptor, the contacts made with the receptor were unknown. 
Therefore, to determine the nature of CMF-019 binding into the receptor, molecular 
dynamics simulation studies were performed by our collaborators, Christopher 
Fitzpatrick and Dr Richard Foster in the University of Leeds and Professor Robert Glen 
in the University of Cambridge (Read et al., 2016). They utilised a homology model 
constructed from the 2.5Å resolution crystal structure of the human CXCR4 chemokine 
receptor (Brame et al., 2015) and docking was performed in the absence of water and 
ions using the programme GOLD (CCDC 2015; Jones et al., 1995, Jones et al., 1997).  
It was found that CMF-019 bound into a mainly hydrophobic cavity on the apelin 
receptor near the SHK region of bound apelin-13. The carboxylic acid of CMF-019 was 
predicted to form a strong hydrogen bond (2.3Å) with the side-chain of Arg168. The 
thiophene, which is important for maintenance of good potency, formed a π-stacking 
interaction with residue Tyr88. A ligand/protein plot of these close interactions between 
CMF-019 and the apelin receptor was generated (Figure 3.12A), as well as a close up 
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view of the ligand receptor interactions (Figure 3.12B). CMF-019 and the predicted 
apelin-13 docked structure are overlaid in Figure 3.12C to compare the similarity in the 
expected binding regions. 
Figure 3.12: Computational docking of CMF-019 into a homology model of the apelin receptor.  
(A) A 2D interaction map showing the binding site and interactions between CMF-019 and the apelin 
receptor. The key interactions are π-stacking (thiophene to Tyr88, green line) and ionic (carboxylate 
to Arg168, purple lines) bonds.  
(B) CMF-019 (pale blue sticks) docked via GOLD into the apelin receptor (green). The key binding 
interactions between the ligand and apelin receptor (at Arg168 and Tyr88) are highlighted (dotted 
yellow lines) with intermolecular distances shown.  
(C) The favoured overlay of apelin 13 (red lines) with CMF-019 (grey lines) places CMF-019 at the 
SHK region, suggesting that the SHK sequence of apelin-13 is the most promising region for binding 
of CMF-019 to the APJ receptor. Figure taken from Read et al. 2016.  
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Interestingly, analysis of the predicted binding region of CMF-019 within this 
hydrophobic cavity near the SHK region of bound apelin-13 revealed close proximity 
to the only reported naturally occurring mutation in the apelin receptor to date. In the 
zebrafish, Danio rerio, a single allele of a recessive mutation, grinchs608, leads to a 
Trp85 to Leu85 amino acid change in the second transmembrane domain and results in 
a complete loss of apelin binding. As a consequence of this loss of function, in the most 
severely affected mutants the heart fails to develop (Scott et al., 2007). In our model 
the almost adjacent Tyr88 residue is located within the SHK region of the bound apelin-
13 molecule. Both of these residues have been conserved in humans and all species 
where apelin receptor sequences have been reported, suggesting CMF-019 binds in a 
critical region of the receptor. This is a highly desirable characteristic and means that 
CMF-019 is likely to be able to bind to apelin receptors in different experimental models 
and settings, making it very useful as an experimental tool compound. Moreover, the 
receptor is extremely unlikely to be mutated in the CMF-019 binding region in humans, 




















3.4.7 Newly Identified Small Molecule Apelin Agonists Possess Structural 
Similarities to CMF-019 
In support of our findings, several series of small molecule apelin agonists that share 
some structural similarity to CMF-019 have recently been reported by Amgen (Chen et 
al., 2017b), Bristol-Myers Squibb (Myers et al., 2017), RTI International (Narayanan et 
al., 2016) and Sanford-Burnham (Pinkerton and Smith, 2015).  They all possess two 
hydrophobic substituents extending from a heterocyclic core, reminiscent of the Sanofi 
series of compounds from which CMF-019 is derived (Hachtel et al., 2014; Figure  
3.13).  
The compound CMF-167, described earlier, attempted to combine some of the 
characteristics of the Sanofi (CMF-019), Sanford-Burnham and RTI International series 
but was unsuccessful.  
The structural similarities between these compounds suggests that they may bind 
within the same site in the apelin receptor and computational docking experiments 
performed by Dr David Huggins support this (Figure 3.14). The identification of five 
series of small molecule apelin agonists that bind in the same region of the receptor 
seems a remarkable case of convergent evolution in drug discovery. Furthermore, the 
fact that all of these compounds have been identified from patents likely indicates good 
selectivity of these structures for the apelin receptor as non-selective compounds are 
usually removed from such screens. It will be fascinating to see if the compounds 
display G protein bias similarly to CMF-019. To our knowledge, these experiments 
have not yet been performed. Hopefully, following our observations with CMF-019, this 


























































































































































































































































































































































































































































































































































































The primary aim of this study was to identify a small molecule apelin agonist for use 
as an experimental tool compound. Biased agonism towards the G protein over the β-
arrestin pathway was considered a desirable trait for a potential therapeutic as this 
could prevent receptor internalisation while maintaining beneficial signalling and such 
an approach has previously been demonstrated with a cyclised peptide, MM07.  
This chapter has shown that CMF-019 is a small molecule that possesses very high 
nanomolar affinity for the apelin receptor. It is remarkable that such a small molecule 
is able to bind with such high affinity and that this is close to the affinity with which the 
endogenous molecule binds. This study has demonstrated that biased agonism can 
be maintained in a small molecule and further confirms that the apelin receptor is 
tractable to biased signalling.  
A number of new apelin agonist series have recently been identified with structural 
similarity to CMF-019. It is thought that these molecules are likely to bind in the same 
binding pocket, a highly conserved region within the receptor. It will be very interesting 
to establish whether these molecules also possess bias, similarly to CMF-019, and 
future studies should be performed. Following their identification, it should not be long 
until these new apelin agonists are characterised; hopefully providing new avenues for 










4. In Vivo Cardiovascular Assessment of 
[Pyr1]apelin-13 and CMF-019 Responses in 
Normotensive Male Sprague-Dawley Rats 
4.1 Introduction 
Apelin has been shown to induce vasodilatation in rodents in vivo (Tatemoto et al., 
2001), as well as cardiac inotropy in vivo in rats (Atluri et al., 2007, Berry et al., 2004, 
Jia et al., 2006) and mice (Ashley et al., 2005).  Importantly, similar observations have 
been made in humans (Japp et al., 2008, Brame et al., 2015, Brash et al., 2018). To 
test the activity of apelin compounds in animals in vivo, an assay was developed based 
on the surgical techniques originally described by Pacher et al. (2008) with several 
additions and modifications. These methods are described in Section 2.7. An example 
of the read-out for a baseline PV loop is shown in Figure 4.1.  Initially,  the catheter 
was adjusted to obtain a stable and symmetrical PV loop from which accurate baseline 







Figure 4.1: An example baseline PV loop. A number of cardiovascular parameters can be derived 
from this trace, including the cardiac contractility which is calculated as the maximal change in 
pressure against time. For this reason artefacts that lead to elevated end-systolic pressures can 
give overestimates of contractile function for positive inotropes (see Figure 4.12)   
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Using these techniques, the in vivo responses to [Pyr1]apelin-13 have been robustly 
measured in normotensive male Sprague-Dawley rats over a number of different 
studies. A recent study has used an invasive method of catheterisation to measure 
responses to [Pyr1]apelin-13  in patients with PAH (Brash et al., 2018) and as such our 
study provides a very useful means of establishing the relevance of responses in 
normotensive naïve rats to responses in humans with disease. In initial studies, the 
method of femoral catheterisation had not been developed and activity was primarily 
measured as an increase in cardiac contractility, cardiac output and stroke volume. In 
later studies, the femoral artery was also catheterised and arterial pressure decreases 
measured.  
The lead compound, CMF-019, was studied in two separate in vivo experiments. The 
first study again did not utilise a femoral catheter and aimed to primarily assess in vivo 
activity through cardiac contractility, cardiac output and stroke volume. As arterial 
pressure could not be measured accurately in this experiment, it was not evident 
whether CMF-019 was capable of inducing vasodilatation. This is an important 
question to answer as previous studies have suggested that β-arrestin signalling and 
subsequent receptor internalisation are required for vasodilatation through the apelin 
receptor (El Messari et al., 2004, Ceraudo et al., 2014, Iturrioz et al., 2010b, Besserer-
Offroy et al., 2018). This would suggest that G protein biased molecules, such as CMF-
019, would be less able to induce vasodilatation and could limit their clinical efficacy. 
However, previous experiments in our laboratory have not supported this hypothesis 
and MM07, a cyclised G protein biased peptide, was capable of producing robust 
vasodilatation in humans in vivo (Brame et al., 2015). In order to answer this question, 
a second in vivo study was performed following development of the femoral 
catheterisation technique. Additionally, a fourth dose of [Pyr1]apelin-13 at 50nmol was 
given to all of the animals in this study. This was to assess the relative desensitisation 
of the apelin receptor in vivo by either saline, [Pyr1]apelin-13 or CMF-019 and establish 







4.2 Methods  
4.2.1 [Pyr1]apelin-13: Cross-study Cardiovascular Responses In Vivo 
[Pyr1]apelin-13 (50nmol n=32, 400nmol n=10, 0.5mL, 0.9% saline, pH5) and saline 
(n=17 and 10, respectively, 0.9%, 0.1mL, pH9) responses were taken from six different 
studies (colour coded) conducted over a period of two and a half years and compared. 
N values for the arterial pressures were lower [Pyr1]apelin-13 (50nmol n=24, 400nmol 
n=2) and saline (n=7 and n=4, respectively) since this technique was developed later. 
In so far as it was possible, the [Pyr1]apelin-13 doses were compared to their 
corresponding saline control doses.  All data were tested for normality using the 
D’Agostino-Pearson omnibus K2 test. This was the recommended test and takes into 
account both skewness and kurtosis, as well as how much each individual value differs 
from that expected in a Gaussian distribution. However, the test requires n values of 8 
or more and so the arterial pressure for saline controls (n=7, n=4) and the 400nmol 
dose of [Pyr1]apelin-13 (n=2) could not be computed as the n-values were too low. 
Data were compared using a two-tailed Student’s t-test (GraphPad Prism 6). Statistical 
significance was taken as 5%. 
4.2.2 In Vivo LV Catheterisation for Measurement of Acute Cardiovascular Changes 
Upon Administration of CMF-019: Study 1 
Male Sprague-Dawley rats (273±6g, n=18) underwent jugular vein cannulation and LV 
catheterisation as described in Section 2.7. Owing to solubility issues in saline with the 
original CMF-019 compound (Figure 3.1C), the chemical structure was modified to 
include the incorporation of a potassium salt on the carboxylic acid group (Figure 4.2). 










Three cumulative bolus doses of CMF-019 (50-5000nmol, 0.5mL, 0.9% saline, pH9), 
saline (0.9%, 0.1mL, pH9) or [Pyr1]apelin-13 (50, 400nmol, 0.5mL, 0.9% saline, pH5) 
were then administered intravenously, followed by a saline flush (0.9%, 0.1mL, pH5) 
via the cannula at a minimum of ten minute intervals or when a stable baseline was 
reached before the next injection. Animals were randomly chosen to receive CMF-019, 
saline or [Pyr1]apelin-13.  
4.2.2.1 Analysis of Plasma Samples by Mass Spectrometry 
Analysis of plasma samples was performed by Peakdale Molecular (Chapel-en-la-
Frith, UK). End-point blood samples were taken from rats (n=6) following completion 
of three cumulative doses of CMF-019 in the first in vivo study, approximately 10 
minutes after the last intravenous administration. The blood was collected in heparin-
coated vials and spun at low speed (2000g, 5min), the plasma supernatant was 
removed and frozen. Quantitative analysis was performed using LC-MS/MS with 
metaprolol as an internal standard and CMF-019 to quantify CMF-019 in the samples. 
4.2.3 In Vivo LV and Femoral Artery Catheterisation for Measurement of Acute 
Cardiovascular Changes Upon Administration of CMF-019: Study 2 
The methodology for this study was very similar to the first study; however, in this case 
male Sprague-Dawley rats (271±3g, n=17) also underwent femoral artery 
catheterisation as described in Section 2.7. The [Pyr1]apelin-13 doses were adjusted 
to 10, 50 and 150nmol (0.5mL, 0.9% saline, pH5) and all animals received a 50nmol 
dose of  [Pyr1]apelin-13 as a fourth dose after they had received their first three doses 




Figure 4.3: Dosing schedule for the second acute in vivo study of CMF-019. The LV and femoral 
artery were catheterised in normotensive male Sprague-Dawley rats. The animals were randomly 
chosen to receive either three doses of saline, CMF-019 or [Pyr1]apelin-13, before a fourth dose of 
50nmol [Pyr1]apelin-13 was administered regardless of the previous doses administered. Doses 
were administered at ten minute intervals, or when a stable baseline was reached, after which the 




4.3.1 [Pyr1]apelin-13 Produced Robust Observable Responses In Vivo in Real-Time 
Looking at an example trace following a dose of 50nmol [Pyr1]apelin-13 compared to 
saline (Figure 4.4) in the same animal,  it is clear that [Pyr1]apelin-13 induced robust 
observable vasodilatation (LVSP and arterial pressure) and cardiac inotropy (dp/dtMAX). 
Stroke volume and heart rate may also have slightly increased, leading to an increase 
in cardiac output; however, it is harder to observe clear responses in these parameters 
in real-time. 
Figure 4.4: An example trace showing cardiovascular responses to saline and [Pyr1]apelin-13 
(50nmol) in vivo in one male Sprague-Dawley rat. The read-outs show changes in LVSP, arterial 
pressure, volume, contractility (dp/dtMAX) and heart rate. Real-time observable changes are evident 
in the LVSP (10mmHg decrease), arterial pressure (32mmHg) and contractility (900mmHgs). 
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4.3.2 Cross-study Analysis Comparing Consistency of In Vivo Cardiovascular 
Responses to [Pyr1]apelin-13  
In order to establish the consistency of [Pyr1]apelin-13 responses and to validate the 
statistical tests used for the in vivo analysis, cumulative cross-study data of 
[Pyr1]apelin-13 are presented (Figure 4.5). All responses that could be tested for 
normality using a D’Agostino-Pearson omnibus K2 test were normally distributed. 
[Pyr1]apelin-13 consistently decreased both LVSP (Figure 4.5A) and arterial pressure 
(Figure 4.5B) at both doses administered with changes of 9.43±0.95mmHg 
(****p<0.0001) and 30.62±3.47mmHg (****p<0.0001) at 50nmol and 11.65±2.21mmHg 
(****p<0.0001) and 40.13±4.71mmHg (****p<0.01) at 400nmol, respectively. For 
contractility (Figure 4.5C), the 50nmol dose of [Pyr1]apelin-13 produced a small 
increase of 550±209mmHg/s (*p<0.05), however, at the higher 400nmol dose there 
was a much larger increase of 3100±566mmHg/s (****p<0.0001). There was a 
propensity for [Pyr1]apelin-13 to act as a negative lusitrope at the 50nmol dose causing 
a consistent reduction in the relaxation rate of 819±231mmHg/s (***p<0.001). This 
effect was not observed at the higher 400nmol dose (Figure 4.5D). Increases in cardiac 
output (Figure 4.5E) of 2334±323RVU/min (****p<0.0001) and 3601±518RVU/min 
(****p<0.0001) at 50nmol and 400nmol doses, respectively, were mirrored by 
increases in stroke volume (Figure 4.5F) of 6.37±0.94RVU (****p<0.0001) and 
8.28±1.02RVU (****p<0.0001) but not by heart rate (Figure 4.5G), which only showed 
a significant increase at the 400nmol dose of 16.75±6.37BPM (*p<0.05). The rats that 
are presented in Figure 4.5 had all received [Pyr1]apelin-13 as a first dose or following 
only saline administration and 100% responded by observation. Qualitatively 
assessing responses in all 72 animals that received the 50nmol dose of Pyr1]apelin-13 
at any stage of their dose schedule, 67 demonstrated an observable response, giving 
an overall response rate of 93%. Looking at the 5 ‘non-responders’, all had previously 
received a dose of another compound which may have perturbed their baseline 
parameters. In one case no response was detected to [Pyr1]apelin-13 in two 
consecutive rats and a different batch was used subsequently to the first dose in the 
second rat. A robust response was observed suggesting the first batch as the reason 
for the lack of response and it was not used in further experiments. Therefore, in 
actuality a response rate of 93% to [Pyr1]apelin-13 is likely an underestimate and 


















Figure 4.5: Cardiovascular responses to [Pyr1]apelin-13 (50nmol n=32, 400nmol n=10) or saline 
(n=17 and 10, respectively) administration in vivo. Graphs show changes in LVSP (A), arterial 
pressure (B), contractility (dp/dtMAX; C), relaxation (dp/dtMIN; D), cardiac output (E), stroke volume 
(F), and heart rate (G). The different colours represent different studies in which the data were 
acquired. Each [Pyr1]apelin-13 dose was compared by a Student’s t-test to the corresponding saline 
control and statistical significance was taken as 5%. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001  
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4.3.3 CMF-019 Produced Acute Cardiac Responses In Vivo in Normotensive Male 
Sprague Dawley Rats: Study 1 
4.3.3.1 CMF-019 is a Positive Inotrope In Vivo 
Injection of CMF-019 caused a dose dependent increase in the dP/dtMAX, a measure of 
cardiac contractility, with significance at 500nmol of 703±148mmHg/s (***p<0.001) and 
at 5000nmol of 903±260mmHg/s (**p<0.01) (Figure 4.6A). [Pyr1]apelin-13 also caused 
a dose dependent increase with a significant response at 400nmol of 






[Pyr1]apelin-13 dose dependently caused a significant increase in stroke volume and 
cardiac output of 3.00±0.88RVU (**p<0.01) and 1237±326RVU/min (**p<0.01) at 
50nmol and 8.38±1.23RVU (****p<0.0001) and 3761±721RVU/min (***p<0.001), 
respectively (Figure 4.7D,F). CMF-019 similarly increased these parameters with 
smaller responses of 1.82±0.64RVU (*p<0.05) and 982±302RVU/min (**p<0.01) at 
500nmol, respectively (Figure 4.7C,E). At 500nmol, CMF-019 also resulted in a small 
but significant elevation in the heart rate of 9.18±2.40BPM (**p<0.01, Figure 4.7G). For 
[Pyr1]apelin-13, although there was a trend towards increased heart rate, especially at 
400nmol, the response was more variable and the increase was not significant in this 
Figure 4.6:  The cardiac contractile responses to CMF-019 and [Pyr1]apelin-13 in vivo in the first 
acute study. Dose dependent increases in LV contractility in anaesthetised rats to (A) intravenous 
CMF-019 potassium salt (■, n=7-9) and (B) [Pyr1]apelin-13 (apelin, ▲, n=8) compared to saline (●, 
n=3-5) control. Each dose was compared by a Student’s t-test to its corresponding saline control as 
doses were administered cumulatively and statistical significance was taken as 5%. *p<0.05, 




study (Figure 4.7H). Neither [Pyr1]apelin-13 nor CMF-019 altered the dP/dtMIN, a 

























[Pyr1]apelin-13 caused a significant dose dependent drop in the LVSP with a drop of 
7.29±2.77mmHg at 50nmol (*p<0.05) and a maximal drop of 13.97±4.16mmHg 
detected at 400nmol (**p<0.01) (Figure 4.7B). In contrast, CMF-019 resulted in an 
increase in pressure of 8.64±3.61mmHg at 5000nmol (*p<0.05) (Figure 4.7A). No 
adverse effects were observed at any of the concentrations administered.  
 
 
Figure 4.7: Cardiovascular responses to CMF-019 and [Pyr1]apelin-13 in vivo. Graphs showing 
changes in LVSP (A-B), stroke volume (C-D), cardiac output (E-F), heart rate (G-H) and relaxation 
(dp/dtMIN) (I-J) for CMF-019 potassium salt (■, n=7-9, A,C,E,G) and [Pyr1]apelin-13 (apelin, ▲, n=8, 
B,D,F,H) compared to saline (●, n=3-5, A-H) when injected intravenously into anaesthetised male 
Sprague-Dawley rats. Each dose was compared by a Student’s t-test to its corresponding saline 
control as doses were administered cumulatively and statistical significance was taken as 5%. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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4.3.3.2 CMF-019 is Present in Rat Plasma Samples 
Analysis of the plasma samples taken from rats treated with CMF-019 demonstrated a 
mean plasma concentration of 25.4±2.5µM (heparinised samples, n=6).  
4.3.4 CMF-019 Produced Acute Cardiac and Vascular Responses In Vivo in 
Normotensive Male Sprague Dawley Rats: Study 2 
4.3.4.1 CMF-019 is a Vasodilator In Vivo 
A further study was conducted whereby in addition to a ventricular catheter, a femoral 
artery catheter was inserted to measure arterial blood pressure changes. To study the 
consistency of responses between the two studies, all of the cardiac parameters from 
the previous study have been analysed. CMF-019 again caused an increase in cardiac 
contractility with a change of 251±89mmHg/s (*p<0.05) observed at 500nmol (Figure 
4.8A). At the higher 5000nmol dose the response was not significant. The response to 
[Pyr1]apelin-13 was also consistent and an increase of 1038±464mmHg/s (***p<0.001) 





For the arterial pressure, CMF-019 caused a dose-dependent decrease at 50nmol and 
500nmol of 4.16±1.18mmHg (**p<0.01) and 6.62±1.85mmHg (**p<0.01), respectively 
(Figure 4.9A). At the highest dose the response was not significant. [Pyr1]apelin-13 
Figure 4.8:  The cardiac contractile response to CMF-019 and [Pyr1]apelin-13 in vivo in the second 
acute study. Increases in LV contractility in anaesthetised male Sprague-Dawley rats to (A) 
intravenous CMF-019 potassium salt (■, n=8) and (B) [Pyr1]apelin-13 (apelin, ▲, n=5) compared to 
saline (●, n=4) control. Each dose was compared by a Student’s t-test to its corresponding saline 
control as doses were administered cumulatively and statistical significance was taken as 5%. 




caused a dose dependent and larger decrease in blood pressure at all doses 
administered; 10nmol 12.06±3.51mmHg (*p<0.05), 50nmol 31.24±8.70mmHg 






The responses in the other cardiovascular parameters measured in response to CMF-
019 and [Pyr1]apelin-13 were largely consistent. Both CMF-019 and [Pyr1]apelin-13 
caused dose-dependent increases in stroke volume and cardiac output (Figure 4.10C-
F). CMF-019 resulted in increases of 2.63±0.82RVU (**p<0.01) and 
1097±284RVU/min (**p<0.01) at 50nmol and 2.48±0.87RVU (*p<0.05) and 
1012±340RVU/min (*p<0.05) at 500nmol, respectively. At the highest dose of 
5000nmol neither of these parameters were significant. Meanwhile, [Pyr1]apelin-13 
induced increases of 4.72±0.98RVU (**p<0.01) and 2008±464RVU/min (**p<0.01) at 
10nmol, 9.70±1.93RVU (**p<0.01) and 3618±818RVU/min (**p<0.01) at 50nmol and 
9.84±3.02RVU (*p<0.05) and 3961±1154RVU/min (*p<0.05) at 150nmol, respectively.  
 
 
Figure 4.9:  The arterial pressure change in response to CMF-019 and [Pyr1]apelin-13 in vivo in the 
second study. Decreases in arterial pressure in anaesthetised male Sprague-Dawley rats to (A) 
intravenous CMF-019 potassium salt (■, n=8) and (B) [Pyr1]apelin-13 (apelin, ▲, n=5) compared to 
saline (●, n=4) control. Each dose was compared by a Student’s t-test to its corresponding saline 
control as doses were administered cumulatively and statistical significance was taken as 5%. 




































Again at 500nmol, CMF-019 a small elevation in heart rate of 5.46±2.32BPM (*p<0.05) 
was observed (Figure 4.10G). An increase in heart rate to [Pyr1]apelin-13 of 
12.94±4.95BPM (*p<0.05) was also observed at 150nmol (Figure 4.10H). Unlike in the 
first study, some small lusitropic changes were observed (Figure 4.10I-J). CMF-019 
led to a potential decrease in relaxation of 210±70mmHg/s (*p<0.05) at the lowest dose 
administered of 50mnol, whilst [Pyr1]apelin-13 led to a decrease of 1143±378mmHg/s 
(*p<0.05) at 150nmol . Finally, the changes in LVSP observed in this study to CMF-
019 were different to those observed in the first study. Whereas, in the first study CMF-
Figure 4.10: Cardiovascular responses to CMF-019 and [Pyr1]apelin-13 in vivo in the second acute 
study. Graphs showing changes in LVSP (A-B), stroke volume (C-D), cardiac output (E-F), heart 
rate (G-H) and relaxation (dp/dtMIN) (I-J) for CMF-019 potassium salt (■, n=8, A,C,E,G) and 
[Pyr1]apelin-13 (apelin, ▲, n=5, B,D,F,H) compared to saline (●, n=4, A-H) when injected 
intravenously into anaesthetised male Sprague-Dawley rats. Each dose was compared by a 
Student’s t-test to its corresponding saline control as doses were administered cumulatively and 
statistical significance was taken as 5%. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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019 caused small dose-dependent increases in LVSP (Figure 4.7A), here it decreased 
LVSP (Figure 4.10A) in concert with the arterial pressure. CMF-019 resulted in LVSP 
decreases of 1.88±0.57mmHg (**p<0.01) at 50nmol and 2.23±0.80mmHg (*p<0.05) at 
500nmol. No significant change was observed at the highest dose of 5000nmol. 
[Pyr1]apelin-13 also decreased LVSP (Figure 4.10B) and this was consistent with the 
first study (Figure 4.7B). [Pyr1]apelin-13 led to decreases of 5.66±0.81mmHg 
(***p<0.001) at 10nmol, 11.02±1.70mmHg (***p<0.001) at 50nmol and 
9.47±1.16mmHg (****p<0.0001) at 150nmol. Similarly, no adverse effects were 
observed at any of the doses administrated.  
4.3.4.2 CMF-019 Does Not Desensitise the Apelin Receptor In Vivo 
To study desensitisation at the apelin receptor in vivo a fourth dose of [Pyr1]apelin-13 
at 50nmol was administered to all of the treatment groups used in the study (Figure 
4.11). In this figure the x-axis denotes whether the preceding three doses were saline 
or increasing cumulative doses of CMF-019 or [Pyr1]apelin-13. Qualitatively, the 
responses to 50nmol [Pyr1]apelin-13 were larger if the animal had previously received 
saline or CMF-019 than if they had received [Pyr1]apelin-13. This was only significant 
for the change in cardiac contractility where [Pyr1]apelin-13 treated animals had a 
difference in response compared to saline treated animals of 544±81mmHg/s 
(***p<0.001). The responses to [Pyr1]apelin-13 in CMF-019 treated animals compared 






























Figure 4.11: Cardiovascular responses to 
[Pyr1]apelin-13 at 50nmol administered as a 
fourth dose following three cumulative doses 
of either saline (pH9), CMF-019 or 
[Pyr1]apelin-13 in vivo in the second acute 
study. Graphs show changes in arterial 
pressure (A), contractility (dp/dtMAX) (B), 
LVSP (C), stroke volume (D), cardiac output 
(E), heart rate (F) and relaxation (dp/dtMIN) 
(G) to 50nmol [Pyr1]apelin-13 in 
anaesthetised male Sprague-Dawley rats 
previously administered with three doses of 
either  CMF-019 potassium salt (■, n=8), 
[Pyr1]apelin-13 (▲, n=5) or saline (●, n=4). 
Each treatment group was compared by a 
Student’s t-test to the corresponding saline 
control and statistical significance was taken 





4.4.1 [Pyr1]apelin-13 Produced Robust Cardiovascular Responses In Vivo 
Supporting the Apelin Receptor as a Suitable Therapeutic Target 
Apelin has previously been reported to produce cardiovascular responses in rodents 
(Jia et al., 2006, Tatemoto et al., 2001, Ashley et al., 2005, Atluri et al., 2007, Berry et 
al., 2004). Therefore, to validate the in vivo assay developed, [Pyr1]apelin-13, the most 
abundant cardiovascular isoform (Maguire et al., 2009), was tested. The example trace 
shown in Figure 4.4, clearly demonstrates that [Pyr1]apelin-13 administered at the 
intermediate dose of 50nmol was capable of producing robust vasodilatation and 
cardiac inotropy as expected for apelin from these previous studies. Moreover, 
responses were sufficiently robust that they could be observed in real-time.  
Having established that clear responses to [Pyr1]apelin-13 were observable, it was 
important to assess the reproducibility of these responses. To do this data from across 
a number of studies where [Pyr1]apelin-13 had been used as a positive control were 
compared. The different studies have been colour-coded in Figure 4.5 so that any 
trends could be more easily picked out. The data were assessed for normality using 
the D’Agostino-Pearson omnibus K2 test. This is the recommended test for normality 
but requires n values of 8 or greater and so cannot be used for smaller data sets. By 
analysing this large data set of [Pyr1]apelin-13 responses, it clearly demonstrated that 
the in vivo [Pyr1]apelin-13 responses were normally distributed in every parameter that 
could be measured. In many in vivo studies sufficient n values cannot be obtained to 
calculate the D’Agostino-Pearson omnibus K2 test as it is important to reduce animal 
use. Alternative tests, for example, the Shapiro-Wilks test may be used as this requires 
a minimum of 3 n values; however, this test is less robust and is not recommended. 
Instead, by demonstrating that collectively the responses to [Pyr1]apelin-13 are 
normally distributed across all of the experiments performed, it seems justifiable to 
assume normality of the responses within individual experiments. As such, the 
Student’s t-test, a parametric statistical calculation, has been used for all of the acute 
in vivo analysis as this is the most appropriate test to use for normally distributed data.  
Overall, all of the animals administered the 50nmol or 400nmol dose of [Pyr1]apelin-13 
responded and there seem to be no obvious differences between the studies 
conducted over the two and a half year period. The responses observed were 
consistent with [Pyr1]apelin-13 as a reported vasodilator and cardiac inotrope. 
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Crucially, in a study using invasive catheterisation in patients with PAH to assess 
responses to [Pyr1]apelin-13, it was found that it primarily reduced total pulmonary 
vascular resistance and increased cardiac output (Brash et al., 2018), suggesting that 
the responses measured in our study in naïve normotensive male Sprague-Dawley 
rats are comparable to those one would expect in humans, even those with disease.  
The clearest response observed in our study was a substantial reduction in arterial 
pressure, which was as much as 30mmHg with the 50nmol dose and 40mmHg with 
the 150nmol dose. Such a response is remarkable and demonstrates the potency of 
the apelin system, though it should be noted that such large responses have not been 
observed in humans. In the rats, the dilatation was sufficiently large that a drop in LVSP 
was observed, despite the inotropic effects of the compound. The most likely 
explanation for this is that the arterial dilatation led to a sufficient drop in afterload to 
reduce the pressure within the ventricular cavity. Simultaneously, the molecule acted 
as a positive inotrope, increasing the contractility of the LV, while enhancing stroke 
volume and cardiac output. The contractility showed a smaller response at 50nmol 
than at 150nmol where the responses were large but substantially more variable. A 
likely explanation for this comes from the fact that the dp/dtMAX measurements are 
highly dependent on catheter location. In particular, with positive inotropes, it has been 
reported that the catheter can be pushed into the ventricular wall, giving an artificial 
elevation in the end-systolic pressure and an overestimate of the dp/dtMAX (Wei et al., 
2014). An example of such an artefact is shown below (Figure 4.12), in some cases 
these artefacts can be difficult to detect as the catheter movement can be gradual. In 
these studies, an attempt has been made to exclude such aberrant measurements by 
adjusting the catheter after the dose and demonstrating that a shift in location had 
occurred. Nevertheless, very large elevations or reductions in contractility should be 
















A potential limitation of this in vivo study was the need to anaesthetise the animals with 
isoflurane which could have impacted responses. A possible manifestation of this could 
have been reduced or delayed homeostatic mechanisms and thus, enhanced 
responses relative to those that might be observed in a conscious animal. This could 
particularly have impacted vasodilatation and may have resulted in greater and more 
sustained drops in blood pressure than one would otherwise expect. However, this 
would not have been the case for the cardiac parameters, since isoflurane is a well 
characterised negative inotrope and is known to reduce cardiac contractility, stroke 
volume and output (Philbin and Lowenstein, 1975, Makela and Kapur, 1987, Lynch, 
1990). Therefore, the cardiac responses measured were likely blunted compared to 
those in a conscious animal. It is arguable that alternative anaesthetics might have 
been preferable in this study because of the cardiac impact of isoflurane. However, 
other anaesthetics would also act as cardiac depressants and because many of them 
must be administered by injection, rather than inhalation as for isoflurane, it is harder 
to maintain a consistent level of anaesthesia. Instead isoflurane was considered the 
Figure 4.12: PV loops demonstrating artificial elevation of the end-systolic pressure due to catheter 
movement into the endocardial wall following a single 150nmol dose of ELA-32, a very powerful 
inotrope through the apelin receptor. Since cardiac contractility is calculated as the maximal change 
in pressure against time as shown in figure 4.1, such artefacts can lead to a dramatically 
overestimated Dp/DtMAX unless accounted for. In this case as the initial systolic pressure levels off 
before the peak artefact, the Dp/DtMAX would not actually be substantially perturbed, however, the 
Dp/DtMIN, a measure of lusitropy, would be overestimated.   
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best option and, in order to impact responses as little as possible, the animal was 
carefully monitored, by both heart and breathing rate, such that as light anaesthesia 
as possible could be maintained throughout the experiment.  
One advantage of this cross-study comparison is that all of the rats used were outbred, 
suggesting that there should be genetic variation between batches. Many drugs are 
limited and fail in phase III clinical trials due to a lack of clinical efficacy. This is largely 
due to a lack of response in a subset or subsets of the population. Here, the number 
of ‘responders’ and ‘non-responders’ to [Pyr1]apelin-13 were identified. It is remarkable 
that overall 93% of the animals tested with the 50nmol dose of [Pyr1]apelin-13 
responded. Moreover, of those that did not, there were clear reasons why they may 
not have responded, having previously received apelin mimetics that may have 
desensitised the receptor. Crucially, all of the animals that received either nothing or 
only saline (essentially naïve rats) before the [Pyr1]apelin-13 dose responded. This 
100% response rate is remarkably high and implies that the apelin system is efficacious 
across the population and would, therefore, be extremely suitable as a therapeutic 
target. A limitation of this study is that there is likely to be far less genetic variation in 
Sprague-Dawley populations, outbred or not, than is desirable for a cross-population 
study of responses. To better assess the consistency of apelin responses across rat 
populations, it would be interesting to perform similar experiments in different outbred 
rat strains. Such studies, while often not performed as they do not identify novel or 
controversial findings, would nonetheless be critical to confirming response within 
populations and have the potential to reduce phase III attrition by ensuring broad 
clinical efficacy from an early stage in the drug development process. 
4.4.2 CMF-019 is a Cardiac Inotrope and Vasodilator In Vivo 
In two separate in vivo studies conducted in normotensive male Sprague-Dawley rats, 
CMF-019 produced consistent cardiovascular responses compared to saline. In both 
cases an increase in contractility with concurrent increases in stroke volume and 
cardiac output were observed. Furthermore, in the second study in which a femoral 
artery catheter was employed, vasodilatation was observed. These responses are 
consistent with CMF-019 acting at the apelin receptor and the responses mimicked 
those observed with the endogenous agonist, [Pyr1]apelin-13, a positive inotrope and 
vasodilator. It should be noted that the responses to CMF-019 were much smaller than 
those observed for [Pyr1]apelin-13 and the highest dose of CMF-019 often did not 
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reach statistical significance. This suggests that either the maximal response to CMF-
019 was achieved at the 500nmol dose or above this concentration no further drug 
was able to reach the receptor in vivo. The reasons as to why this might be are 
discussed later. Nevertheless, these studies critically showed that CMF-019 is active 
in vivo and that the activity observed in the in vitro screening assays translated 
effectively.  
The use of the femoral artery catheter in the second study addressed a crucial question 
in the apelin signalling field, namely whether β-arrestin biased ligands are better able 
to induce vasodilatation. Such a result would imply that G protein biased ligands, such 
as CMF-019, would be less able to induce dilatation. This could limit their clinical 
efficacy, particularly as pulmonary dilatation is the main mechanism by which current 
PAH therapeutics function. The observation of enhanced dilatation in β-arrestin biased 
ligands has been reported on several occasions by the same group (El Messari et al., 
2004, Iturrioz et al., 2010b, Ceraudo et al., 2014, Murza et al., 2015), however, it should 
be noted that the reported β-arrestin responses in these studies were modest. Their 
most recent publication argues for a correlation between β-arrestin signalling and 
propensity to induce hypotensive activity in Sprague-Dawley rats (Besserer-Offroy et 
al., 2018). A significant limitation is that the authors did not perform a similar correlation 
analysis against the G protein signalling pathway. From their data, a correlation looks 
likely and perhaps their observation is actually a correlation between in vitro efficacy 
through multiple pathways and hypotensive action in vivo. Indeed, they also falsely 
reported that MM07, a G protein biased cyclic peptide, was unable to induce 
vasodilatation. These studies from our laboratory, therefore, dispute their conclusions 
since we observed robust and sustained dilatation in humans with MM07 in forearm 
blood-flow and Aellig hand vein plethysmography experiments (Brame et al., 2015). 
Nonetheless, CMF-019 shows a much greater degree of bias than MM07 with very low 
potency in the β-arrestin assay in vitro and is a much keener test of whether G protein 
biased molecules can induce vasodilatation. The small but significant decrease in 
blood pressure of approximately 5mmHg with CMF-019 suggests that vasodilatation 
can occur independently of β-arrestin through alternative signalling pathways. While it 
could be argued that the smaller response to CMF-019 compared to [Pyr1]apelin-13 
(approximately 30mmHg decrease) is due to the bias of CMF-019, this seems unlikely 
and the responses in other cardiovascular parameters were also smaller for CMF-019. 
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4.4.3 CMF-019 Does Not Desensitise the Apelin Receptor In Vivo 
To assess the ability of CMF-019 to internalise the apelin receptor in vivo, a protocol 
was devised whereby subsequent to the three cumulative doses of saline, CMF-019 
or [Pyr1]apelin-13 administered to test responses, a fourth dose of [Pyr1]apelin-13 was 
administered at 50nmol to every animal regardless of the previous three doses. These 
fourth doses were compared to assess whether there was any desensitisation of the 
response as a consequence of the previous doses administered. Although this study 
was limited by the number of animals used and a high variance in the 50nmol 
[Pyr1]apelin-13 responses, there is a clear trend across the parameters. There was 
very little difference in responses to 50nmol [Pyr1]apelin-13 in any parameter when 
they had received either saline or CMF-019 for the first three doses. However, when 
they had received [Pyr1]apelin-13, they displayed qualitatively reduced responses 
compared to the animals that had received saline in every parameter and this was 
statistically significant for contractility. A potential limitation of this study which should 
be considered is that the responses induced by CMF-019 compared to [Pyr1]apelin-13 
were smaller. This might suggest that had larger responses to CMF-019 been 
achievable in vivo then it would desensitise the receptor similarly to [Pyr1]apelin-13. 
However, given there was no observable trend towards desensitisation, in contrast to 
[Pyr1]apelin-13, overall the data suggest that CMF-019 did not desensitise the apelin 
receptor in vivo and that this corroborates the G protein bias observed in vitro. 
4.4.4 CMF-019 In Vivo vs In Vitro 
The responses to CMF-019 were much smaller than for [Pyr1]apelin-13 in vivo, despite 
the fact that larger concentrations of CMF-019 were used. The reason for such a lower 
activity of CMF-019 is difficult to explain because CMF-019 displayed very similar 
binding affinity to [Pyr1]apelin-13 at the apelin receptor in human and rat heart 
homogenates in vitro. A possible explanation is that CMF-019 is limited 
pharmacokinetically when administered in vivo. Prior to in vivo experimentation the 
predicted pharmacokinetic desirability of CMF-019 was considered computationally 
(Figure 4.13; data from Leen Kalash and Professor Robert Glen). CMF-019 displayed 
drug-like properties and a good physiochemical profile when compared to an oral drug 
library for Lipinski’s rules (Figure 4.13A), Verber’s rules (Figure 4.13B) and in a 
Principal Component Analysis (PCA) of 15 physiochemical descriptors (Figure 4.13C). 
CMF-019 had one Lipinski’s Rule-of-Five violation (logP), although this was 
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ameliorated by the ionisation of the carboxylic acid at physiological pH, reducing the 
logD to a more acceptable range (logD=2.74 at pH7.4). Nevertheless, the solubility of 
the compound was not ideal and the potassium salt dissolved in pH9 saline was used 
in the in vivo studies to attain higher concentrations. Despite this, it is likely that the 
maximal solubility of CMF-019 was attained with the 500nmol dose, perhaps explaining 


















Figure 4.13: Assessment of drug-like properties of CMF-019 using FAF-Drugs3.  
(A) The properties of CMF-019 (HBD; H-bond donors; HBA, H-bond acceptors; logP, octanol-water 
partition coefficient; MW, molecular weight) are shown as a dark blue line. A compound library of 
oral drugs was also assessed for these characteristics to illustrate the desirable physiochemical 
properties for a drug-like molecule according to Lipinski’s rules (light blue line). The red area denotes 
where it was not possible to have a molecule with those properties, or where there was a lack of 
data in the library.  
(B) An oral absorption estimation for CMF-019 (dark blue line) (HBD; H-bond donors; HBA, H-bond 
acceptors; RotB, rotatable bonds, logP, octanol-water partition coefficient; MW, molecular weight; 
tPSA, topological polar surface area). A compound library of oral drugs was also assessed for these 
characteristics to illustrate the desirable physiochemical properties for a drug-like molecule 
according to Verber’s rules (dark green line). The red area denotes where it was not possible to 
have a molecule with those properties, or where there was a lack of data in the library.  
(C) An oral property space obtained by applying a Principal Component Analysis (PCA) of 15 
physicochemical descriptors of CMF-019 (shown as the red dot), compared to properties of oral 
drugs in current use, extracted as sublibraries from the databases, eDrugs (blue) and DrugBank 
(orange). Figure from Read et al. (2016).  
129 
 
Moreover, the plasma binding of the molecule was predicted to be in excess of 99% in 
favour of the bound form. This would likely substantially limit the responses that could 
be observed in vivo as the plasma would effectively act as a reservoir for the drug, 
limiting the amount that could perfuse into the tissue and engage the receptor target. 
Although a limitation for acute in vivo measurement, some plasma binding is generally 
considered beneficial for long-term therapeutics by acting as a mechanism for slow 
drug release. However, in this case with binding in excess of 99%, this is unlikely and 
it is probable that much of the drug remains in a bound and inaccessible form within 
the plasma.  
To attempt to assess the stability of CMF-019 in vivo, following completion of the first 
study, blood samples were taken and the CMF-019 concentrations measured. A mean 
plasma concentration of ~25µM was detected. This blood was collected approximately 
ten minutes after the final dose of 5000nmol was administered; however, exact timings 
were not possible as blood could only be collected as part of the exsanguination 
protocol and regular blood sampling for pharmacokinetic analysis was not possible with 
our project licence. Approximating the rat blood volume as 20mL, one would expect a 
plasma concentration of 250µM immediately following this final injection of CMF-019. 
This would leave only 10% of the parent compound in the blood and since doses 
administered were cumulative, the concentration detected in the plasma was 
substantially lower than that administered over the course of the experiment. This 
suggests that CMF-019 is being rapidly metabolised or excreted and does not support 
it as a particularly stable compound in vivo, in contrast to the predicted stability from 
computational studies.  
Despite these pharmacokinetic limitations, the very high concentrations of CMF-019 
used in these experiments should have been sufficient to negate them as an issue. 
Taking the average plasma concentration of CMF-019 measured at the end of the first 
study of 25µM and the pKi of CMF-019 in rat heart homogenate of 8.49, one can 
approximate the receptor occupancy at the rat heart as in excess of 99%. By taking 
the measured plasma concentration from the first study both solubility and 
excretion/metabolism have been removed as variables, suggesting that the maximal 
response to CMF-019 should have been achievable in both studies despite the 
pharmacokinetic issues. Therefore, this may explain why no increase in response was 
seen between the 5000nmol dose and the 500nmol dose of CMF-019 since maximal 




The purpose of this study was to assess the in vivo activity of CMF-019. To do this an 
assay was developed and validated, during which it was demonstrated that 
cardiovascular responses to the endogenous molecule, [Pyr1]apelin-13, are robust and 
highly reproducible. Such a finding supports the apelin system as a therapeutic target. 
Studying CMF-019, it was shown that it was active in vivo, demonstrating that in vitro 
binding and cell signalling efficacy were translatable to a whole-organism experimental 
set-up. Moreover, CMF-019 was shown to be both a positive inotrope and a 
vasodilator, mimicking all aspects of the [Pyr1]apelin-13 response, despite reports that 
G protein biased ligands are limited to cardiac effects without vascular dilatation. 
Finally, it was shown that CMF-019 did not desensitise the apelin receptor in vivo. This 
corroborated the bias predicted from in vitro assays and again supports the 
translatability of these assays to a whole-organism system. Overall, this study supports 















5. CMF-019 and MM07 as Disease-Modifying 
Compounds for Pulmonary Arterial Hypertension 
In Vitro and In Vivo 
5.1 Introduction 
This chapter focuses on PAH, a disease in which both endogenous ligands of the 
apelin receptor, apelin (Goetze et al., 2006, Kim et al., 2013, Alastalo et al., 2011) and 
ELA (Yang et al., 2017b), have been shown to be downregulated. However, receptor 
expression is maintained (Andersen et al., 2009, Falcao-Pires et al., 2009) and 
crucially remains responsive to [Pyr1]apelin-13 in human patients with PAH (Brash et 
al., 2018). This suggests that replacing the missing endogenous ligands could be a 
suitable therapeutic strategy for treating the disease. Indeed, it has been demonstrated 
in the MCT rat model of PAH that exogenous administration of both [Pyr1]apelin-13 
(Falcao-Pires et al., 2009), the most abundant form in the cardiovascular system 
(Maguire et al., 2009),  and ELA-32 (Yang et al., 2017b) could prevent disease onset 
when given by IP injection daily for 21 days. However, both apelin and ELA have limited 
therapeutic potential being limited by half-life and route of administration. Furthermore, 
the apelin receptor is a GPCR and repeat stimulation by endogenous molecules will 
lead to β-arrestin recruitment and internalisation of the receptor, potentially blunting 
their therapeutic efficacy in the long-term. A preferable strategy is to utilise G protein 
biased ligands which would not induce receptor internalisation, such as, MM07 and 
CMF-019.  
Having already established that both MM07 and CMF-019 are capable of inducing 
vasodilatation and cardiac inotropy in vivo mimicking the apelin response, an assay 
assessing prevention of apoptosis in human PAECs was used to study their disease-
modifying potential. In the advanced stages of PAH, pathological remodelling of 
pulmonary vessels occurs including endothelial proliferation and the development of 
distinctive plexiform lesions which may in part be driven by imbalances in apelin 
signalling (Andersen et al., 2011, Yang et al., 2015a). However, in early disease it is 
thought that endothelial cell apoptosis, leading to vascular dysfunction may drive onset 
(Wilson et al., 1992, Rabinovitch, 2012) and that this is then followed by the 
hyperproliferation of a population of apoptosis-resistant endothelial cells (Sakao et al., 
2005). Apelin has been suggested to mitigate this early apoptosis and promotes 
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survival of pulmonary vascular endothelial cells (Alastalo et al., 2011, Kim et al., 2013). 
This suggests that apelin not only benefits the heart and lungs in the disease situation 
to alleviate symptoms but also addresses the aetiology of the disease itself, something 
that current therapies do not do. Here the ability of the G protein biased apelin agonists, 
MM07 and CMF-019, to promote human PAEC survival in response to apoptotic 
stimulation with TNFα/CHX have been studied. TNFα usually prevents apoptosis of 
endothelial cells through activation of the NF-κB pathway, however, in conditions of 
global protein synthesis suppression, such as, with concurrent application of CHX, 
signalling through TNF-R1 dominates leading to JNK phosphorylation and apoptosis 
(Wajant et al., 2003).  
Following assessment of disease-modification in vitro, the compounds were evaluated 
in the MCT rat model of PAH to establish whether they could prevent onset of PAH in 
vivo. This model has been used for decades (Kay et al., 1967) and causes PAH as a 
result of widespread pneumotoxicity (Wilson et al., 1989). The model has attracted 
criticism because it causes a complex multi-organ disease which ultimately results in 
PAH and RV failure and does not recapitulate all aspects of PAH, such as, the 
formation of plexiform lesions. However, the model recapitulates many other aspects 
of human disease, including changes in proximal bronchovascular structures (Colvin 
and Yeager, 2014). Furthermore, it remains the only animal model of PAH that has 
successfully translated a therapeutic from the laboratory to the clinic, this was 
Bosentan, the first endothelin receptor antagonist. 
Other models of PAH in both the rat and mouse exist and these have been 
comprehensively reviewed (Colvin and Yeager, 2014). Studies in mice have often 
focussed on the genetics of the disease and several genetic models based around the 
BMPR2 receptor (bone morphogenetic protein receptor type 2), the most mutated gene 
in human PAH, have been developed (Long et al., 2015, West et al., 2004, Hong et 
al., 2008). In contrast, in rats where there has been less focus on genetic manipulation, 
other models have relied upon hypoxia with and without the VEGF receptor 2 inhibitor 
sugen-5416. Interestingly, hypoxia alone is sufficient to double mean pulmonary 
arterial pressure and cause structural changes in the pulmonary vasculature but the 
disease does not progress to RV failure (Taichman and Mandel, 2013), the ultimate 
cause of death in humans. However, when used in combination with sugen-5416, the 
disease progresses rapidly and severe PAH with RV failure develops (Taraseviciene-
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Stewart et al., 2001, Toba et al., 2014, Christou et al., 2018, Shields et al., 2016). This 
model has also shown potential to develop plexiform lesions, a characteristic trait of 
human disease (Abe et al., 2010), although these only develop at a very late stage of 
the disease and most probably at a point where disease progression is irretrievable 
(Toba et al., 2014). It has also been suggested that other aspects of the sugen-
5416/hypoxia model do not correlate well with human disease and certain aspects of 
the model may be reversible on return to normoxia (Colvin and Yeager, 2014). 
Furthermore, the severity of disease caused by sugen-5416/hypoxia raises a 
significant issue for animal welfare and disease progression can often be so severe 
that euthanasia is required prior to the end-point of the experiment. For this reason 
obtaining approval to perform such studies can represent a significant hurdle.  
Taking all of the information into account, it was decided that the MCT model was 
preferable for our purposes, representing a model that recapitulates many aspects of 
the disease without causing excessive distress. Furthermore, both endogenous 
agonists of the apelin receptor, apelin and ELA, have prevented disease progression 
in this model (Falcao-Pires et al., 2009, Yang et al., 2017b), suggesting that other 
apelin agonists should similarly be efficacious. Most importantly, the MCT model is the 
only animal model of PAH that has seen a drug translated into the clinic and therefore, 
remains the only model that has demonstrated clinical relevance in humans.  
This chapter demonstrates that both MM07 and CMF-019 are capable of preventing 
apoptosis in human PAECs in vitro and consequently, are able to protect against what 
is regarded as one of the key drivers of disease development. However, in the in vivo 









5.2 Methods  
5.2.1 Human PAEC Apoptosis Assay 
The ability of [Pyr1]apelin-13 (10 µM), MM07 (10µM) and CMF-019 (1-10µM) to rescue 
TNFα/CHX induced apoptosis of endothelial cells was compared to rhVEGF (10ng/mL) 
as described in the optimised protocol in Section 2.5. The average induction of 
apoptosis of the analysed experiments was 19.53±1.76%. Data were normally 
distributed using the D’Agostino-Pearson omnibus K2 test and trends were compared 
using a matched ANOVA to account for variability observed in the basal amount of 
apoptotic induction observed between replicates. Statistical significance was taken as 
5%. 
5.2.2 Assessment of CMF-019 Administered Chronically in the Rat MCT Model of 
PAH 
Male Sprague-Dawley rats (209±2g, n=35; Charles River Laboratories, Margate, UK) 
underwent a MCT prevention protocol as described in Section 2.7.1. CMF-019 
(10mg/kg, n=18) or saline (equivalent volume by weight, n=17) were administered as 
a daily IP injection for 21 days. The MCT CMF-019 group was slightly but significantly 
heavier than the saline CMF-019 group at the start of the protocol (8.33±3.17, *p<0.05). 
The other groups were not significantly different in weight. The Fulton index, RVSP 
and LVSP were measured and analysis performed a two-tailed Student’s t-test. 
Although n values were too small to use the recommended D’Agostino-Pearson 
omnibus K2 test to test for normality, data were normally distributed using a Shapiro-










5.3 Results  
5.3.1 Human PAEC Apoptosis Assay  
5.3.1.1 Apelin Did Not Rescue Human PAEC Apoptosis Induced by TNFα/CHX 
The ability of [Pyr1]apelin-13 to prevent TNFα/CHX induced apoptosis in human 
PAECs was tested at 10µM (Figure 5.1). TNFα/CHX significantly increased the 
percentage of annexin+/PI- cells (20.53±1.67%, ####p<0.0001) compared to the EBM-2 
2% FBS control and rhVEGF was able to partially rescue this (12.20±2.01%, **p<0.01). 















Figure 5.1: Dot plot of the percentage of annexin+/PI- stained human PAECs with mean±SEM data 
superimposed for ‘control’ (EBM-2 2%FBS), ‘apoptotic’ (TNFα/CHX) or cells pre-treated with 
rhVEGF (10ng/mL) or [Pyr1]apelin-13 (10µM) prior to induction of apoptosis with TNFα/CHX. 
TNFα/CHX significantly increased the percentage of annexin+/PI- human PAECs and this could be 
rescued by 10ng/mL rhVEGF but not 10µM [Pyr1]apelin-13. Each dot represents data from one 
experiment and data were collected from 3 cell lines. A matched ANOVA compared each treatment 
to TNFα/CHX and statistical significance was taken as 5%. *p<0.05, **p<0.01, ***p<0.001 and 
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5.3.1.2 [Pyr1]apelin-13 in Combination with a Protease Inhibitor Cocktail 
A potential cause for apelin displaying no rescue of TNFα/CHX induced apoptosis in 
human PAECs could have been its short half-life and potential instability in media and 
FBS over the 18 hour incubation time. To attempt to mitigate this as a factor, a protease 
inhibitor cocktail (PIC) was added to the [Pyr1]apelin-13 treatment condition in one 
experiment. The results are shown in Figure 5.2 and it is clear that the PIC dramatically 






Figure 5.2: Dot plots of annexin staining vs PI staining in human PAECs when ‘healthy’ (EGM-2 
10% FBS), ‘control’ (EBM-2 2% FBS), ‘apoptotic’ (TNFα/CHX) or pre-treated with rhVEGF 
(10ng/mL), [Pyr1]apelin-13 + a protease inhibitor cocktail (PIC) or PIC only prior to induction of 
apoptosis with TNFα/CHX. TNFα/CHX induced apoptosis compared to the EGM-2 10% FBS 
‘healthy’ control and the EBM-2 2% FBS serum and GF starved control. This was partially rescued 
by rhVEGF and wholly prevented by both conditions using the PIC.  
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5.3.1.3 [Pyr1]apelin-13 Did Not Rescue Human PAEC Apoptosis Induced by Growth 
Factor and Serum Starvation 
The ability of [Pyr1]apelin-13 to prevent GF and serum starvation induced apoptosis in 
human PAECs was tested at 10µM as a control (Figure 5.3). GF and serum starvation 
significantly increased the percentage of annexin+/PI- cells (7.58±0.97%, ###p<0.001) 
compared to the EGM-2 10% FBS control and rhVEGF was able to completely rescue 
this (8.05±0.81%, ***p<0.001). However, 10µM [Pyr1]apelin-13 provided no significant 















Figure 5.3: Dot plot of the percentage of annexin+/PI- stained human PAECs with mean±SEM data 
superimposed when ‘healthy’ (EGM-2 10%FBS), ‘control’ (EBM-2 2% FBS) or treated with rhVEGF 
(10ng/mL) or [Pyr1]apelin-13 (10µM). GF and serum starvation (EBM-2 2% FBS) significantly 
increased the percentage of annexin+/PI- human PAECs and this could be rescued by 10ng/mL 
rhVEGF but not 10µM [Pyr1]apelin-13. Each dot represents data from one experiment and data were 
collected from 3 cell lines. A matched ANOVA compared each treatment to the EBM-2 2% FBS 
condition and statistical significance was taken as 5%. *p<0.05, **p<0.01, ***p<0.001 and 
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5.3.1.4 MM07 and CMF-019 Rescued Human PAEC Apoptosis Induced by 
TNFα/CHX 
The ability of MM07 and CMF-019 to prevent TNFα/CHX induced apoptosis in human 
PAECs were tested at 10µM and 1-10µM, respectively (Figure 5.4). TNFα/CHX 
significantly increased the percentage of annexin+/PI- cells (19.54±1.76%, 
####p<0.0001) compared to the EBM-2 2% FBS control and rhVEGF was able to 
partially rescue this (11.59±1.85%, **p<0.01). As with MM07 at 10µM (4.45±0.89%, 
**p<0.01) and CMF-019 at 1µM (5.66±0.97%, **p<0.01). CMF-019 at 10µM displayed 













Figure 5.4: Dot plot of the raw percentage of annexin+/PI- stained human PAECs with mean±SEM 
data superimposed when ‘control’ (EBM-2 2% FBS), ‘apoptotic’ (TNFα/CHX) or pre-treated with 
rhVEGF, MM07 (10µM) or CMF-019 (1-10µM) prior to induction of apoptosis with TNFα/CHX. 
TNFα/CHX significantly increased the percentage of annexin+/PI- human PAECs and this could be 
rescued by 10ng/mL rhVEGF, MM07 at 10µM and CMF-019 at 1µM also displayed some rescue, 
however, CMF-019 at 10µM did not. Each dot represents data from one experiment and data were 
collected from 3 cell lines. A matched ANOVA compared each condition to TNFα/CHX and statistical 
significance was taken as 5%. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. #### indicates 
p<0.0001 compared to control (EBM-2 2% FBS). It should be noted that some of the control data 
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5.3.1.5 MM07 and CMF-019 Did Not Rescue Human PAEC Apoptosis Induced by 
Growth Factor and Serum Starvation 
The ability of MM07 and CMF-019 to prevent GF and serum starvation induced 
apoptosis in human PAECs was tested at 10µM and 1-10µM, respectively, as a control 
(Figure 5.5). GF and serum starvation significantly increased the percentage of 
annexin+/PI- cells (9.33±1.94%, ##p<0.01) compared to the EGM-2 10% FBS control 
and rhVEGF was able to completely rescue this (8.86±1.07%, ***p<0.001). However, 
MM07 at 10 µM (-1.09±0.97%, ns) and CMF-019 at 1 µM (1.04±0.86%, ns) and 10µM 














Figure 5.5: Dot plot of the percentage of annexin+/PI- human PAECs with mean±SEM data 
superimposed when ‘healthy’ (EGM-2 10%FBS), ‘control’ (EBM-2 2%FBS) or treated with rhVEGF 
(10ng/mL), MM07 (10µM) or CMF-019 (1-10µM). GF and serum starvation (EBM-2 2% FBS) 
significantly increased the percentage of annexin+/PI- human PAECs and this could be rescued by 
10ng/mL rhVEGF. MM07 and CMF-019 did not rescue. Each dot represents data from one 
experiment and data were collected from 3 cell lines. A matched ANOVA compared each condition 
to the EBM-2 2% FBS condition and statistical significance was taken as 5%. *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. ## indicates p<0.01 compared to the ‘healthy’ control (EGM-2 10% 
FBS). It should be noted that some of the control data points are the same as for the [Pyr1]apelin-
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5.3.2 CMF-019 Did Not Prevent the Onset of PAH In Vivo in a Rat MCT Model 
A single subcutaneous injection of 60mg/kg MCT (n=20) induced PAH in rats 
compared to an equivalent volume of saline (n=15) as illustrated in the saline treated 
control groups (Figure 5.6). Rats that received MCT demonstrated elevated RVSP 
(33.83±4.00mmHg, ****p<0.0001), reduced LVSP (-13.44±5.36mmHg, *p<0.05), 
increased RV hypertrophy (Fulton Index; 0.20±0.03, ****p<0.0001) and reduced body 















Figure 5.6: Terminal (day 21) measurements from a rat MCT-induced model of PAH assessing 
CMF-019 as a preventative therapeutic agent. Male Sprague-Dawley rats (n=35) received a 
subcutaneous injection of saline (n=15) or MCT (n=20) followed by 21 days of either daily IP 
injections of saline (n=17) or CMF-019 (n=18). The MCT animals displayed increased RVSPs and 
Fulton indices with reduced LVSPs and weights. There were no differences between saline and 
CMF-019 receiving MCT animals. Data were compared using a two-tailed Student’s t-test and 




CMF-019 administered daily by IP injection for 21 days at 10mg/kg showed no 
improvements compared to saline controls in preventing the onset of PAH in these 
MCT-treated animals. Compared to their corresponding saline CMF-019 treated 
controls, they also displayed elevated right ventricular systolic pressures (RVSP; 
35.06±4.13mmHg, ****p<0.0001), reduced LVSP (-16.54±2.81mmHg, ****p<0.0001), 
increased RV hypertrophy (Fulton Index; 0.20±0.03, ****p<0.0001) and reduced body 






















5.4.1 MM07 and CMF-019 are Disease-Modifying In Vitro 
Current therapeutics for PAH, such as prostanoid infusions and endothelin 
antagonists, work by relieving pulmonary vasoconstriction to reduce pulmonary 
pressure and alleviate afterload on the RV. However, they do not benefit the heart itself 
to reduce remodelling and ultimately failure of the RV still leads to mortality.  Moreover, 
they are only symptomatic and do not address the underlying cause of the pulmonary 
vasoconstriction and hypertension, the drivers of disease. Apelin is advantageous in 
both these regards. It acts as a vasodilator and an inotrope to provide benefit to the 
pulmonary vasculature and the heart. Furthermore, there is growing evidence that it 
may be able to alleviate disease progression by protecting the pulmonary vasculature, 
particularly by preventing endothelial damage in the early stages of the disease 
(Alastalo et al., 2011, Kim et al., 2013, Sakao et al., 2005). To this end, an apoptosis 
assay in human PAECs (Long et al., 2015) was employed (following optimisation and 
adaptation  as detailed in Section 2.5) to assess the disease-modifying potential of 
apelin mimetics. This assay utilised TNFα/CHX to induce apoptosis in human PAECs 
which was subsequently measured by annexin V-FITC and PI staining detected by flow 
cytometry.  
Initially, [Pyr1]apelin-13 was used to assess whether rescue of apoptosis could be 
achieved with the endogenous agonist; however, none was observed either in the 
TNFα/CHX treated or the serum and GF starved control arm of the experiment. This 
could have been due to instability of the endogenous peptide during the 18 hour 
incubation time in media and FBS, the latter of which likely contains a number of 
proteases. To overcome this, a PIC was added to the apelin-treated wells. In both the 
apelin and PIC control wells, there was a substantial reduction in apoptosis. Such a 
result is unsurprising as inhibiting proteases within the experiment would effectively 
negate the effects of CHX by enhancing longevity of cellular peptides. Thus, without 
protein synthesis inhibition, TNFα functions to a greater extent through the 
antiapoptotic NF-κB pathway rather than promoting JNK phosphorylation and 
enhancing apoptosis. While this experiment did not establish whether apelin is capable 
of preventing TNFα/CHX induced apoptosis in human PAECs, it did act as an effective 
control for the experiment and confirm the necessity of protein synthesis inhibition by 
CHX for TNFα-induced apoptosis.  
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Alternatively, it is well known that media and serum contain a large number of plasma 
binding proteins and these might have acted as a reservoir, reducing the amount of 
free [Pyr1]apelin-13 available to bind to the apelin receptor. To overcome this, cells 
were serum starved in 2% FBS prior to experimentation and a relatively high 10µM 
concentration of [Pyr1]apelin-13 was used. It was decided not to serum starve with 
concentrations below 2% FBS as the aim was to induce apoptosis from a relatively 
healthy initial human PAEC population. This should better mimic early disease, where 
healthy human PAECs undergo apoptosis and also provide a larger window because 
healthy cells would be more prone to apoptotic stimuli, having not been conditioned 
previously. Given this, the concentrations of apelin were comparative to previous 
studies that have shown in 0.5% FBS serum starved PAECs apelin at 0.1µM promoted 
survival (Alastalo et al., 2011) and that 1µM was sufficient to lead to miRNA expression 
changes (Kim et al., 2013).  
Even though [Pyr1]apelin-13 was unable to rescue apoptosis induced by TNFα/CHX,  
MM07 and CMF-019 were nonetheless tested in the assay as they have greater 
predicted in vitro stability. Again similar concentrations to those with [Pyr1]apelin-13 
were used to overcome potential plasma protein binding. Both MM07 (10µM) and 
CMF-019 (1µM) displayed significant rescue, with CMF-019 at 10µM trending towards 
significance. The rescue of both compounds was approximately 50% of that observed 
for the positive control, rhVEGF, and supports a role for apelin agonists in preventing 
endothelial damage in healthy human PAECs when challenged with an apoptotic 
stimulus. The mechanism by which this occurs is not well characterised; however, both 
[Pyr1]apelin-13 and ELA-32, endogenous agonists of the apelin receptor, promote 
ERK1/2 phosphorylation in human PAECs (Yang et al., 2017b), while some apelin 
isoforms have been shown to downregulate the JNK and p-38 pathways in osteoblasts 
(Tang et al., 2007) and neurons (Liu et al., 2018). These pathways both have known 
roles in apoptosis and are thought to be key ways that rhVEGF prevents apoptosis in 
endothelial cells induced by serum and GF starvation. Furthermore, there is evidence 
that apelin regulates myocyte enhancer factor 2 , which in turn activates miR-424/miR-
503 and genes contributing to endothelial homeostasis. This axis may also be 
beneficial in PAH by acting on pulmonary arterial smooth muscle cells. Here it inhibits 
the expression of fibroblast growth factor 2 and its receptor, and thus exerts anti-
proliferative effects, potentially preventing their over-proliferation and the subsequent 
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vessel muscularisation that contributes to elevated pulmonary pressures (Alastalo et 
al., 2011, Kim et al., 2013, Kim et al., 2015, Helenius et al., 2015). Finally, agents that 
activate apelin expression or act as downstream effectors of apelin signalling have 
demonstrated beneficial effects in PAH animal models (Kim et al., 2013, Nickel et al., 
2015, Spiekerkoetter et al., 2013, Bertero et al., 2014).  
Interestingly, neither MM07 nor CMF-019 rescued apoptosis induced by serum and 
GF starvation in the control arm of the experiment, although the positive control 
rhVEGF did. This suggests that rescue from serum and GF starvation is through a 
different mechanism to rescue from TNFα/CHX induced apoptosis. GF and serum 
starvation is something that has been widely observed in various endothelial cell lines 
(Gama Sosa et al., 2016, Gerber et al., 1998b, Karsan et al., 1997, Ueda et al., 2005, 
Date et al., 2005, Raymond et al., 2004) and the mechanisms for rescue with rhVEGF 
are thought to occur by both upregulation of the MAPK/ERK pathway alongside 
downregulation of JNK pathway (Gupta et al., 1999), leading to enhanced bcl-2 and 
decreased bax signalling (Gerber et al., 1998a, Ueda et al., 2005, Karsan et al., 1997). 
In contrast, TNFα/CHX stimulates apoptosis primarily through the TNF-R1 leading to 
induction of the JNK and p-38 MAPK pathways. As discussed earlier, both [Pyr1]apelin-
13 and ELA-32 have been shown to promote ERK1/2 phosphorylation in human 
PAECs (Yang et al., 2017b), while some apelin isoforms have been shown to 
downregulate the JNK and p-38 pathways in osteoblasts (Tang et al., 2007) and 
neurons (Liu et al., 2018). This suggests that the apelin mimetics might be promoting 
rescue through similar mechanisms to rhVEGF and does not explain why they do not 
promote rescue in response to serum and GF starvation. On balance there is greater 
evidence of apelin promoting ERK/MAPK signalling, especially in PAECs, and perhaps 
activation of this pathway was more efficacious in rescuing from JNK/p-38 mediated 
apoptosis induced by TNFα/CHX, rather than the more multi-factorial apoptotic 
mechanisms induced by serum and GF starvation.  
Overall, it was considered appropriate to exclude experiments where there was limited 
or no induction of apoptosis by TNFα/CHX, such as with donors 4 and 5, since the 
mechanisms of apoptotic induction were different and would, therefore, impact upon 
the mechanisms of rescue. Both MM07 and CMF-019 rescued healthy endothelial cells 
from apoptosis in conditions induced by a severe stimulus using TNFα/CHX but not by 
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a weaker stimulus using GF and serum starvation, suggesting that they could be more 
beneficial as disease modifiers in early severe disease driving pathology.  
It is arguable that such benefits in the context of early disease development may not 
be translatable to a therapeutic setting where the disease is already established. As 
such it would be interesting to assess whether CMF-019 and MM07 could have 
beneficial effects on HPAECs taken from patients with established disease. However, 
HPAECs from PAH patients are rare, difficult to obtain and since from pathological 
tissue likely reflect end-stage disease and not the progressive disease pathology. It is 
hoped that new methodologies, such as the use of blood outgrowth endothelial cells 
(Ormiston et al., 2015), might enable the production of stable cell lines from patients 
with established disease. Given these current limitations, it was decided to perform 
experiments on HPAEC lines from ‘healthy’ donors and therefore, assess early disease 
pathology as a proof-of-concept for the benefits of apelin agonism.   
5.4.2 MM07 Prevents PAH Progression in an MCT Model  
A MCT prevention study of PAH using MM07 (1mg/kg) injected IP for 21 days was 
performed by Peiran (Brian) Yang (Yang et al., 2018 In Revision). This study showed 
that in addition to acting as a disease-modifier in human PAECs in vitro, MM07 could 
prevent the onset of PAH in vivo. MM07-injected rats were shown to have significantly 
lower RVSP in response to MCT exposure compared to those not treated with MM07, 
as well as less pronounced MCT-induced RV hypertrophy. Additionally, MM07 
attenuated pulmonary vascular remodelling with reduced arteriolar muscularisation 
and wall thickening, mitigating a key driving feature in the pathogenesis of PAH 
(Rabinovitch, 2012, Morrell et al., 2016). This evidence of disease-modification in vivo 
strongly supports the observation that MM07 is capable of protecting human PAECs 
in vitro. 
5.4.3 CMF-019 Did Not Prevent the Onset of PAH in an MCT Rat Model 
Having established that CMF-019 could reduce TNFα/CHX induced apoptosis of 
disease relevant human PAECs in vitro and that such a result with MM07 translated to 
efficacy in vivo in an MCT prevention study of PAH, it was tested whether CMF-019 
had similar therapeutic potential. The MCT rat model of PAH was chosen as a model 
that recapitulates many aspects of human disease without causing excessive distress 
to the animal. Furthermore, both endogenous agonists of the apelin receptor, apelin 
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and ELA, as well as the apelin mimetic, MM07, have demonstrated efficacy in the 
model (Falcao-Pires et al., 2009, Yang et al., 2017b). However, most importantly the 
MCT model is the only animal model of PAH that has enabled translation from the 
laboratory bench to the clinic and therefore, remains the only model that has 
demonstrated clinical relevance in humans. 
In this study, MCT robustly induced PAH in male Sprague-Dawley rats; however, this 
was not prevented by CMF-019. CMF-019 displayed great promise in early in vitro 
studies demonstrating high binding affinity and efficacy at the apelin receptor, as well 
as disease-modifying potential in human PAECs. Furthermore, it showed activity in 
vivo and looked promising as a potential therapeutic, therefore, it is surprising that it 
was unsuccessful in preventing disease and there are a number of reasons why this 
might be. 
One reason could have been the severity of disease observed in these animals. The 
average RVSP in the saline control MCT group was 65.44±3.23mmHg and PAH is 
defined when the pulmonary pressure exceeds 20mmHg. Therefore, these animals 
had dramatically elevated RVSPs and subsequent analysis of the Fulton index 
confirmed that they also had severely hypertrophied hearts. Furthermore, it was 
observed that the LVSPs were reduced in the MCT-treated animals suggesting that 
the hypertrophy of the RV was severe enough to compromise LV function. It is possible 
that the severe onset of the disease contributed to the lack of apparent efficacy of 
CMF-019.  
Another potential issue with CMF-019 could have been the pharmacokinetics of the 
compound. It has already been discussed for the acute in vivo studies in Chapter 4 
that doses of CMF-019 were limited by solubility. A potassium salt form of the 
compound was used and to overcome this and dissolved in pH9 saline. Following the 
first in vivo studies, plasma concentrations of CMF-019 were found to be substantially 
lower than the predicted concentrations following injection. This suggests that CMF-
019 is not stable in vivo, despite computational studies suggesting it has a beneficial 
pharmacokinetic profile and may explain the limited responses observed acutely. 
Nevertheless, receptor occupancy calculations using the measured plasma 
concentrations of CMF-019 at the terminal end-point suggested that receptor 
occupancy would still be in excess of 99% even with this potential instability, yet 
responses to CMF-019 were smaller than those with [Pyr1]apelin-13. These responses 
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should still have been sufficient to observe some benefit and it was hoped that potential 
issues might be overcome by regular daily dosing and the strong plasma binding of the 
molecule could have been beneficial in a long-term study. However, despite the 
maximal concentration attainable with CMF-019 (10mg/kg) being administered, there 
was insufficient target engagement to prevent PAH onset.  
It is possible that high plasma protein binding restricted the amount reaching the 
receptor target and combined with a high clearance any free drug was rapidly 
metabolised. Equally, IP administration and low solubility could have resulted in the 
compound precipitating in the IP cavity. This might prevent the compound reaching the 
circulation and ultimately the target. These potential limiting factors, combined with the 
severity of disease in these animals, were the likely reasons that a beneficial 
therapeutic effect could not be observed. To better establish the reasons for the lack 
of efficacy of CMF-019 in vivo, a thorough pharmacokinetic analysis is required, such 


















The purpose of this study was to assess the disease-modifying potential of MM07 and 
CMF-019 as G protein biased apelin agonists. It has previously been shown that both 
[Pyr1]apelin-13 and ELA-32 can prevent disease progression in an MCT rat model of 
PAH. Moreover, there is growing evidence that the benefits of apelin may not only be 
due to haemodynamic alleviation of the disease but also through addressing disease 
aetiology within the pulmonary vasculature. 
In this study, both MM07 and CMF-019 were effective in preventing apoptosis induced 
in healthy human PAECs in vitro, suggesting that they could be beneficial in preventing 
early disease onset in PAH. For MM07 this translated to an in vivo MCT prevention 
study of PAH where it displayed protection from RV hypertrophy and elevated RVSPs. 
Crucially, MM07-treated animals also showed improvements in pulmonary vascular 
remodelling, the driver of disease, with reduced pulmonary artery wall thickening and 
muscularisation. The beneficial effects seen with MM07 were not mimicked by CMF-
019, despite similar results being obtained in vitro. The reason for this could have been 
instability or metabolic clearance of the small molecule when administered to a whole 
organism system and pharmacokinetic study of the molecule would be necessary to 









6. An Apelin Mimetic Peptide, MM202, Linked to an 
Anti-Serum Albumin Domain Antibody 
(AlbudAbTM) is Efficacious In Vitro and In Vivo 
6.1 Introduction 
Previous chapters have focussed on identifying a biased small molecule apelin agonist 
to overcome the potential limitations of apelin and ELA as peptides in terms of 
bioavailability and half-life. An alternative approach is to utilise modified peptide 
mimetics which would have a selectivity advantage over small molecules by making 
use of highly specific protein-protein interactions. Appropriate modifications could be 
used to increase half-life and although unlikely to improve bioavailability, could vastly 
decrease the frequency of administration required, thus effectively negating this as a 
limitation. To date such approaches in the apelin signalling system have used 
unnatural amino acids, PEGylation and cyclisation, all of which have been discussed 







In this study, a peptide mimetic, MM202, featuring unnatural amino acids has been 
generated and then linked chemically using sSMCC (sulphosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate) and maleimide  chemistry via a (PEG)4 
linker to an AlbudAbTM construct (Figure 6.1). The purpose of the norleucine 
Figure 6.1: The structures of the endogenous peptides, [Pyr1]apelin-13 and apelin-17, the analogue, 
MM202, and the MM202-AlbudAbTM construct. Substituted residues in MM202 are shown in red, 
pyroglutamate in pink and AlbudAbTM in orange.  MM202 features a norleucine substituted for 
methionine to improve stability by reducing propensity for oxidation during subsequent reaction 
stages. Meanwhile, the tri-fluoro group attached to phenylalanine improves stability by reducing C-
terminal cleavage by ACE2. In the AlbudAbTM construct, MM202 has first been linked to a PEG chain 
and then via a sulpho-SMCC (sulphosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate) linker to the AlbudAbTM moiety using maleimide chemistry.   
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substitution was to reduce the potential for oxidation of the methionine in the 
subsequent chemical manipulation of the molecule. The unnatural tri-fluoro 
phenylalanine amino acid and the (PEG)4 linker were used to reduce proteolysis by 
protecting the peptide from peptidase degradation, especially ACE2 cleavage of the 
C-terminal phenylalanine. Meanwhile, the AlbudAbTM construct was to bind the 
molecule to HSA, therefore, retaining the molecule in the plasma and reducing renal 
clearance by preventing glomerular filtration.  
The MM202-AlbudAbTM construct represents a novel approach to drug design. 
Although molecules have previously been conjugated to AlbudAbTM (Bao et al., 2013, 
O'Connor-Semmes et al., 2014, Goodall et al., 2015, Lin et al., 2015, Walker et al., 
2010, Holt et al., 2008), these have been conjugated genetically and used endogenous 
molecules. An example of such a conjugation is the GLP-1 AlbudAbTM conjugate, 
GSK2374697, which has progressed to phase I clinical trials (Lin et al., 2015). The 
construct has demonstrated an improved half-life in humans of 6-10 days compared to 
~5 minutes for the endogenous molecule and crucially demonstrated retention of GLP-
1 receptor agonism (O'Connor-Semmes et al., 2014). Therefore, conjugation of 
endogenous molecules already presents a significant therapeutic advantage.  
The study presented here demonstrates further improvements on the use of the 
AlbudAbTM platform. This is the first time that a molecule has been conjugated to 
AlbudAbTM chemically and the first time that a non-endogenous molecule featuring 
unnatural amino acids has been used. This process is possible because the AlbudAbTM 
has been modified such that it possesses only one cysteine residue at position 108, 
distant from the albumin binding domain. Using maleimide chemistry the thiol group on 
this cysteine could be linked to an sSMCC reagent with high efficiency (>95%). 
Subsequently, the sSMCC due to its possession of a thiol, as well as a maleimide 
group, could then be further combined with the MM202-(PEG)4 construct using the 
same chemical reaction.  
This proof-of-principle represents a great advance in the potential use of the AlbudAbTM 
platform by enabling conjugation of molecules that are not liable to proteolytic 
degradation, unlike previously used endogenous molecules, such as GLP-1. In this 
study, the MM202-AlbudAbTM conjugate has been pharmacologically characterised 





MM202 was covalently bonded to AlbudAbTM using sSMCC (sulphosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate) and maleimide chemistry via a (PEG)4 
linker at the pyroglutamate on the N-terminus to retain binding at the apelin receptor 
as previously outlined in Patent WO 2012022703 (Holt et al., 2008). This strategy was 
selected based on extensive structure-activity relationship data that indicate that 
substitutions at the N-terminus of the ligand are well tolerated by the apelin receptor.  
6.2.2 Competitive Radioligand Binding Assays 
Competitive radioligand binding assays were performed in human LV homogenates 
(1.5mg/mL) using [Glp65,Nle75,Tyr77][125I]apelin-13 (0.1nmol/L) and increasing 
concentrations of [Pyr1]apelin-13 (1pmol/L-5µmol/L), apelin-17 (1fmol/L-0.1µmol/L), 
MM202 (1fmol/L-0.1µmol/L) and MM202-AlbudAbTM (0.5pmol/L-1µmol/L) as 
previously described in Section 2.3. Binding in the presence of 2µmol/L of [Pyr1]apelin-
13 was considered to be non-specific.  
6.2.3 Cell Signalling Assays  
6.2.3.1 β-Arrestin Assay 
[Pyr1]apelin-13 (0.1pmol/L-1µmol/L), apelin-17 (1pmol/L-1µmol/L), MM202 (10fmol/L-
3nmol/L) and MM202-AlbudAbTM (1pmol/L-0.1µmol/L)  were screened for their ability 
to recruit β-arrestin to the apelin receptor in a CHO based cell assay as described in 
Section 2.4.1.  
6.2.3.2 cAMP Assay 
[Pyr1]apelin-13 (1pmol/L-30nmol/L), apelin-17 (1pmol/L-30nmol/L), MM202 (1pmol/L-
30nmol/L) and MM202-AlbudAbTM (10pmol/L-1nmol/L) were screened for their ability 
to reduce cAMP expression following forskolin stimulation in a CHO based cell assay 




6.2.4 In Vivo LV and Femoral Artery Catheterisation for Measurement of Acute 
Cardiovascular Changes upon Administration of MM202-AlbudAbTM  
Male Sprague-Dawley rats (266±5g, n=27; Charles River Laboratories, Margate, UK) 
underwent jugular vein cannulation and LV and femoral artery catheterisation as 
described in Section 2.7.1. A first dose of either saline (0.9%, 0.5mL, Macopharma, 
n=12) or the MM202-AlbudAbTM conjugate (5nmol, 0.5mL) was administered to 
randomly chosen animals. Animals then received a second cumulative dose of 
[Pyr1]apelin-13 (50nmol, 0.5mL). All doses were followed by a saline flush (0.9%, 
0.1mL, Macopharma) to clear the cannula. In a preliminary study not using a femoral 
artery catheter, MM202 (n=2, 5, 50nmol, 0.5mL) was administered to see if responses 
were similar to the conjugated form. 
6.2.5 A Time-Course in Heparinised Human Plasma Ex Vivo to Determine Compound 
Half-life 
[Pyr1]apelin-13, MM202 and MM202-AlbudAbTM (0.3 and 3nmol/L) were incubated in 
heparinised human plasma samples ex vivo (n=3) at 37ºC. 0.3nmol/L and 3nmol/L 
concentrations were chosen as they cross-reacted near the top of the linear portion of 
the [Pyr1]apelin-13 standard curve (Figure 6.2). Heparinised blood was used as EDTA 
would likely have impacted on the half-lives measured by inhibiting proteases. 
Samples were snap-frozen at 30seconds, 5minutes, 15minutes, 1hour, 2hours and 
24hours and subsequently run in an ELISA as detailed in Section 2.8. Cross-reactivity 
of all three peptides in the ELISA displayed parallelism over the same concentration 
range (Figure 6.2) and consequently plasma concentrations were calculated by 
interpolation from the [Pyr1]apelin-13 standard curve.  Plasma half-lives of the 
compounds were calculated by fitting the interpolated data to a single exponential 





Figure 6.2: Concentration vs absorbance at 450nm for [Pyr1]apelin-13, MM202 and MM202-
AlbudAbTM in an ELISA. MM202 and MM202-AlbudAbTM cross-reacted and displayed parallelism 





6.2.6 A Rat MCT Prevention Study of PAH Using MM202-AlbudAbTM  
Male Sprague-Dawley rats (213±2g, n=31; Charles River Laboratories, Margate, UK) 
underwent a MCT prevention protocol as described in Section 2.7.2.  They received 
either IP injections of MM202-AlbudAbTM (1mg/kg, n=14) twice weekly or saline 
(equivalent volume by weight, n=17) daily for 21 days. The Fulton index, RVSP and 
LVSP were measured and analysis performed as described. Blood samples were 
collected in heparin-coated tubes during exsanguination following catheterisation.  
6.2.6.1 Analysis of Plasma Samples by ELISA 
Heparinised blood samples from each treatment group (n=6) were run in an ELISA as 
detailed in Section 2.8. Since cross-reactivity of MM202-AlbudAb™ occurred under the 
same concentration range as [Pyr1]apelin-13 (Figure 6.2), plasma concentrations were 
calculated by interpolation from the [Pyr1]apelin-13 standard curve.  
6.2.7 Statistical Analysis 
Binding experiments were performed in triplicate and Ki±SEM values calculated using 
the Cheng-Prusoff methodology. Cell based screening assays were performed in 
triplicate and presented as pD2±SEM values. ELISAs were performed in duplicate and 
data are presented as mean±SEM. For the human plasma time-course, data were 
fitted to a single exponential curve to determine half-life and the 3nmol/L data 
compared using a two-tailed Student’s t-test. For rat samples collected following 
chronic administration and in vivo analysis, data were compared using a two-tailed 












6.3.1 Apelin-17 Displayed Similar Binding and Potency in Functional Assays to 
[Pyr1]apelin-13 
Apelin-17 bound to the native apelin receptor in human LV homogenates 
(pKi=9.57±0.08) with approximately 7-fold greater binding affinity than [Pyr1]apelin-13 
(pKi=8.82±0.05; Figure 6.3). In functional assays, whereas [Pyr1]apelin-13 was 
approximately 10-fold more potent in the cAMP inhibition (pD2=9.52±0.05) than β-
arrestin (pD2=8.53±0.03) signalling assay, apelin-17 was equipotent in both 












6.3.2 MM202 and MM202-AlbudAbTM Bound with High Affinity Comparable to the 
Endogenous Agonist, [Pyr1]apelin-13, at the Native Human Apelin Receptor 
In competitive radioligand binding assays, MM202 bound to the native apelin receptor 
in human LV homogenates with high nanomolar affinity (pKi=10.24±0.07). This was 
ten-fold greater than the endogenous peptide, [Pyr1]apelin-13 (pKi=8.82±0.05). 
Conjugating MM202 to AlbudAbTM slightly decreased the binding affinity of MM202 
(pKi=9.39±0.09; Figure 6.3).  
Figure 6.3:  Competition radioligand binding of the endogenous peptides [Pyr1]apelin-13 and apelin-
17, as well as the synthetic peptide MM202 and its albudAb™ conjugate against 
[Glp65,Nle75,Tyr77][125I]apelin-13 in human LV homogenates. All peptides competed with similar 





6.3.3 MM202 and MM202-AlbudAbTM Displayed Functional Activity in Cell-Based 
Signalling Assays with Similar or Greater Potency than the Endogenous Agonist 
[Pyr1]apelin-13 
MM202 was able to recruit β-arrestin to the human apelin receptor in a CHO cell 
signalling assay (pD2=10.71±0.58) with much greater potency than the endogenous 
agonist [Pyr1]apelin-13 (pD2=8.52±0.06; Figure 6.4A). It was also able to inhibit cAMP 
stimulated by forskolin (pD2=9.96±0.14) with similar potency to [Pyr1]apelin-13 
(pD2=9.70±0.08; Figure 6.4B). MM202, therefore, displayed considerable β-arrestin 
signalling bias. In both assays, the EMAX values for MM202 were similar to [Pyr1]apelin-
13, suggesting it acts as a full agonist through both pathways. Conjugating AlbudAbTM 
to MM202 reduced potency in the β-arrestin assay (pD2=9.26±0.03; Figure 6.4A) but 
to a lesser extent in the cAMP inhibition assay (pD2=9.15±0.12; Figure 6,4B), leading 
to a reduction in the degree of biased signalling at the receptor. The conjugate also 






Figure 6.4:  The functional activities of the endogenous peptides [Pyr1]apelin-13 and apelin-17, as 
well as the synthetic peptide MM202 and its AlbudAb™ conjugate in human apelin receptor 
expressing CHO cell β-arrestin recruitment (A) and cAMP inhibition assays (B). In the β-arrestin 
assay the potencies generally corresponded to the rank order of the binding affinities, however, for 






6.3.4 MM202-AlbudAbTM Produced Acute Cardiovascular Responses In Vivo in 
Normotensive Male Sprague-Dawley Rats 
Bolus injections of the MM202-AlbudAbTM conjugate (5nmol, 0.5mL, n=15) through the 
jugular vein resulted in robust cardiovascular responses compared to saline (0.5mL, 
n=12) in normotensive male Sprague-Dawley rats (Figure 6.5). There was a small but 
significant difference in weight between the two groups with the treatment group 
24.7±8.60g (**p<0.01) heavier than the saline group (data not shown). The LVSP was 
reduced by 6.61±1.46mmHg (***p<0.001) and the arterial pressure underwent a 
greater drop of 14.12±3.35mmHg (**p<0.01). The dp/dtMAX, a measure of cardiac 
contractility, increased by 533±170mmHg/s (**p<0.01), meanwhile the dp/dtMIN a 
measure of cardiac relaxation (where a negative value indicates greater relaxation) 
increased but by a smaller margin of 381±178mmHg (*p<0.05, data not shown). 
Additionally, the cardiac output increased by 1277±190RVU/min (****p<0.0001) and 
this was mirrored by an increase in stroke volume of 3.09±0.47RVU (****p<0.0001), as 
well as a small but significant increase in heart rate of 4.64±2.24BPM (*p<0.05).   
These effects were very similar to those obtained with MM202 alone in a preliminary 
study at the same concentration (5nmol, 0.5mL, n=2). MM202 showed a dose-
dependent cardiovascular action (Table 6.1) to elicit a reduction in LVSP and to 
increase cardiac output and increase contractility in a manner comparable to 
[Pyr1]apelin-13. Effects at the higher concentration of MM202 (50nmol, 0.5mL, n=2) 
were similar or greater than that obtained with the 400nmol bolus administration of 
[Pyr1]apelin-13 as previously reported in Section 4.3.2.  The lower dose of MM202 
(5nmol) was equivalent to the maximal attainable dose that could be administered of 
the MM202-AlbudAbTM conjugate.  
Table 6.1:  Average changes in cardiovascular parameters from baseline values following bolus 









































































































































































































































































































































































A second dose of [Pyr1]apelin-13 (50nmol, 0.5mL) was administered to all animals 
subsequently to the initial dose of either MM202-AlbudAbTM or saline. All animals 
responded except the first two, one of which was then given a third dose of [Pyr1]apelin-
13 from a different batch to which it responded robustly. This second batch of 
[Pyr1]apelin-13 was used for subsequent experiments and these first two excluded 
from the second dose analysis. The pattern of responses to [Pyr1]apelin-13 was similar 
to that of the MM202-AlbudAbTM conjugate and there were no significant differences 
between those that had received saline first or MM202-AlbudAbTM (Figure 6.6). The 
LVSP was reduced by 12.89±2.21mmHg and 11.64±2.58mmHg and the arterial 
pressure by 24.75±1.47mmHg and 31.18±5.73mmHg in the saline and MM202-
AlbudAbTM groups, respectively. Similarly, the dp/dtMAX was increased by 
1660±210mHg/s and 890±434mmHg/s and the dp/dtMIN by 658±499mmHg/s and 
1553±494mmHg/s, respectively. Once again the cardiac output increased, 
3143±707RVU/min and 2492±620RVU/min, with a concurrent stroke volume increase, 
7.93±1.96RVU and 6.38±1.32RVU. The heart rate did not change in either the saline 


















































































































































































































































































































































































































6.3.5 MM202-AlbudAbTM Displayed an Improved Plasma Half-life in Heparinised 
Human Plasma Samples Ex Vivo 
MM202 demonstrated an extended plasma half-life ex vivo compared to the 
endogenous agonist, [Pyr1]apelin-13 (3nmol/L: 23±6minutes, *p<0.05). MM202-
AlbudAbTM demonstrated a further improvement over both [Pyr1]apelin-13 (3nmol/L: 
65±4minutes, ****p<0.0001) and also over MM202 (3nmol/L: 42±7minutes, **p<0.01) 














Figure 6.7: A time-course of concentrations of apelin-like cross-reactivity (mean±SEM) measured 
in plasma samples (n=3) when spiked with 3nmol/L or 0.3nmol/L of either [Pyr1]apelin-13, MM202 
or MM202-AlbudAbTM. Data were fitted as a single exponential for each donor to calculate the half-




Table 6.2: The calculated plasma half-lives for [Pyr1]apelin-13, MM202 or MM202-AlbudAbTM (n=3). 
MM202 had an improved plasma half-life compared to [Pyr1]apelin-13 with MM202-AlbudAbTM 






6.3.6 Chronic Administration of MM202-AlbudAbTM Did Not Prevent Onset of PAH in 
a MCT Prevention Study In Vivo 
Chronic IP injection of the MM202-AlbudAbTM conjugate (1mg/kg, n=14) twice weekly 
in male Sprague-Dawley rats was compared to saline controls (n=17) in a 21 day MCT 
study. At the end point of the study there was a small but significant difference in weight 
between control animals (n=13) receiving either saline or MM202-AlbudAbTM with the 
latter on average 32.52±13.83g (*p<0.05) heavier. Animals that received MCT (n=18) 
weighed significantly less than their corresponding controls with the saline group 
38.14±11.39g (**p<0.01) and the treatment group 64.92±15.32g (**p<0.01) lighter. 
Additionally, these animals displayed RV hypertrophy with Fulton indices increased by 
0.195±0.028 (****p<0.0001) and 0.233±0.036 (****p<0.0001), respectively. The 
RVSPs were increased by 33.83±3.99mmHg (****p<0.0001) and 31.30±3.13mmHg 
(****p<0.0001), with a reduction in the LVSP of 13.44±5.36mmHg (*p<0.05) and 
23.58±5.81mmHg (**p<0.01), respectively. There was no significant difference 
between the saline and MM202-AlbudAbTM conjugate treated MCT groups in these 
three parameters (Figure 6.8). 
6.3.6.1 Apelin-Like Reactivity was Detectable in Plasma from Rats Treated 
Chronically with MM202-AlbudAbTM 
Concentrations of apelin-like cross-reactivity were elevated in both saline control and 
MCT-treated groups when they had been administered MM202-AlbudAb™ 
(12.3±1.9nmol/L and 17.2±4.7nmol/L, respectively) compared to saline 
(5.9±0.6nmol/L, **p<0.01 and 6.6±1.1nmol/L, *p<0.05, respectively). The last MM202-
AlbudAb™ dose administered to the animals was three days prior to catheterisation 
and blood collection. There was no significant difference in endogenous apelin levels 















Figure 6.8:  Terminal (day 21) measurements from an MCT-induced model of PAH assessing 
MM202-AlbudAbTM as a preventative therapeutic agent. Male Sprague-Dawley rats (n=31) received 
a subcutaneous injection of saline (n=13) or MCT (n=18) followed by 21 days of either daily IP 
injections of saline (n=17) or twice weekly MM202-albudAb™ (n=14). The MCT animals displayed 
increased RVSPs and Fulton indices with reduced LVSPs and weights. There were no differences 
between saline and MM202-albudAb™ receiving MCT animals. Data were compared using a two-









































Figure 6.9:  Plasma concentrations of apelin-like cross-reactivity measured in an ELISA from end-
point plasma samples collected following chronic IP administration of MM202-AlbudAb™ in rats 
twice weekly for 21 days. Animals that received MM202-AlbudAb™ demonstrated significantly 
elevated concentrations of apelin-like cross-reactivity compared to saline controls. Data were 
compared using a two-tailed Student’s t-test and statistical significance was taken as 5%. *p<0.05, 











6.4.1 Spacer and Apelin-17 
Apelin-17 bound to the native human apelin receptor with slightly higher affinity than 
[Pyr1]apelin-13. In functional assays, apelin-17 was similarly slightly more potent than 
[Pyr1]apelin-13 but displayed a different signalling profile with some β-arrestin bias as 
has previously been suggested (El Messari et al., 2004). The fact that additional amino 
acids did not reduce binding affinity or functional activity in cell-based signalling 
assays, confirms tolerance to the addition of a spacer to apelin-13 at the N-terminus if 
required. Additionally, extensive homology modelling implies that the amino acids at 
the N-terminus added to the RPRL recognition sequence project beyond the receptor 
binding region into solvent and associate with the extracellular loop of the apelin 
receptor (collaborative work by Dr David Huggins and Professor Robert Glen). This 
suggests that an appropriate linker at the N-terminus should allow apelin binding while 
not causing interference by the conjugated antibody. 
6.4.2 MM202 and MM202-AlbudAbTM Bound to the Human Apelin Receptor and 
Showed Functional Activity 
MM202 bound to the apelin receptor with high affinity and showed activity in cell-based 
functional assays. The high activity in the β-arrestin assay likely correlated with the 
higher binding affinity and is something that has been observed before, for instance 
with apelin-17. It is possible that the longer peptides, which have increased binding 
affinity, stabilise regions of the apelin-13 sequence within the binding pocket which 
increases β-arrestin signalling (Murza et al., 2015, Iturrioz et al., 2010b, El Messari et 
al., 2004, Ceraudo et al., 2014).  
The addition of linker motifs to MM202 at the N-terminus and combining these with 
AlbudAbTM did not result in a large loss in binding affinity at the apelin receptor. This 
suggests the linkers did not directly affect binding to the receptor but were able to 
provide sufficient mobility with reduced steric hindrance around the apelin binding 
pocket. In fact, although conjugating AlbudAbTM to MM202 reduced the binding affinity 
to the receptor slightly, it led to a much greater decrease in β-arrestin signalling 
compared to cAMP signalling. In this case, it is probable that the steric bulk of the 
AlbudAbTM molecule would partially restrict access of MM202 to the receptor, though 
this would largely be negated by the (PEG)4 spacer and result in a small loss in affinity 
but a proportionally larger decrease in β-arrestin signalling. Fortuitously, reduced 
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signalling through the β-arrestin pathway is something that has been considered 
beneficial for apelin mimetics as has previously been discussed with MM07 and CMF-
019 (Brame et al., 2015, Read et al., 2016).  
6.4.3 Conjugating AlbudAbTM to Apelin Peptides Retained AlbudAbTM Activity at HSA 
Experiments were performed using the Biacore T200 system (GE Healthcare Life 
Sciences, Little Chalfont, UK) by Total Scientific Ltd (Cambridge, UK) to determine the 
binding characteristic of AlbudAbTM (0.156-80nmol/L) and the MM202-AlbudAbTM 
conjugate (0.156-160nmol/L) to HSA. This involved HSA protein immobilised onto the 
Biacore CM5 chip and a multi-cycle kinetic binding study using increasing 
concentrations of both species. AlbudAbTM bound with high nanomolar affinity 
(pKD=9.27, n=2) and conjugating MM202 to the AlbudAbTM molecule only very slightly 
reduced the binding affinity to HSA (pKD=9.02, n=2). This demonstrates that the ability 
of the AlbudAbTM moiety to bind to HSA was retained and is consistent with previous 
AlbudAbTM conjugates. 
6.4.4 MM202-AlbudAbTM was Active Acutely In Vivo 
Injecting MM202-AlbudAbTM intravenously through the jugular vein resulted in robust 
cardiovascular responses as expected for an apelin agonist. The LVSP was reduced 
and this was likely due to a decrease in arterial pressure leading to a reduced afterload 
on the heart. At the same time the cardiac output increased in concert with the stroke 
volume and there was a small increase in heart rate, though this was probably not the 
driving factor in increasing cardiac output. Finally, the contractility of the heart 
(measured as change in maximal pressure over time, dp/dtMAX) was also increased, as 
predicted for a positive inotrope. These cardiovascular changes have also been seen 
with [Pyr1]apelin-13.  
The fact that there was little difference in the [Pyr1]apelin-13 responses following either 
treatment suggests that there was little desensitisation of the receptor by MM202-
AlbudAbTM. The responses to 5nmol MM202-AlbudAbTM were smaller than those to 
50nmol [Pyr1]apelin-13, this is not surprising as MM202-AlbudAbTM displayed similar 
activity in binding to the receptor and in functional assays. Doses higher than 5nmol 
could not be administered as the MM202-AlbudAbTM conjugate was limited by its 
solubility in saline. Moreover, one would expect that the high HSA binding of MM202-
AlbudAbTM could limit the amount able to reach the cardiovascular tissues acutely, 
though this could have been balanced by protection from degradation. Importantly, the 
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magnitude of the effects of 5nmol MM202-AlbudAbTM were comparable to those 
obtained with 5nmol MM202 in a preliminary study, suggesting that the plasma protein 
bound AlbudAbTM conjugate is available for binding to the receptor. Only two animals 
were tested with MM202 alone as a control in order to preserve the supply of the 
compound for conjugation to AlbudAbTM such that enough might be available for the 
subsequent MCT study and to reduce unnecessary animal use. Indeed, it was clear 
from these two animals that responses to MM202 were robust and the use of more 
compound or animals was not required.  
6.4.5 MM202-AlbudAbTM Displayed an Improved Plasma Half-life Ex Vivo 
In a time-course experiment using human plasma samples spiked with 3nmol/L 
[Pyr1]apelin-13, MM202 or MM202-AlbudAbTM ex vivo, MM202-AlbudAbTM displayed a 
2.5-fold improvement over [Pyr1]apelin-13 and a 1.6-fold improvement over MM202. 
This suggests that the peptide modifications in MM202 were sufficient to reduce 
proteolysis by plasma proteases. MM202-AlbudAbTM displayed such a further 
improvement in half-life over MM202 and likely reflects the PEG linker and AlbudAbTM 
moieties acting to sterically hinder plasma proteases. The extended plasma half-life 
observed with MM202-AlbudAbTM is consistent with observations of extended half-life 
in other AlbudAbTM constructs (Bao et al., 2013, O'Connor-Semmes et al., 2014, 
Goodall et al., 2015, Lin et al., 2015, Walker et al., 2010, Holt et al., 2008).  
It is important to note that such a plasma half-life measured in vitro does not take into 
account renal filtration or metabolic clearance from the liver which are likely to be the 
largest contributors to peptide breakdown. As such, it is probable that MM202-
AlbudAbTM is even more long-lived compared to either [Pyr1]apelin-13 or MM202 in 
vivo. Indeed, the half-life of 43minutes measured for [Pyr1]apelin-13 is exceptionally 
long for a peptide. Previously, its in vivo half-life in rats has been demonstrated to be 
only 2 minutes (Brame et al., 2015). An additional caveat is that endogenous apelin-
like reactivity could not be distinguished from the exogenously administered 
compounds in the ELISA and so the half-lives of the compounds have likely been 
underestimated.  
In order to calculate plasma half-lives, data were fitted to a single exponential curve 
and this provided a good fit to the data. For the experiments spiked with 3nmol/L, the 
C0 values were as expected as the concentration was high enough to negate the 
effects of any endogenous apelin-like reactivity. For the 0.3nmol/L experiments, the C0 
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values were closer to 0.5nmol/L and again this was as expected since endogenous 
apelin-like reactivity has previously been demonstrated to be around 0.3nmol/L in 
healthy heparinised human plasma (Yang et al., 2017b). Although the half-lives 
measured were similar using both concentrations as one would expect, the 0.3nmol/L 
was more variable and this probably reflects the fact that the drug concentrations were 
of the same order of magnitude as the endogenous apelin-like reactivity. For this 
reason these experiments were not analysed statistically but nonetheless are 
supportive of the conclusions drawn.  
6.4.6 MM202-AlbudAbTM Did Not Prevent PAH when Administered Twice Weekly to 
MCT Treated Animals 
Despite the efficacy of MM202-AlbudAbTM acutely and the extended plasma half-life it 
displayed, it was unable to prevent PAH in an MCT rat model when administered 
chronically by IP injection twice weekly at 1mg/kg for three weeks. The low dosing 
schedule was chosen due to the longer ex vivo plasma half-life and proposed 
improvements in metabolic stability and reduction in renal clearance. 
Interestingly, the dose administered was sufficient that apelin-like reactivity could be 
detected in heparinised plasma samples collected during terminal exsanguination by 
ELISA. This may suggest that MM202-AlbudAbTM was sufficiently stable and long-lived 
in vivo that it could be detected. Performing calculations based upon the in vitro human 
plasma half-life of MM202-AlbudAbTM, only 5fmol/L of MM202-AlbudAbTM would be 
expected to remain after three days. Nonetheless, it is possible that the IP cavity could 
have acted as a reservoir to enable release of the cumulative doses over an extended 
period of time. Moreover, it is notable that the basal levels of apelin-like reactivity in 
the rat saline controls were around 6nmol/L and approximately 20-fold greater than 
those occurring in humans (~0.3nmol/L; (Yang et al., 2017b). This suggests that apelin 
peptides are longer-lived in rat plasma and therefore, significantly higher levels of 
MM202-AlbudAbTM might well have been detectable in rat plasma 3 days subsequent 
to administration. Alternatively, MM202-AlbudAbTM might have resulted in upregulation 
of endogenous apelin levels. Such an effect has not been previously demonstrated at 
the plasma level following exogenous [Pyr1]apelin-13 administration but has been 
demonstrated in specific tissues (Falcao-Pires et al., 2009). It is interesting that there 
was no decrease in endogenous apelin-like reactivity in plasma samples from MCT 
treated animal compared to saline controls given tissue-specific downregulation has 
been previously reported (Kim et al., 2013, Falcao-Pires et al., 2009).   
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Estimating the receptor occupancy at the measured plasma concentration in MM202-
AlbudAbTM treated animals (17nmol/L) suggests that it would be in excess of 99%. This 
implies that the reason for a lack of efficacy is more likely to be due to an inability of 
the molecule to access the target, something that could be the case if the serum 
albumin binding of MM202-AlbudAbTM prevented it from being released from the blood. 
This might have been compounded by the severity of the disease response to MCT in 
this cohort of animals, which in addition to drastically elevated RVSPs (>60mmHg), 




















The aim of the study was to pharmacologically characterise a chemically conjugated 
apelin mimetic peptide containing unnatural amino acids linked to an AlbudAbTM 
molecule, in order to demonstrate retained activity of both constituent parts. Such a 
construct would represent a significant advance in use of the AlbudAbTM platform which 
has previously only used genetic conjugation of endogenous molecules, for example, 
the GLP-1 AlbudAbTM construct GSK2374697. 
In this study, it has been demonstrated that MM202-AlbudAbTM retained a high 
nanomolar binding affinity to the human apelin receptor, as well as activity in in vitro 
cell screening assays. Meanwhile, the AlbudAbTM moiety also retained the ability to 
bind to HSA in vitro and displayed an improved plasma half-life over both its parent 
compound and the endogenous agonist. Finally, MM202-AlbudAbTM was active in vivo 
and demonstrated similar activity to both the endogenous molecule, [Pyr1]apelin-13, 
and MM202. Crucially, such a study opens up the possibility that additional modified 
peptides could be used in concert with the AlbudAbTM platform by chemical rather than 
genetic conjugation, therefore, allowing for the use of proteolytically protected 
molecules. Hopefully, with such advances, other short peptide agonists can be 














7.  Concluding Remarks 
The apelin system is an evolving transmitter system consisting of the class A G protein 
coupled apelin receptor (O'Dowd et al., 1993), its cognate ligand apelin (Tatemoto et 
al., 1998) and the recently discovered ELA (Chng et al., 2013, Pauli et al., 2014), a 
second endogenous agonist (Yang et al., 2017b). Apelin receptor agonists have been 
implicated as potential therapeutic agents for a number of diseases, especially 
cardiovascular and metabolic disorders (Yang et al., 2015a, Castan-Laurell et al., 
2011, Castan-Laurell et al., 2012). Meanwhile, antagonists had shown potential in 
cancer (Yang et al., 2016, Harford-Wright et al., 2017). This study has focussed on the 
cardiovascular system where both apelin and ELA act through the receptor in the heart 
to increase the force of contraction (Maguire et al., 2009, Perjes et al., 2014, Szokodi 
et al., 2002, Yang et al., 2017b, Murza et al., 2016, Perjes et al., 2016, Atluri et al., 
2007, Berry et al., 2004, Jia et al., 2006, Ashley et al., 2005, Japp et al., 2010, Japp et 
al., 2008) and in the vasculature to induce vasodilatation (Maguire et al., 2009, Brame 
et al., 2015, Tatemoto et al., 2001).  
Targeting the apelin receptor with agonists in cardiovascular diseases, such as PAH, 
would be beneficial by effectively replacing the endogenous ligands which are 
downregulated. This hypothesis is supported by prevention studies in the MCT rat 
model of PAH, which show that exogenous administration of [Pyr1]apelin-13 and ELA-
32 significantly improves outcome (Falcao-Pires et al., 2009, Yang et al., 2017b). 
However, these small endogenous peptides are limited in their therapeutic potential as 
they lack bioavailability and are liable to metabolic and renal clearance.  
To overcome these issues, this study attempted to identify a small molecule apelin 
agonist and simultaneously studied an apelin mimetic peptide containing unnatural 
amino acids conjugated to an AlbudAbTM moiety. Both of these approaches have the 
potential to overcome the limitations of the endogenous peptides by improving 
longevity and, in the case of the small molecule, oral bioavailability. Furthermore, a 
small molecule apelin agonist would be invaluable to the field of research by providing 
a much needed experimental tool compound. In order to pharmacologically 
characterise these molecules, activity has been measured relative to the most 
abundant apelin isoform in the cardiovascular system, [Pyr1]apelin-13 (Maguire et al., 
2009), and PAH has been used as a model disease to evaluate therapeutic potential.  
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7.1 CMF-019, the First G Protein Biased Small Molecule Apelin 
Agonist 
Despite the potential benefits of apelin agonists, few molecules that might find use as 
therapeutic agents have been identified. Moreover, with only expensive peptides 
available, research into the apelin system is limited. Readily available, easy to 
manufacture small molecule agonists and antagonists as experimental tool 
compounds could greatly progress this field of research. To this end, one of the primary 
aims of this study was to identify and pharmacologically characterise a small molecule 
apelin agonist for use as a tool compound in apelin research. Such a molecule could 
then be further evaluated for therapeutic potential subsequently.  
As discussed in Section 1.4, previous small molecules at the apelin receptor have 
possessed significant limitations. In contrast, the molecule identified in this study, 
CMF-019, had a suitably low molecular weight (455Da) and very high nanomolar 
affinity for the apelin receptor. This high binding affinity was invariant between rodent 
species and man, supporting its use as an experimental tool compound across 
species. Such a finding ensures that development as a potential therapeutic agent 
would not be hindered by species variability, as has been the case for other molecules, 
such as, the urotensin-II receptor antagonist Palosuran. 
The high binding affinity of CMF-019 translated into functional efficacy with similar 
levels of cAMP inhibition to [Pyr1]apelin-13 observed in cells expressing the 
recombinant human apelin receptor. Interestingly, the molecule showed much lower 
activity in recruiting β-arrestin and in internalising the apelin receptor, suggesting that 
it was highly biased towards the G protein signalling pathway. Such bias could be very 
useful in an apelin therapeutic agent by enabling it to activate the beneficial G protein 
pathway without internalising the receptor and thereby maintaining response over time. 
Furthermore, it could simultaneously reduce activation of the β-arrestin stretch-
mediated hypertrophic pathway (Scimia et al., 2012). A potential limitation of this study 
was that signalling through the Gαq pathway was not measured as a suitable assay 
could not be identified. It would be interesting to establish if the Gαi bias identified in 
this study is also seen with Gαq signalling. Arguably, the Gαq pathway is more 
therapeutically relevant and is thought to mediate some key aspects of the apelin 
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response, especially in cardiomyocytes (Yang et al., 2015a, Szokodi et al., 2002, 
Perjes et al., 2014). 
Biased signalling displayed by a small molecule is an intriguing phenomenon and has 
not been widely studied to date. Such an observation is very revealing about signalling 
through the apelin receptor and supports the existing theory that longer agonists are 
better able to reach deeper regions of the apelin binding pocket to activate β-arrestin 
signalling motifs (El Messari et al., 2004). Following the recent crystal structure of the 
apelin receptor (Ma et al., 2017), it would be of great interest if CMF-019 could be 
crystallised within the binding pocket to better inform the design of future biased apelin 
ligands.  
When assessed in normotensive male Sprague-Dawley rats in vivo, CMF-019 
produced responses that were similar to the endogenous molecule, [Pyr1]apelin-13, 
although smaller in magnitude. Both molecules acted as positive inotropes on the 
heart, increasing the dp/dtMAX, a measure of cardiac contractility. At the same time the 
cardiac output was seen to increase and this was largely due to a corresponding 
increase in stroke volume. Finally, both molecules acted as vasodilators, decreasing 
the arterial pressure and in most cases causing a corresponding decrease in LVSP by 
reducing the afterload on the heart. The fact that CMF-019, a G protein biased agonist, 
could mirror all aspects of the [Pyr1]apelin-13 response contrasts with observations by 
the Marsault group who have previously suggested that β-arrestin biased molecules 
exert greater hypotensive actions (El Messari et al., 2004, Iturrioz et al., 2010b, 
Ceraudo et al., 2014, Murza et al., 2015, Besserer-Offroy et al., 2018). Importantly, 
despite producing the same response profile to [Pyr1]apelin-13, CMF-019 was much 
less effective at desensitising the apelin receptor in vivo, confirming that its in vitro bias 
was translatable.  
Evaluating CMF-019 as a potential disease-modifying molecule in the prevention of 
PAH, it was found that it could demonstrate beneficial effects in an in vitro human 
PAEC apoptosis assay. This suggests that the advantages of apelin agonism extend 
beyond only haemodynamic alleviation and actually address the underlying aetiology 
of the disease itself. These results further support the stability of CMF-019 in vitro and 
suggest that it is a robust and useful experimental tool compound in vitro, as well as, 
for short-term acute in vivo study.  
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A potential drawback of CMF-019 was its high logD, which resulted in limited solubility 
and prevented high doses from being administered in in vivo studies. Furthermore, it 
was predicted to bind very strongly to plasma proteins and was probably 
pharmacokinetically unstable once in vivo, despite computational studies suggesting it 
demonstrates similar properties to currently available oral drugs. These 
pharmacokinetic limitations likely contributed to the molecule’s lack of efficacy in 
preventing PAH in an MCT rat prevention study of the disease. Receptor occupancy 
calculations using the ~25µM concentration measured from plasma taken at the end-
point of the first acute in vivo study, suggest that occupancy would still be in excess of 
99% even though only approximately 10% of the drug remains in the system. However, 
if substantial amounts of the drug remained bound to plasma proteins and inaccessible 
to the receptor target then any free drug might be rapidly cleared. Additionally, in the 
chronic study the lack of solubility could have resulted in compound precipitation within 
the IP cavity, reducing the effective dose administered.  Therefore, although the 
implication is that the molecule was not as effective in vivo as predicted in vitro, such 
a result is difficult to explain. Indeed, the molecule displayed such similar activity to the 
endogenous molecule in vitro and it seems more likely that the molecule’s limitations 
are pharmacokinetic rather than pharmacodynamic.  
Despite potential limitations of CMF-019 as a chronic in vivo drug treatment for PAH, 
it provides the most suitable scaffold upon which to explore new small molecule apelin 
agonists as a high affinity biased agonist. Interestingly, the scaffold of CMF-019 
consisting of a heterocycle with two attached hydrophobic groups, appears to be very 
similar to four recent compound series identified in patents from Amgen (Chen et al., 
2017b), Bristol-Myers Squibb (Myers et al., 2017), RTI International (Narayanan et al., 
2016) and Sanford-Burnham (Pinkerton and Smith, 2015) (Figure 3.13), suggesting a 
remarkably convergent evolution of apelin small molecules. Indeed, molecular docking 
of these compounds in the apelin binding pocket supports clear similarities in their 
binding motifs (Figure 3.14). Despite this, it is unknown whether these compounds will 
also display bias in a similar manner to CMF-019. One suspects that such experiments 
will be forthcoming following this study. 
One of the primary aims of this study was to identify a small molecule apelin agonist 
for use as an experimental tool compound and as a potential therapeutic lead 
compound. This aim has been met and illustrates the success of the project. Indeed, 
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the identification of CMF-019 represents a great advance in the development of small 
molecule apelin agonists for use as experimental tool compounds. This is confirmed 
by the fact that it is already widely commercially available and methods to improve the 
synthesis of the molecule have been attempted (Trifonov et al., 2018). The high binding 
affinity displayed for a small molecule combined with biased signalling, make it very 
interesting for further study. Moreover, it has shown activity in vitro in modifying disease 
and when administered acutely in vivo. One expects that soon it will be used widely for 
in vitro study in the apelin field. It could also form the basis for the development of 




















7.2 MM202-AlbudAbTM, a Proof-of-Principle Study of a Chemically 
Conjugated Unnatural Peptide to an AlbudAbTM Moiety   
The development of new apelin agonists has largely been driven by a desire to move 
away from the endogenous peptides, apelin and ELA, which are not orally bioavailable, 
metabolically stable or massive enough to escape glomerula filtration. While the 
identification of CMF-019 as a small molecule can overcome many of these issues, an 
alternative approach is to utilise a modified peptide. Previous studies have developed 
modified apelin peptides with improved metabolic properties either through PEGylation 
(Jia et al., 2012), cyclisation (Brame et al., 2015, Hamada et al., 2008, Macaluso and 
Glen, 2010, Murza et al., 2017, Golosov et al., 2013) or the incorporation of unnatural 
amino acids (Wang et al., 2013b, Murza et al., 2015, Juhl et al., 2016). Similarly, 
previous studies in other transmitter systems have utilised endogenous molecules 
conjugated genetically to the ~81KDa AlbudAbTM moiety to provide protection from 
renal filtration (Bao et al., 2013, O'Connor-Semmes et al., 2014, Goodall et al., 2015, 
Lin et al., 2015, Holt et al., 2008, Walker et al., 2010). The most successful of these, a 
GLP-1 AlbudAbTM conjugate, has progressed to phase I clinical trials where it 
demonstrated improved plasma half-life and retained GLP-1 activity (Lin et al., 2015, 
O'Connor-Semmes et al., 2014). However, this approach using endogenous molecules 
and genetic conjugation does not offer any protection from proteolytic cleavage.  
This study aims to act as a proof-of-principle by combining the two approaches for the 
first time. The resulting molecule would consist of a modified apelin mimetic peptide 
containing unnatural amino acids chemically conjugated to an AlbudAbTM moiety. The 
unnatural amino acids would protect it from proteolytic degradation, meanwhile the 
AlbudAbTM moiety would retain it in the plasma and allow it to avoid renal filtration. To 
do this, MM202, an apelin mimetic peptide, where the C-terminal phenylalanine has 
been tri-fluorinated to protect it from cleavage by ACE2, was linked via a (PEG)4 linker 
to AlbudAbTM using an sSMCC reagent and maleimide chemistry. 
The resulting MM202-AlbudAbTM molecule was assessed for binding to the native 
human apelin receptor and cell signalling in vitro. It retained activity and showed similar 
activities to the original MM202 molecule and [Pyr1]apelin-13. Furthermore, the 
AlbudAbTM moiety retained the ability to bind to HSA. Given that the MM202 peptide is 
~15KDa and the AlbudAbTM moiety is ~81KDa, the fact that the individual active parts 
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of the combined construct retained such high activity is remarkable; one would have 
anticipated that steric hindrance would have had a greater impact. It is testament to 
the careful consideration of the structure-activity data available and use of 
appropriately sized linkers that two large peptides could be conjugated together so 
successfully, greatly supporting chemical conjugation as an effective method to 
generate a peptide-AlbudAbTM construct.  
The study went on to show that MM202-AlbudAbTM was active in vivo when 
administered acutely and that it produced responses consistent for an apelin mimetic. 
Moreover, these responses were similar to those obtained with MM202 administered 
alone in a preliminary experiment, suggesting the molecule possessed similar activity 
to the parent compound in support of the in vitro data. Finally, the construct was tested 
in an MCT prevention study of PAH, however, no benefits were observed and it is most 
likely that the dose and frequency of administration were too low to attain a therapeutic 
effect.  
It is interesting that the construct displayed an enhanced plasma half-life when 
incubated ex vivo in heparinised human plasma. Although had it been possible on the 
project licence, it would have been useful to obtain in vivo pharmacokinetic data. 
Nonetheless, it was possible to detect elevated apelin-like reactivity following chronic 
IP administration twice weekly for three weeks in rat plasma, perhaps supporting the 
construct’s stability in vivo. Without detailed pharmacokinetic data on the compound it 
is difficult to assess how much was reaching the target and, therefore, how appropriate 
the dosing schedule was. Moreover, the fact that it displayed similar activity in vivo to 
the parent molecule either suggests it is engaging the receptor target successfully or 
the construct is breaking down and releasing MM202 to bind the receptor. From the in 
vitro plasma time-course, the fact that MM202-AlbudAbTM had such a longer half-life 
does not support this scenario but it is difficult to know for certain without accurate 
pharmacokinetic data on metabolism and clearance.  
Overall this proof-of-principle study of an unnatural peptide mimetic of apelin, MM202, 
combined with an AlbudAbTM moiety by chemical conjugation demonstrates the utility 
and potential of the approach. The conjugation was successful and produced a 
construct in which both the AlbudAbTM and apelin agonist retained full activity relative 
to their respective targets when tested alone. This is the first time that such an 
approach has been attempted and its success opens up the possibility that it could be 
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more widely applicable to other transmitter systems where the endogenous agonist is 

























The studies presented here represent a significant advance in the discovery and 
development of synthetic agonists at the apelin receptor through a range of 
multidisciplinary methods. Such molecules are necessary for the progression of the 
apelin system as a therapeutic target since both of the endogenous agonists, apelin 
and ELA, are limited by oral bioavailability, half-life and excretion. A proteolytically 
protected peptide could avoid metabolism and, if combined with a suitable antibody to 
sufficiently extend half-life, could reduce the frequency of administration required such 
that a lack of oral bioavailability is no longer a concern. An additional constraint is that 
the endogenous apelin agonists lead to rapid desensitisation of the apelin receptor and 
would thus, be expected to produce only transient benefits in preventing disease 
progression. In contrast, a G protein biased small molecule apelin agonist would have 
great potential to overcome all of the issues of the endogenous molecules by providing 
an orally bioavailable drug that could avoid excretion and not desensitise the receptor, 
therefore, providing a long-term treatment for chronic disease.  
Previous studies have utilised peptide modification to improve plasma stability and 
affinity through a range of methods, including PEGylation, cyclisation and the addition 
of unnatural amino acids. Here an alternative and novel approach was used. By 
combining a modified peptide agonist containing unnatural amino acids conjugated 
chemically to AlbudAbTM, it has been demonstrated that activity of both parts of the 
molecule could be retained and the molecule displayed activity in vivo. This is the first 
time that a non-endogenous peptide has been conjugated chemically to an AlbudAbTM 
and presents a novel approach to drug design.   
Initial studies to identify small molecules at the apelin receptor have been limited and 
although some successes have been reported, they have often had significant issues. 
Perhaps, the greatest advance demonstrated in this study has been the discovery and 
identification of CMF-019 as a G protein biased small molecule apelin agonist. This 
molecule will be very useful in future studies as an experimental tool compound, 
exemplified by the fact it is already available commercially and newer syntheses are 
being researched. CMF-019 has great potential as a starting point for the development 
of newer biased small molecule therapeutics at the apelin receptor with improved 
pharmacokinetic profiles. Such molecules could overcome all of the issues posed by 
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the short-lived endogenous peptides, apelin and ELA, as therapeutic agents and 
provide drugs with oral bioavailability, long half-lives and no desensitisation of the 
receptor; thereby, providing effective and easily manufactured treatments for chronic 
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